aspirin has been researched along with Thromboembolism, Venous in 403 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study compares the symptomatic 90-day venous thromboembolism (VTE) rates in patients receiving aspirin to patients receiving low-molecular weight heparin (LMWH) or direct oral anticoagulants (DOACs), after total hip (THA) and total knee arthroplasty (TKA)." | 9.69 | Comparative effectiveness of aspirin for symptomatic venous thromboembolism prophylaxis in patients undergoing total joint arthroplasty, a cohort study. ( A Harris, I; Adie, S; Badge, H; Churches, T; Maree Naylor, J; Sidhu, V, 2023) |
| "Among patients undergoing hip or knee arthroplasty for osteoarthritis, aspirin compared with enoxaparin resulted in a significantly higher rate of symptomatic VTE within 90 days, defined as below- or above-knee DVT or pulmonary embolism." | 9.51 | Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial. ( Ackerman, I; Adie, S; Bastiras, D; Brighton, R; Buchbinder, R; Burns, AWR; Cashman, K; Chong, BH; Clavisi, O; Cripps, M; de Steiger, R; Dekkers, M; Dixon, M; Ellis, A; Graves, SE; Griffith, EC; Hale, D; Hansen, A; Harris, A; Harris, IA; Hau, R; Horsley, M; James, D; Kelly, TL; Khorshid, O; Kuo, L; Lewis, P; Lieu, D; Lorimer, M; MacDessi, S; McCombe, P; McDougall, C; Mulford, J; Naylor, JM; Page, RS; Pratt, N; Radovanovic, J; Sidhu, VS; Solomon, M; Sorial, R; Summersell, P; Tran, P; Walter, WL; Webb, S; Wilson, C; Wysocki, D, 2022) |
| "Aspirin, as a routine venous thromboembolism (VTE) prophylaxis, is approved along with pneumatic compression pumps by the American College of Chest Physicians." | 9.51 | Randomized Trial of Postoperative Venous Thromboembolism Prophylactic Compliance: Aspirin and Mobile Compression Pumps. ( Dietz, MJ; Frye, BM; Klein, AE; Lindsey, BA; Moushmoush, O; Murphy, TR, 2022) |
| " No significant differences in deep venous thrombosis, pulmonary embolism, and bleeding complications rates were found between aspirin and LMWH." | 9.41 | The role of aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis after total knee arthroplasty: a meta-analysis of randomized controlled trials. ( Gao, S; Liu, W; Meng, J; Tang, H; Wu, Y; Xiao, Y, 2023) |
| "Aspirin has demonstrated safety and efficacy for venous thromboembolism (VTE) prophylaxis following total hip arthroplasty (THA); however, inconsistent dose regimens have been reported in the literature." | 9.41 | Comparable efficacy of 100 mg aspirin twice daily and rivaroxaban for venous thromboembolism prophylaxis following primary total hip arthroplasty: a randomized controlled trial. ( Cao, SL; Feng, B; Li, Z; Luo, T; Ren, Y; Weng, XS, 2021) |
| "CRISTAL (cluster-randomised, crossover, non-inferiority trial of aspirin compared to low molecular weight heparin for venous thromboembolism prophylaxis in hip or knee arthroplasty, a registry nested study) aims to determine whether aspirin is non-inferior to low molecular weight heparin (LMWH) in preventing symptomatic venous thromboembolism (VTE) following hip arthroplasty (HA) or knee arthroplasty (KA)." | 9.41 | CRISTAL (a cluster-randomised, crossover, non-inferiority trial of aspirin compared to low molecular weight heparin for venous thromboembolism prophylaxis in hip or knee arthroplasty, a registry nested study): statistical analysis plan. ( Ackerman, I; Adie, S; Bastiras, D; Buchbinder, R; Cashman, K; de Steiger, R; Graves, S; Harris, I; Kelly, TL; Lorimer, M; Naylor, J; Pratt, N; Sidhu, VS, 2021) |
| "Emerging evidence suggests aspirin may be an effective venous thromboembolism (VTE) prophylaxis for orthopaedic trauma patients, with fewer bleeding complications." | 9.34 | Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial. ( Castillo, RC; Haac, BE; Manson, TT; O'Hara, NN; O'Toole, RV; Slobogean, GP; Stein, DM, 2020) |
| "There has been significant debate in the surgical and medical communities regarding the appropriateness of using aspirin alone for venous thromboembolism (VTE) prophylaxis following total knee arthroplasty (TKA)." | 9.30 | Association of Aspirin With Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty Compared With Other Anticoagulants: A Noninferiority Analysis. ( Cowen, ME; Hallstrom, BR; Hood, BR; Hughes, RE; Singal, B; Zheng, HT, 2019) |
| "Routine thromboprophylaxis (TP) in newly-diagnosed multiple myeloma (NDMM) patients comprises either aspirin for standard risk patients or low molecular weight heparin for high risk patients." | 9.30 | What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feas ( Arya, R; Benjamin, R; Cornelius, V; Czuprynska, J; Patel, JP; Patel, RK; Roberts, LN; Sayar, Z, 2019) |
| "Orthopedic trauma patients are often treated with venous thromboembolism (VTE) chemoprophylaxis with aspirin or low molecular weight heparin (LMWH) after discharge from their index admission, but adherence patterns are not known." | 9.27 | Post-discharge adherence with venous thromboembolism prophylaxis after orthopedic trauma: Results from a randomized controlled trial of aspirin versus low molecular weight heparin. ( Berger, PZ; Connelly, D; Degani, Y; Haac, BE; Johal, H; Manson, TT; Marinos, D; Mascarenhas, D; O'Hara, NN; O'Toole, RV; Reahl, GB; Scalea, TM; Slobogean, GP; Stein, DM; Van Besien, R, 2018) |
| "Among patients with venous thromboembolism in equipoise for continued anticoagulation, the risk of a recurrent event was significantly lower with rivaroxaban at either a treatment dose (20 mg) or a prophylactic dose (10 mg) than with aspirin, without a significant increase in bleeding rates." | 9.24 | Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. ( Bauersachs, R; Berkowitz, SD; Beyer-Westendorf, J; Bounameaux, H; Brighton, TA; Cohen, AT; Davidson, BL; Decousus, H; Freitas, MCS; Haskell, L; Holberg, G; Kakkar, AK; Lensing, AWA; Pap, AF; Prandoni, P; Prins, MH; van Bellen, B; Verhamme, P; Weitz, JI; Wells, PS, 2017) |
| "Aspirin at 325 mg twice daily is now included as a nationally approved venous thromboembolism (VTE) prophylaxis protocol for low-risk total knee arthroplasty (TKA) patients." | 9.24 | Efficacy in Deep Vein Thrombosis Prevention With Extended Mechanical Compression Device Therapy and Prophylactic Aspirin Following Total Knee Arthroplasty: A Randomized Control Trial. ( Gregg, JL; Hussain, LR; Scheuerman, CM; Snyder, MA; Sympson, AN, 2017) |
| "An individual patient data analysis of these trials was planned, before their results were known, to assess the effect of aspirin versus placebo on recurrent VTE, major vascular events (recurrent VTE, myocardial infarction, stroke, and cardiovascular disease death) and bleeding, overall and within predefined subgroups." | 9.19 | Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. ( Agnelli, G; Becattini, C; Brighton, TA; Eikelboom, JW; Kirby, AC; Mister, R; Prandoni, P; Simes, J, 2014) |
| "To compare extended prophylaxis with aspirin and dalteparin for prevention of symptomatic venous thromboembolism (VTE) after THA." | 9.17 | Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. ( Anderson, DR; Andreou, P; Belzile, E; Bohm, ER; Carrier, M; Crowther, M; Davis, N; Dunbar, MJ; Fisher, W; Gofton, W; Gross, P; Kahn, SR; Kim, P; Kovacs, M; MacDonald, S; Pelet, S; Pleasance, S; Ramsay, T; Rodger, MA; Vendittoli, PA; Wells, P; Zukor, D, 2013) |
| "Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism (VTE)." | 9.16 | Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. ( Beggiato, E; Boccadoro, M; Bringhen, S; Cafro, AM; Carella, AM; Catalano, L; Cavalli, M; Cavallo, F; Cavo, M; Corradini, P; Crippa, C; Di Raimondo, F; Di Toritto, TC; Evangelista, A; Falanga, A; Larocca, A; Nagler, A; Palumbo, A; Patriarca, F; Peccatori, J; Petrucci, MT; Pezzatti, S; Siniscalchi, A; Stanevsky, A; Yehuda, DB, 2012) |
| "Aspirin reduced the risk of recurrence when given to patients with unprovoked venous thromboembolism who had discontinued anticoagulant treatment, with no apparent increase in the risk of major bleeding." | 9.16 | Aspirin for preventing the recurrence of venous thromboembolism. ( Ageno, W; Agnelli, G; Becattini, C; Bianchi, M; Bucherini, E; Eichinger, S; Grandone, E; Moia, M; Prandoni, P; Schenone, A; Silingardi, M; Vandelli, MR, 2012) |
| "We randomly assigned 822 patients who had completed initial anticoagulant therapy after a first episode of unprovoked venous thromboembolism to receive aspirin, at a dose of 100 mg daily, or placebo for up to 4 years." | 9.16 | Low-dose aspirin for preventing recurrent venous thromboembolism. ( Brighton, TA; Diaz, R; Eikelboom, JW; Gallus, A; Gibbs, H; Hague, W; Kirby, A; Mann, K; Mister, R; Ockelford, P; Simes, J; Xavier, D, 2012) |
| "Aspirin is perceived to be non-inferior to enoxaparin, a low-molecular-weight heparin, for the prevention of venous thromboembolism (VTE) following elective arthroplasty of the hip or knee and is recommended in clinical guidelines internationally." | 9.12 | Aspirin versus enoxaparin for the initial prevention of venous thromboembolism following elective arthroplasty of the hip or knee: A systematic review and meta-analysis. ( An, VVG; Farey, JE; Harris, IA; Karunaratne, S; Sidhu, V, 2021) |
| "To evaluates the efficacy and safety of rivaroxaban versus aspirin in prevention of venous thromboembolism (VTE) following total hip (THA) or knee arthroplasty (TKA) or hip fracture surgery." | 9.12 | Rivaroxaban versus aspirin in prevention of venous thromboembolism following total joint arthroplasty or hip fracture surgery: a meta-analysis. ( Dai, Z; Hu, B; Hu, M; Jiang, L; Tang, H; Yu, J, 2021) |
| "To study the efficacy and safety of aspirin in prophylaxis of venous thromboembolism (VTE) after total joint arthroplasty." | 9.12 | [Efficacy and safety of aspirin in prevention of venous thromboembolism after total joint arthroplasty]. ( Liu, Y; Song, F; Tian, H; Zhang, K, 2007) |
| " There were no significant differences in symptomatic pulmonary embolism, symptomatic deep vein thrombosis, 90-day mortality, or major bleeding between patients receiving low-dose or high-dose aspirin." | 9.05 | Low-Dose Aspirin Is Adequate for Venous Thromboembolism Prevention Following Total Joint Arthroplasty: A Systematic Review. ( Azboy, I; Goswami, K; Groff, H; Parvizi, J; Vahedian, M, 2020) |
| " The computer-based searches combined terms and combinations of keywords related to the population (eg, hip replacement, knee replacement, hip arthroplasty, and knee arthroplasty), drug intervention (eg, aspirin, heparin, clexane, dabigatran, rivaroxaban, and warfarin), and outcome (eg, venous thromboembolism, deep vein thrombosis, pulmonary embolism, and bleeding) in humans." | 9.05 | Clinical Effectiveness and Safety of Aspirin for Venous Thromboembolism Prophylaxis After Total Hip and Knee Replacement: A Systematic Review and Meta-analysis of Randomized Clinical Trials. ( Blom, AW; Judge, A; Kunutsor, SK; Matharu, GS; Whitehouse, MR, 2020) |
| "A considerable proportion of patients with atrial fibrillation (AF) are still treated with aspirin despite current guidelines due to presumed favorable safety." | 9.05 | Bleeding risk comparison between direct oral anticoagulants at doses approved for atrial fibrillation and aspirin: systematic review, meta-analysis and meta-regression. ( Georgiopoulos, G; Korompoki, E; Leventis, I; Lip, GYH; Makaritsis, K; Milionis, H; Ntaios, G; Sagris, D; Vemmos, K, 2020) |
| " The use of aspirin has been implicated in reducing VTE events and is potentially advantageous compared to other agents in respect to cost, access, route of administration and reduced adverse effects such as bleeding." | 9.01 | Aspirin for prevention of venous thromboembolism in recipients of major lower-limb orthopedic surgery: a systematic review of Level I evidence. ( Fletcher, JP; Hitos, K; Seagrave, KG, 2019) |
| " This article evaluates the preventive effects of rivaroxaban versus aspirin on venous thromboembolism (VTE) through meta-analysis of recent randomized controlled trials (RCTs)." | 9.01 | Rivaroxaban versus Aspirin in Prevention of Venous Thromboembolism: A Meta-Analysis of 9 Randomized Controlled Trials comprising 7,656 Patients. ( Deng, H; Jiang, M; Li, L; Lin, Y; Xie, J; Xie, X, 2019) |
| "Studies have consistently demonstrated the need for venous thromboembolism (VTE) prophylaxis in patients with newly diagnosed multiple myeloma (NDMM) or relapsed refractory multiple myeloma (RRMM), receiving lenalidomide-based therapy." | 8.93 | Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review. ( Al-Ani, F; Bermejo, JM; Louzada, M; Mateos, MV, 2016) |
| "To compare venous thromboembolism (VTE) and bleeding rates in adult patients receiving aspirin versus anticoagulants after major lower extremity orthopedic surgery." | 8.90 | Aspirin versus anticoagulation for prevention of venous thromboembolism major lower extremity orthopedic surgery: a systematic review and meta-analysis. ( Chiang, WH; Drescher, FS; Larson, RJ; Lee, A; Morrison, DH; Sirovich, BE, 2014) |
| "While there is conclusive evidence that aspirin plays a role in reducing the risk of clinically relevant venous thromboembolism (VTE) arising in a number of surgical and non-surgical situations at risk, little is known of the potential of aspirin for the long/term prevention of recurrent VTE." | 8.89 | Aspirin and recurrent venous thromboembolism. ( Milan, M; Noventa, F; Prandoni, P, 2013) |
| "Currently multiple antithrombotic agents are used for thalidomide thromboprophylaxis in multiple myeloma patients." | 8.88 | Thalidomide thromboprophylaxis in multiple myeloma: a review of current evidence. ( Alexander, M; Kirsa, S; Mellor, JD, 2012) |
| " The risk of VTE is higher in multiple myeloma (MM) patients who receive thalidomide or lenalidomide, especially in combination with dexamethasone or chemotherapy." | 8.84 | Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. ( Anderson, KC; Attal, M; Barlogie, B; Belch, A; Bladé, J; Boccadoro, M; Bringhen, S; Cavo, M; Dimopoulos, MA; Durie, BG; Harousseau, J; Hussein, MA; Joshua, D; Knop, S; Kyle, R; Lonial, S; Ludwig, H; Morgan, GJ; Niesvizky, R; Orlowski, RZ; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Shimizu, K; Sonneveld, P; Vesole, D; von Lilienfeld-Toal, M; Waage, A; Weber, D; Westin, J; Zangari, M; Zonder, JA, 2008) |
| "While there is good evidence for a protective effect of aspirin against occlusive vascular events in individuals with arterial disease, its role in preventing venous thromboembolism (VTE) is unclear." | 8.84 | Aspirin and other antiplatelet drugs in the prevention of venous thromboembolism. ( Chee, YL; Watson, HG, 2008) |
| "Aspirin and enoxaparin are commonly used for venous thromboembolism (VTE) prophylaxis following total hip arthroplasty (THA) or total knee arthroplasty (TKA)." | 8.31 | Post-discharge patient-reported non-adherence to aspirin compared to enoxaparin for venous thromboembolism prophylaxis after hip or knee arthroplasty. ( Ackerman, I; Adie, S; Bastiras, D; Buchbinder, R; Harris, IA; Naylor, JM; Sidhu, V, 2023) |
| "While aspirin is acceptable for venous thromboembolism (VTE) prophylaxis following total joint arthroplasty in most patients, more potent agents are used in patients considered higher risk for VTE." | 8.31 | Comparison of 90-Day Adverse Events Associated With Aspirin and Potent Anticoagulation Use for Venous Thromboembolism Prophylaxis: A Cohort Study of 72,288 Total Knee and 35,142 Total Hip Arthroplasty Patients. ( Kroger, EW; Prentice, HA; Singh, G; Winston, BA, 2023) |
| "Administration of aspirin for VTE prophylaxis, compared to other chemoprophylaxis agents may have an association with lower risk of major bleeding following TJA." | 8.12 | Aspirin Thromboprophylaxis Is Associated With Less Major Bleeding Events Following Total Joint Arthroplasty. ( Chisari, E; Goh, GS; Ludwick, L; Parvizi, J; Shohat, N; Streicher, S, 2022) |
| "Patient-reported allergies to aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) may preclude certain patients from receiving aspirin as venous thromboembolism (VTE) prophylaxis after total joint arthroplasty (TJA)." | 8.12 | Patients Who Do Not Receive Aspirin Because of Allergy Have an Increased Risk of Venous Thromboembolism Following Total Joint Arthroplasty. ( Goh, GS; Kozaily, E; Parvizi, J; Tan, TL, 2022) |
| "Aspirin has become the main agent for venous thromboembolism (VTE) prophylaxis following total knee arthroplasty (TKA)." | 8.12 | Aspirin Administered for Venous Thromboembolism Prophylaxis May Protect Against Stiffness Following Total Knee Arthroplasty. ( Chisari, E; Ludwick, L; Parvizi, J; Shohat, N; Sutton, R, 2022) |
| "The attitude and approach of orthopedic community for minimizing venous thromboembolism (VTE) has evolved over the last decade with the trend toward use of aspirin (and mechanical modalities) in lieu of aggressive anticoagulation." | 8.12 | Time to Venous Thromboembolism Events Following Total Hip Arthroplasty: A Comparison Between Aspirin and Warfarin. ( Goel, R; Ludwick, L; Parvizi, J; Shohat, N, 2022) |
| "In recent years, aspirin has become a popular agent for venous thromboembolism (VTE) prophylaxis following total joint arthroplasty (TJA)." | 8.12 | Aspirin May Be a Suitable Prophylaxis for Patients with a History of Venous Thromboembolism Undergoing Total Joint Arthroplasty. ( Ledesma, J; Ludwick, L; Paladino, J; Parvizi, J; Shohat, N; Van Nest, D, 2022) |
| "Aspirin as a venous thromboembolism (VTE) prophylactic agent has been shown to have antistaphylococcal and antibiofilm roles." | 8.12 | Low-Dose Aspirin for Venous Thromboembolism Prophylaxis is Associated With Lower Rates of Periprosthetic Joint Infection After Total Joint Arthroplasty. ( Bernthal, NM; Ciesielka, KA; Kendal, JK; Najafi, F; Parvizi, J; Peterson, NV; Restrepo, C, 2022) |
| "The primary aim was to assess the incidence of venous thromboembolism (VTE) following total hip replacements (THR) in a low-risk patient group when using 150 mg aspirin as the pharmacological component of VTE prophylaxis on discharge." | 8.12 | Incidence and risk factors associated with venous thromboembolism following primary total hip arthroplasty in low-risk patients when using aspirin for prophylaxis. ( Clement, ND; Howard, TA; Judd, CS; Lambert, RJ; Snowden, GT, 2022) |
| " The purpose of this study is to examine if aspirin (ASA), when used as venous thromboembolism (VTE) prophylaxis, influenced the rate of HO formation following TJA." | 8.02 | Low-Dose Aspirin Administered for Venous Thromboembolism Prophylaxis Reduces the Incidence of Heterotopic Ossification in Total Joint Arthroplasty. ( Chisari, E; Clarkson, S; Parvizi, J; Sherman, MB; Van Nest, DS, 2021) |
| "Uncertainty remains surrounding the use of aspirin as a sole chemoprophylactic agent to reduce the risk of venous thromboembolism (deep vein thrombosis or pulmonary embolism) and bleeding after primary total hip arthroplasty." | 8.02 | Non-Inferiority of Aspirin for Venous Thromboembolism Prophylaxis After Hip Arthroplasty in a Statewide Registry. ( Cowen, ME; Hallstrom, BR; Hughes, RE; Muscatelli, SR; Zheng, H, 2021) |
| "Consensus on whether low-dose (81 mg) or regular-dose (325 mg) aspirin (ASA) is more effective for venous thromboembolism (VTE) chemoprophylaxis in primary total joint arthroplasties (TJAs) is not reached." | 8.02 | Low-Dose vs Regular-Dose Aspirin for Venous Thromboembolism Prophylaxis in Primary Total Joint Arthroplasty. ( Abdel, MP; Mabry, TM; Perry, KI; Siljander, MP; Taunton, MJ; Uvodich, ME, 2021) |
| "The optimal length of aspirin prophylaxis to minimize venous thromboembolism (VTE) following total knee arthroplasty (TKA) remains unknown." | 8.02 | Thirty Days of Aspirin for Venous Thromboembolism Prophylaxis Is Adequate Following Total Knee Arthroplasty, Regardless of the Dose Used. ( Goel, R; Ledesma, J; Ludwick, L; Parvizi, J; Shohat, N; Streicher, S, 2021) |
| " The purpose of this study is to evaluate a weight-based aspirin dosing regimen for prevention of venous thromboembolism (VTE) following TJA." | 8.02 | Weight-Based Aspirin Dosing May Further Reduce the Incidence of Venous Thromboembolism Following Primary Total Joint Arthroplasty. ( Brown, TS; Gulbrandsen, TR; Halbur, CR; Noiseux, NO; West, CR, 2021) |
| "Among older patients with cancer, aspirin was associated with lower VTE incidence and overall inhospital mortality without significantly increased bleeding." | 7.96 | Aspirin Is Associated With Reduced Rates of Venous Thromboembolism in Older Patients With Cancer. ( Cai, P; Dixon, RAF; Hadley, M; Li, M; Li, P; Liu, EY; Liu, Q; Ning, Y; Pan, S; Siddiqui, AD; Wu, F, 2020) |
| "Few studies have compared aspirin with direct oral anticoagulants (DOACs) (DOACs = direct thrombin inhibitors and factor Xa inhibitors) for venous thromboembolism (VTE) prophylaxis after total hip arthroplasty (THA) and total knee arthroplasty (TKA)." | 7.96 | Is Aspirin as Effective as the Newer Direct Oral Anticoagulants for Venous Thromboembolism Prophylaxis After Total Hip and Knee Arthroplasty? An Analysis From the National Joint Registry for England, Wales, Northern Ireland, and the Isle of Man. ( Garriga, C; Judge, A; Matharu, GS; Rangan, A; Whitehouse, MR, 2020) |
| "The purpose of this meta-analysis is to compare the efficacy and safety of aspirin and rivaroxaban in the prevention of venous thromboembolism (VTE) following either total knee arthroplasty or total hip arthroplasty." | 7.96 | Efficacy and safety of aspirin and rivaroxaban for venous thromboembolism prophylaxis after total hip or knee arthroplasty: A protocol for meta-analysis. ( Le, G; Luo, H; Tang, J; Xi, L; Yang, C; Zhang, M; Zhao, J, 2020) |
| "To determine using a simplified risk-stratified protocol to select candidates for aspirin therapy have similar death and postoperative complications as universal warfarin therapy in patients undergoing total joint replacement (TJR)." | 7.96 | Evaluation of a Simplified Risk Stratification Twice-Daily Aspirin Protocol for Venous Thromboembolism Prophylaxis After Total Joint Replacement. ( Adams, W; Davis, ES; Ng, C; Pinzur, MS; Zavala, S, 2020) |
| " Aspirin has been considered a safe and cost-effective prophylaxis for venous thromboembolism (VTE), and there have been some reports about the incidence of PTE (0%-0." | 7.96 | Clinical efficacy of risk-stratified prophylaxis with low-dose aspirin for the management of symptomatic venous thromboembolism after total hip arthroplasty. ( Hirakawa, K; Mihara, M; Nakura, N; Ochiai, S; Saito, A; Takayanagi, S; Tamaki, Y, 2020) |
| "To compare the efficacy and safety of aspirin with rivaroxaban following treatment with enoxaparin for prevention of venous thromboembolism (VTE) after hip fracture surgery (HFS)." | 7.91 | Comparison of the Efficacy and Safety of Aspirin and Rivaroxaban Following Enoxaparin Treatment for Prevention of Venous Thromboembolism after Hip Fracture Surgery. ( Huang, Q; Shen, B; Si, HB; Xing, SX; Zeng, Y; Zhou, ZK, 2019) |
| "The use of aspirin as prophylaxis against venous thromboembolism (VTE) following total joint arthroplasty (TJA) has increased in popularity; however, the potential cardioprotective effects of aspirin when administered as VTE prophylaxis remain unknown." | 7.91 | The Use of Aspirin for Prophylaxis Against Venous Thromboembolism Decreases Mortality Following Primary Total Joint Arthroplasty. ( Goswami, K; Huang, RC; Parvizi, J; Rondon, AJ; Shohat, N; Tan, TL, 2019) |
| "The risks of venous thromboembolism (VTE) and bleeding with direct oral anticoagulants (DOACs) and aspirin for thromboprophylaxis after orthopedic surgery were studied." | 7.91 | Direct oral anticoagulants versus aspirin for venous thromboembolism prophylaxis after orthopedic surgery. ( Muntz, J; Murillo, M; Putney, D; Vadhariya, A; Wilson, A; Yang, T, 2019) |
| "Although guidelines now allow the use of aspirin as an alternative to anticoagulants for venous thromboembolism prophylaxis after knee or hip arthroplasty, there is limited data on contemporary use and outcomes with aspirin." | 7.91 | Aspirin Compared with Anticoagulation to Prevent Venous Thromboembolism After Knee or Hip Arthroplasty: a Large Retrospective Cohort Study. ( Auerbach, AD; Baumgartner, C; Fang, MC; Maselli, J, 2019) |
| ": There is a good rationale for the use of aspirin in venous thromboembolism prophylaxis in some orthopaedic procedures, as already proposed by the 9th American College of Chest Physicians' guidelines (Grade 1C)." | 7.88 | European guidelines on perioperative venous thromboembolism prophylaxis: Aspirin. ( Jenny, JY; Pabinger, I; Samama, CM, 2018) |
| "Aspirin is an effective prophylaxis for venous thromboembolism (VTE) after total knee arthroplasty (TKA)." | 7.88 | Low-Dose Aspirin Is Safe and Effective for Venous Thromboembolism Prophylaxis Following Total Knee Arthroplasty. ( Barsoum, WK; Brigati, DP; Faour, M; Higuera, CA; Klika, AK; Mont, MA; Piuzzi, NS, 2018) |
| "Full- or lower-dose anticoagulant therapy or aspirin can be used for extended therapy in patients with venous thromboembolism (VTE), but information on their relative benefit-risk profiles is limited." | 7.88 | Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. ( Bauersachs, R; Beyer-Westendorf, J; Bounameaux, H; Cohen, AT; Davidson, BL; Gebel, M; Homering, M; Lensing, AWA; Levitan, B; Pap, AF; Prandoni, P; Prins, MH; van Bellen, B; Verhamme, P; Weitz, JI; Wells, PS; Yuan, Z, 2018) |
| "Recent guidelines include aspirin as an option to prevent venous thromboembolism (VTE) in selected patients undergoing hip or knee replacement surgery." | 7.85 | The risk of venous thromboembolism with aspirin compared to anticoagulants after hip and knee arthroplasty. ( Auerbach, AD; Chu, JN; Fang, MC; Maselli, J, 2017) |
| "Aspirin is a safe and effective prophylaxis for the prevention of venous thromboembolism following total joint arthroplasty." | 7.85 | Low-Dose Aspirin Is Effective Chemoprophylaxis Against Clinically Important Venous Thromboembolism Following Total Joint Arthroplasty: A Preliminary Analysis. ( Austin, MS; Chen, AF; Hozack, WJ; Huang, R; Lonner, JH; Parvizi, J; Restrepo, C, 2017) |
| "ESSENTIALS: We audited venous thromboembolism (VTE) in Achilles injuries after the use of prophylactic aspirin." | 7.83 | Venous thromboembolism rates in patients with lower limb immobilization after Achilles tendon injury are unchanged after the introduction of prophylactic aspirin: audit. ( Beasley, R; Braithwaite, I; Dunbar, L; Eathorne, A; Weatherall, M, 2016) |
| "Although recent guidelines suggest aspirin for venous thromboembolism (VTE) prophylaxis in low risk patients following total hip arthroplasty (THA) and total knee arthroplasty (TKA), there are no cost-effectiveness studies comparing aspirin and warfarin." | 7.81 | Cost-effective prophylaxis against venous thromboembolism after total joint arthroplasty: warfarin versus aspirin. ( Maltenfort, MG; Mostafavi Tabatabaee, R; Parvizi, J; Rasouli, MR, 2015) |
| "Interest in aspirin as an alternative strategy for venous thromboembolism prophylaxis after arthroplasty has grown, as studies have suggested improved clinical efficacy and lower complication rates with aspirin compared to warfarin." | 7.81 | Direct Costs of Aspirin versus Warfarin for Venous Thromboembolism Prophylaxis after Total Knee or Hip Arthroplasty. ( Gutowski, CJ; Lonner, JH; Parvizi, J; Purtill, JJ; Zmistowski, BM, 2015) |
| "The efficacy and safety of aspirin (ASA) for prevention of venous thromboembolism (VTE) following total joint arthroplasty (TJA) have been demonstrated." | 7.81 | Administration of Aspirin as a Prophylaxis Agent Against Venous Thromboembolism Results in Lower Incidence of Periprosthetic Joint Infection. ( Buckley, PS; Huang, R; Parvizi, J; Purtill, JJ; Scott, B, 2015) |
| "Combined anticoagulant and aspirin therapy is associated with increased bleeding risk in patients with atrial fibrillation, but the bleeding risk of combined use of anticoagulant and nonsteroidal anti-inflammatory drugs (NSAIDs) is poorly documented." | 7.80 | Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. ( Brighton, TA; Davidson, BL; Gebel, M; Lensing, AW; Lyons, RM; Prins, MH; Rehm, J; Verheijen, S, 2014) |
| "We used a Markov cohort model with health states of healthy after surgery, no postphlebitic syndrome after venous thromboembolism, postphlebitic syndrome after venous thromboembolism, and survival after intracranial hemorrhage to compare treatment with low-molecular-weight heparin or aspirin (160 mg) for fourteen days after total knee arthroplasty or total hip arthroplasty in patients with an age of fifty-five, sixty, sixty-five, seventy, seventy-five, eighty, or eighty-five years." | 7.79 | Cost-effectiveness of low-molecular-weight heparin compared with aspirin for prophylaxis against venous thromboembolism after total joint arthroplasty. ( Brown, GA; Schousboe, JT, 2013) |
| "The objectives of this study were to compare the risk of venous thromboembolism (VTE), bleeding, surgical site infection, and mortality in patients receiving aspirin or guideline-approved VTE prophylactic therapies (warfarin, low-molecular-weight heparins, synthetic pentasaccharides) in total knee arthroplasty (TKA)." | 7.76 | Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? ( Auerbach, AD; Bozic, KJ; Lindenauer, PK; Maselli, JH; Pekow, PS; Vail, TP, 2010) |
| "To determine whether arterial cardiovascular events, use of statins and low-dose aspirin were associated with the risk of venous thromboembolism." | 7.75 | Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. ( Baron, JA; Christensen, S; Horvath-Puho, E; Johnsen, SP; Prandoni, P; Søgaard, KK; Sørensen, HT; Thomsen, RW, 2009) |
| "In a monocentric prospective study, patients with stage II-IV breast cancer, who underwent CVC insertion for continuous infusional chemotherapy, were assigned to receive low-dose aspirin (100 mg daily)." | 7.74 | Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter. ( Balduzzi, A; Cardillo, A; Colleoni, M; Curigliano, G; Dellapasqua, S; Ghisini, R; Goldhirsch, A; Lunghi, L; Orlando, L; Peruzzotti, G; Torrisi, R, 2007) |
| "Patients with multiple myeloma are at increased risk of vascular thromboembolic events (VTEs)." | 7.11 | Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study. ( Anderson, LD; Baljevic, M; Bartlett, JB; Chari, A; Cortoos, A; Costa, LJ; Efebera, YA; Holstein, SA; Kaufman, JL; Laubach, J; Lin, TS; Patel, S; Pei, H; Reeves, B; Richardson, PG; Rodriguez, C; Sborov, DW; Shah, N; Silbermann, R; Vermeulen, J; Voorhees, PM, 2022) |
| "Although venous thromboembolism is one of the leading causes of morbidity after knee arthroplasty, little data exist on the risk of deep venous thrombosis (DVT) after unicompartmental knee arthroplasty (UKA)." | 6.84 | Deep Venous Thrombosis Prophylaxis After Unicompartmental Knee Arthroplasty: A Prospective Study on the Safety of Aspirin. ( Boettner, F; Mayman, DJ; Pearle, AD; Schmidt-Braekling, T; Waldstein, W; Westrich, GH, 2017) |
| "However, more recently, the rate of deep vein thrombosis (DVT) has been reported to be approximately 10%." | 6.80 | Prevention of Venous Thromboembolism after Arthroscopic Knee Surgery in a Low-Risk Population with the Use of Aspirin. A Randomized Trial. ( Alaia, MJ; Garofolo, G; Jazrawi, LM; Kaye, ID; Martinez, A; Patel, DN; Strauss, EJ, 2015) |
| " The purpose of this study was to evaluate the role of aspirin combined with mechanical measures in the prevention of VTE after total knee arthroplasty (TKA)." | 6.79 | Aspirin combined with mechanical measures to prevent venous thromboembolism after total knee arthroplasty: a randomized controlled trial. ( Du, H; Jiang, Y; Liu, J; Zhou, Y, 2014) |
| "Aspirin has long been an inexpensive cornerstone of arterial vascular disease therapy, but its role in the primary or secondary prophylaxis of VTE has been debated." | 6.66 | Does aspirin prevent venous thromboembolism? ( Diep, R; Garcia, D, 2020) |
| " The aim of this study was to determine whether a protocol of 81-mg aspirin (ASA) bis in die (BID) is safe and/or sufficient in preventing VTE in patients undergoing rTKAs versus 325-mg ASA BID." | 5.72 | Low-Dose Aspirin is Safe and Effective for Venous Thromboembolism Prevention in Patients Undergoing Revision Total Knee Arthroplasty: A Retrospective Cohort Study. ( Bosco, JA; Iorio, R; Schwarzkopf, R; Slover, JD; Tang, A; Waren, D; Zak, SG, 2022) |
| " The aim of this study is to determine if discontinued use of outpatient IPCDs is safe and does not increase the rate of VTE or any other related complications in patients following TKA." | 5.72 | Discontinued Use of Outpatient Portable Intermittent Pneumatic Compression Devices May Be Safe for Venous Thromboembolism Prophylaxis in Primary Total Knee Arthroplasty Using Low-Dose Aspirin. ( Lajam, C; Lygrisse, K; Macaulay, W; Meftah, M; Schwarzkopf, R; Slover, J; Tang, A; Zak, S, 2022) |
| "Rates of hemorrhage were similar for aspirin in combination with warfarin or direct-acting oral anticoagulants." | 5.72 | Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study. ( Colucci, PM; Grunwald, MR; Lessen, DS; Paranagama, D; Zwicker, JI, 2022) |
| "Among women with endometrial cancer, aspirin use exerted a modest effect on VTE prophylaxis, whereas statin use was associated with a decreased prevalence of VTE, especially in women with obesity and type II cancer, compared with those in non-users." | 5.72 | Effects of aspirin and statin use on venous thromboembolism prophylaxis and survival in patients with endometrial cancer. ( Klar, M; Matsuo, K; Matsuzaki, S; Miller, H; Takiuchi, T, 2022) |
| "In this pilot study, there were no significant differences in any outcome assessed; however, recurrent thromboembolic events and minor bleeding events occurred numerically less frequently in the rivaroxaban plus aspirin group." | 5.69 | Rivaroxaban plus aspirin versus acenocoumarol to manage recurrent venous thromboembolic events despite systemic anticoagulation with rivaroxaban. ( Erika, MH; Jaime, GC; Maximiliano, CL, 2023) |
| "In patients with extremity fractures that had been treated operatively or with any pelvic or acetabular fracture, thromboprophylaxis with aspirin was noninferior to low-molecular-weight heparin in preventing death and was associated with low incidences of deep-vein thrombosis and pulmonary embolism and low 90-day mortality." | 5.69 | Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture. ( Bosse, MJ; Carlini, AR; Castillo, RC; Degani, Y; Firoozabadi, R; Frey, KP; Goldhaber, SZ; Haut, ER; Marvel, D; O'Hara, NN; O'Toole, RV; Obremskey, W; Scharfstein, DO; Slobogean, GP; Stein, DM; Sudini, K; Taylor, TJ, 2023) |
| " Due to its antiplatelet and cardioprotective properties, aspirin has been proposed as an agent that could reduce mortality when used as venous thromboembolism (VTE) prophylaxis following these procedures." | 5.69 | Effect of Aspirin vs Enoxaparin on 90-Day Mortality in Patients Undergoing Hip or Knee Arthroplasty: A Secondary Analysis of the CRISTAL Cluster Randomized Trial. ( Ackerman, IN; Adie, S; Bastiras, D; Brighton, R; Buchbinder, R; Burns, AWR; Cashman, K; Chong, BH; Clavisi, O; Cripps, M; de Steiger, R; Dekkers, M; Dixon, M; Ellis, A; Graves, SE; Griffith, EC; Hale, D; Hansen, A; Harris, A; Harris, IA; Hau, R; Horsley, M; James, D; Kelly, TL; Khorshid, O; Kuo, L; Lewis, PL; Lieu, D; Lorimer, M; MacDessi, SJ; McCombe, P; McDougall, C; Mulford, J; Naylor, JM; Page, RS; Pratt, N; Radovanovic, J; Sidhu, VS; Solomon, M; Sorial, R; Summersell, P; Tran, P; Walter, WL; Webb, S; Wilson, C; Wysocki, D, 2023) |
| "This study compares the symptomatic 90-day venous thromboembolism (VTE) rates in patients receiving aspirin to patients receiving low-molecular weight heparin (LMWH) or direct oral anticoagulants (DOACs), after total hip (THA) and total knee arthroplasty (TKA)." | 5.69 | Comparative effectiveness of aspirin for symptomatic venous thromboembolism prophylaxis in patients undergoing total joint arthroplasty, a cohort study. ( A Harris, I; Adie, S; Badge, H; Churches, T; Maree Naylor, J; Sidhu, V, 2023) |
| "ASA is safe for VTE prophylaxis after total joint arthroplasty in patients with history of GI issues and is not associated with an increased risk of postoperative GI bleeds." | 5.62 | Aspirin Is Safe for Venous Thromboembolism Prophylaxis for Patients With a History of Gastrointestinal Issues. ( Austin, MS; Grosso, MJ; Kozaily, E; Parvizi, J, 2021) |
| "The aspirin group was older (73 ± 7." | 5.62 | No Increased Risk of Venous Thromboembolism in High-Risk Patients Continuing Their Dose of 75 mg Aspirin Compared to Healthier Patients Given Low-Molecular-Weight Heparin. ( Amlie, EJ; Hovik, O; Jenssen, KK, 2021) |
| " The aim of this study is to determine whether a protocol of 81-mg aspirin (ASA) bis in die (BID) is safe and/or effective in preventing VTE in patients undergoing rTHAs vs 325-mg ASA BID." | 5.56 | Low-Dose Aspirin Is Safe and Effective for Venous Thromboembolism Prevention in Patients Undergoing Revision Total Hip Arthroplasty: A Retrospective Cohort Study. ( Bosco, J; Iorio, R; Schwarzkopf, R; Slover, J; Tang, A; Zak, S, 2020) |
| "Aspirin was administered to all patients once a day." | 5.56 | Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action. ( Frigieri, FC; Gianesello, L; Meconi, T; Pavoni, V; Pazzi, M; Stera, C, 2020) |
| "Among patients undergoing hip or knee arthroplasty for osteoarthritis, aspirin compared with enoxaparin resulted in a significantly higher rate of symptomatic VTE within 90 days, defined as below- or above-knee DVT or pulmonary embolism." | 5.51 | Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial. ( Ackerman, I; Adie, S; Bastiras, D; Brighton, R; Buchbinder, R; Burns, AWR; Cashman, K; Chong, BH; Clavisi, O; Cripps, M; de Steiger, R; Dekkers, M; Dixon, M; Ellis, A; Graves, SE; Griffith, EC; Hale, D; Hansen, A; Harris, A; Harris, IA; Hau, R; Horsley, M; James, D; Kelly, TL; Khorshid, O; Kuo, L; Lewis, P; Lieu, D; Lorimer, M; MacDessi, S; McCombe, P; McDougall, C; Mulford, J; Naylor, JM; Page, RS; Pratt, N; Radovanovic, J; Sidhu, VS; Solomon, M; Sorial, R; Summersell, P; Tran, P; Walter, WL; Webb, S; Wilson, C; Wysocki, D, 2022) |
| "Aspirin, as a routine venous thromboembolism (VTE) prophylaxis, is approved along with pneumatic compression pumps by the American College of Chest Physicians." | 5.51 | Randomized Trial of Postoperative Venous Thromboembolism Prophylactic Compliance: Aspirin and Mobile Compression Pumps. ( Dietz, MJ; Frye, BM; Klein, AE; Lindsey, BA; Moushmoush, O; Murphy, TR, 2022) |
| "The rate of surgical site infection was similar between the aspirin group and the warfarin group (1." | 5.43 | Aspirin Can Be Used as Prophylaxis for Prevention of Venous Thromboembolism After Revision Hip and Knee Arthroplasty. ( Chen, AF; Deirmengian, GK; Heller, S; Maltenfort, M; Parvizi, J; Smith, EB, 2016) |
| " No significant differences in deep venous thrombosis, pulmonary embolism, and bleeding complications rates were found between aspirin and LMWH." | 5.41 | The role of aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis after total knee arthroplasty: a meta-analysis of randomized controlled trials. ( Gao, S; Liu, W; Meng, J; Tang, H; Wu, Y; Xiao, Y, 2023) |
| "Aspirin has demonstrated safety and efficacy for venous thromboembolism (VTE) prophylaxis following total hip arthroplasty (THA); however, inconsistent dose regimens have been reported in the literature." | 5.41 | Comparable efficacy of 100 mg aspirin twice daily and rivaroxaban for venous thromboembolism prophylaxis following primary total hip arthroplasty: a randomized controlled trial. ( Cao, SL; Feng, B; Li, Z; Luo, T; Ren, Y; Weng, XS, 2021) |
| "CRISTAL (cluster-randomised, crossover, non-inferiority trial of aspirin compared to low molecular weight heparin for venous thromboembolism prophylaxis in hip or knee arthroplasty, a registry nested study) aims to determine whether aspirin is non-inferior to low molecular weight heparin (LMWH) in preventing symptomatic venous thromboembolism (VTE) following hip arthroplasty (HA) or knee arthroplasty (KA)." | 5.41 | CRISTAL (a cluster-randomised, crossover, non-inferiority trial of aspirin compared to low molecular weight heparin for venous thromboembolism prophylaxis in hip or knee arthroplasty, a registry nested study): statistical analysis plan. ( Ackerman, I; Adie, S; Bastiras, D; Buchbinder, R; Cashman, K; de Steiger, R; Graves, S; Harris, I; Kelly, TL; Lorimer, M; Naylor, J; Pratt, N; Sidhu, VS, 2021) |
| "The rate of pulmonary embolism was 0." | 5.37 | The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after hip replacement: a non-randomised comparison from information in the National Joint Registry. ( Charman, SC; Gregg, PJ; Jameson, SS; Reed, MR; van der Meulen, JH, 2011) |
| "Emerging evidence suggests aspirin may be an effective venous thromboembolism (VTE) prophylaxis for orthopaedic trauma patients, with fewer bleeding complications." | 5.34 | Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial. ( Castillo, RC; Haac, BE; Manson, TT; O'Hara, NN; O'Toole, RV; Slobogean, GP; Stein, DM, 2020) |
| "There has been significant debate in the surgical and medical communities regarding the appropriateness of using aspirin alone for venous thromboembolism (VTE) prophylaxis following total knee arthroplasty (TKA)." | 5.30 | Association of Aspirin With Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty Compared With Other Anticoagulants: A Noninferiority Analysis. ( Cowen, ME; Hallstrom, BR; Hood, BR; Hughes, RE; Singal, B; Zheng, HT, 2019) |
| "Routine thromboprophylaxis (TP) in newly-diagnosed multiple myeloma (NDMM) patients comprises either aspirin for standard risk patients or low molecular weight heparin for high risk patients." | 5.30 | What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feas ( Arya, R; Benjamin, R; Cornelius, V; Czuprynska, J; Patel, JP; Patel, RK; Roberts, LN; Sayar, Z, 2019) |
| "TRA2P-TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-Thrombolysis in Myocardial Infarction) (vorapaxar) and PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54) (ticagrelor) were blinded, randomized placebo-controlled trials of antiplatelet therapy for the prevention of ischemic events in stable patients with symptomatic atherosclerosis." | 5.27 | Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. ( Bhatt, DL; Bonaca, MP; Braunwald, E; Cavallari, I; Cohen, M; Creager, MA; Goodrich, EL; Morrow, DA; Olin, J; Piazza, G; Sabatine, MS; Scirica, BS; Steg, PG; Storey, RF, 2018) |
| "Orthopedic trauma patients are often treated with venous thromboembolism (VTE) chemoprophylaxis with aspirin or low molecular weight heparin (LMWH) after discharge from their index admission, but adherence patterns are not known." | 5.27 | Post-discharge adherence with venous thromboembolism prophylaxis after orthopedic trauma: Results from a randomized controlled trial of aspirin versus low molecular weight heparin. ( Berger, PZ; Connelly, D; Degani, Y; Haac, BE; Johal, H; Manson, TT; Marinos, D; Mascarenhas, D; O'Hara, NN; O'Toole, RV; Reahl, GB; Scalea, TM; Slobogean, GP; Stein, DM; Van Besien, R, 2018) |
| "Clinical trials and meta-analyses have suggested that aspirin may be effective for the prevention of venous thromboembolism (proximal deep-vein thrombosis or pulmonary embolism) after total hip or total knee arthroplasty, but comparisons with direct oral anticoagulants are lacking for prophylaxis beyond hospital discharge." | 5.27 | Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. ( Abianui, A; Anderson, DR; Andreou, P; Belzile, E; Bohm, E; Carrier, M; Coyle, D; Crowther, M; Dolan, S; Doucette, S; Dunbar, M; Fisher, W; Forsythe, M; Gofton, W; Gross, P; Kahn, SR; Kim, P; Kovacs, MJ; MacDonald, SJ; Murnaghan, J; Pelet, S; Pleasance, S; Rodger, MA; Theriault, C; Vendittoli, PA; Wells, PS; Zukor, D, 2018) |
| "Among patients with venous thromboembolism in equipoise for continued anticoagulation, the risk of a recurrent event was significantly lower with rivaroxaban at either a treatment dose (20 mg) or a prophylactic dose (10 mg) than with aspirin, without a significant increase in bleeding rates." | 5.24 | Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. ( Bauersachs, R; Berkowitz, SD; Beyer-Westendorf, J; Bounameaux, H; Brighton, TA; Cohen, AT; Davidson, BL; Decousus, H; Freitas, MCS; Haskell, L; Holberg, G; Kakkar, AK; Lensing, AWA; Pap, AF; Prandoni, P; Prins, MH; van Bellen, B; Verhamme, P; Weitz, JI; Wells, PS, 2017) |
| "Aspirin at 325 mg twice daily is now included as a nationally approved venous thromboembolism (VTE) prophylaxis protocol for low-risk total knee arthroplasty (TKA) patients." | 5.24 | Efficacy in Deep Vein Thrombosis Prevention With Extended Mechanical Compression Device Therapy and Prophylactic Aspirin Following Total Knee Arthroplasty: A Randomized Control Trial. ( Gregg, JL; Hussain, LR; Scheuerman, CM; Snyder, MA; Sympson, AN, 2017) |
| " The use of tranexamic acid to control surgical bleeding and aspirin for venous thromboembolism prophylaxis has gained popularity." | 5.22 | Closed Suction Drainage Has No Benefits in Anterior Hip Arthroplasty: A Prospective, Randomized Trial. ( Barksdale, LC; Calvo, C; McNamara, CA; Patel, PD; Suarez, JC; Szubski, CR, 2016) |
| "We evaluated the efficacy of low-molecular-weight heparin (LMWH) relative to aspirin in preventing early neurologic deterioration (END), venous thromboembolism (VTE), and outcomes at 6 months." | 5.19 | Low-molecular-weight heparin is more effective than aspirin in preventing early neurologic deterioration and improving six-month outcome. ( Chi, W; Lin, J; Wang, C; Yi, X; Zhang, B, 2014) |
| "An individual patient data analysis of these trials was planned, before their results were known, to assess the effect of aspirin versus placebo on recurrent VTE, major vascular events (recurrent VTE, myocardial infarction, stroke, and cardiovascular disease death) and bleeding, overall and within predefined subgroups." | 5.19 | Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. ( Agnelli, G; Becattini, C; Brighton, TA; Eikelboom, JW; Kirby, AC; Mister, R; Prandoni, P; Simes, J, 2014) |
| "To compare extended prophylaxis with aspirin and dalteparin for prevention of symptomatic venous thromboembolism (VTE) after THA." | 5.17 | Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. ( Anderson, DR; Andreou, P; Belzile, E; Bohm, ER; Carrier, M; Crowther, M; Davis, N; Dunbar, MJ; Fisher, W; Gofton, W; Gross, P; Kahn, SR; Kim, P; Kovacs, M; MacDonald, S; Pelet, S; Pleasance, S; Ramsay, T; Rodger, MA; Vendittoli, PA; Wells, P; Zukor, D, 2013) |
| "Rivaroxaban, a direct factor Xa inhibitor, has demonstrated effectiveness for the management of both venous and arterial thrombosis." | 5.17 | Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber. ( Becka, M; Gouya, G; Kapiotis, S; Kubitza, D; Mueck, W; Wolzt, M, 2013) |
| "Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism (VTE)." | 5.16 | Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. ( Beggiato, E; Boccadoro, M; Bringhen, S; Cafro, AM; Carella, AM; Catalano, L; Cavalli, M; Cavallo, F; Cavo, M; Corradini, P; Crippa, C; Di Raimondo, F; Di Toritto, TC; Evangelista, A; Falanga, A; Larocca, A; Nagler, A; Palumbo, A; Patriarca, F; Peccatori, J; Petrucci, MT; Pezzatti, S; Siniscalchi, A; Stanevsky, A; Yehuda, DB, 2012) |
| "Co-medication use with rivaroxaban or enoxaparin resulted in non-significant increases in bleeding events." | 5.16 | Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. ( Dahl, OE; Eriksson, BI; Friedman, RJ; Homering, M; Rosencher, N, 2012) |
| "Aspirin reduced the risk of recurrence when given to patients with unprovoked venous thromboembolism who had discontinued anticoagulant treatment, with no apparent increase in the risk of major bleeding." | 5.16 | Aspirin for preventing the recurrence of venous thromboembolism. ( Ageno, W; Agnelli, G; Becattini, C; Bianchi, M; Bucherini, E; Eichinger, S; Grandone, E; Moia, M; Prandoni, P; Schenone, A; Silingardi, M; Vandelli, MR, 2012) |
| "We randomly assigned 822 patients who had completed initial anticoagulant therapy after a first episode of unprovoked venous thromboembolism to receive aspirin, at a dose of 100 mg daily, or placebo for up to 4 years." | 5.16 | Low-dose aspirin for preventing recurrent venous thromboembolism. ( Brighton, TA; Diaz, R; Eikelboom, JW; Gallus, A; Gibbs, H; Hague, W; Kirby, A; Mann, K; Mister, R; Ockelford, P; Simes, J; Xavier, D, 2012) |
| "The study reports higher risks of venous thromboembolism, pulmonary embolism, and overall mortality for the patients receiving aspirin before undergoing." | 5.12 | Comparison between use of direct oral anticoagulants and aspirin for risk of thromboembolism complications in patients undergoing total knee and hip arthroplasty: a systematic review and meta-analysis. ( Cai, JY; Cao, YQ; Cui, CM; Min, JK; Zhang, LY, 2021) |
| "Aspirin is perceived to be non-inferior to enoxaparin, a low-molecular-weight heparin, for the prevention of venous thromboembolism (VTE) following elective arthroplasty of the hip or knee and is recommended in clinical guidelines internationally." | 5.12 | Aspirin versus enoxaparin for the initial prevention of venous thromboembolism following elective arthroplasty of the hip or knee: A systematic review and meta-analysis. ( An, VVG; Farey, JE; Harris, IA; Karunaratne, S; Sidhu, V, 2021) |
| "To evaluates the efficacy and safety of rivaroxaban versus aspirin in prevention of venous thromboembolism (VTE) following total hip (THA) or knee arthroplasty (TKA) or hip fracture surgery." | 5.12 | Rivaroxaban versus aspirin in prevention of venous thromboembolism following total joint arthroplasty or hip fracture surgery: a meta-analysis. ( Dai, Z; Hu, B; Hu, M; Jiang, L; Tang, H; Yu, J, 2021) |
| "To study the efficacy and safety of aspirin in prophylaxis of venous thromboembolism (VTE) after total joint arthroplasty." | 5.12 | [Efficacy and safety of aspirin in prevention of venous thromboembolism after total joint arthroplasty]. ( Liu, Y; Song, F; Tian, H; Zhang, K, 2007) |
| "Literature on the efficacy and safety of enoxaparin for thromboembolism and thromboprophylaxis remains scanty, and therefore efficacy was not assessed; in terms of safety, when including other indications for enoxaparin in pregnancy, we found that enoxaparin was associated with significantly lower complications than aspirin." | 5.05 | Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis. ( Jacobson, B; Leisegang, R; Naidoo, P; Paek, D; Rambiritch, V; Sayre, T; Shan, J, 2020) |
| " There were no significant differences in symptomatic pulmonary embolism, symptomatic deep vein thrombosis, 90-day mortality, or major bleeding between patients receiving low-dose or high-dose aspirin." | 5.05 | Low-Dose Aspirin Is Adequate for Venous Thromboembolism Prevention Following Total Joint Arthroplasty: A Systematic Review. ( Azboy, I; Goswami, K; Groff, H; Parvizi, J; Vahedian, M, 2020) |
| " The computer-based searches combined terms and combinations of keywords related to the population (eg, hip replacement, knee replacement, hip arthroplasty, and knee arthroplasty), drug intervention (eg, aspirin, heparin, clexane, dabigatran, rivaroxaban, and warfarin), and outcome (eg, venous thromboembolism, deep vein thrombosis, pulmonary embolism, and bleeding) in humans." | 5.05 | Clinical Effectiveness and Safety of Aspirin for Venous Thromboembolism Prophylaxis After Total Hip and Knee Replacement: A Systematic Review and Meta-analysis of Randomized Clinical Trials. ( Blom, AW; Judge, A; Kunutsor, SK; Matharu, GS; Whitehouse, MR, 2020) |
| "A considerable proportion of patients with atrial fibrillation (AF) are still treated with aspirin despite current guidelines due to presumed favorable safety." | 5.05 | Bleeding risk comparison between direct oral anticoagulants at doses approved for atrial fibrillation and aspirin: systematic review, meta-analysis and meta-regression. ( Georgiopoulos, G; Korompoki, E; Leventis, I; Lip, GYH; Makaritsis, K; Milionis, H; Ntaios, G; Sagris, D; Vemmos, K, 2020) |
| "Focusing on the current state of the art, this article (a) describes recent advances in the understanding of the pathogenesis of venous thromboembolism (VTE), (b) discusses current approaches for the prevention, diagnosis and treatment of VTE, (c) outlines the role of aspirin for VTE prevention and treatment, and (d) highlights the unmet needs in VTE management and describes novel approaches to address them." | 5.05 | Recent advances in understanding, diagnosing and treating venous thrombosis. ( Chan, NC; Weitz, JI, 2020) |
| " The use of aspirin has been implicated in reducing VTE events and is potentially advantageous compared to other agents in respect to cost, access, route of administration and reduced adverse effects such as bleeding." | 5.01 | Aspirin for prevention of venous thromboembolism in recipients of major lower-limb orthopedic surgery: a systematic review of Level I evidence. ( Fletcher, JP; Hitos, K; Seagrave, KG, 2019) |
| "To evaluate efficacy and safety of oral anticoagulant regimens and aspirin for extended venous thromboembolism (VTE) treatment." | 5.01 | Extended treatment of venous thromboembolism: a systematic review and network meta-analysis. ( Büller, HR; Cameron, C; Carrier, M; Castellucci, LA; van Es, N; Wang, KL, 2019) |
| ": Rivaroxaban, a direct oral anticoagulant, is widely used for the treatment of venous thromboembolism (VTE) in adult patients." | 5.01 | Rivaroxaban and the EINSTEIN clinical trial programme. ( Bauersachs, R; Cohen, AT, 2019) |
| " This article evaluates the preventive effects of rivaroxaban versus aspirin on venous thromboembolism (VTE) through meta-analysis of recent randomized controlled trials (RCTs)." | 5.01 | Rivaroxaban versus Aspirin in Prevention of Venous Thromboembolism: A Meta-Analysis of 9 Randomized Controlled Trials comprising 7,656 Patients. ( Deng, H; Jiang, M; Li, L; Lin, Y; Xie, J; Xie, X, 2019) |
| "LMWH increased the risk of surgical site bleeding compared with control, warfarin." | 4.95 | Low-Molecular-Weight Heparin and the Relative Risk of Surgical Site Bleeding Complications: Results of a Systematic Review and Meta-Analysis of Randomized Controlled Trials of Venous Thromboprophylaxis in Patients After Total Joint Arthroplasty. ( Churilov, L; Hardidge, AJ; Suen, K; Westh, RN, 2017) |
| " The cluster ranking of major outcomes indicated that FXI-ASO, ardeparin, aspirin, and apixaban were ideal for preventing all-cause VTE and avoiding all bleeding events." | 4.95 | Effectiveness and Tolerability of Anticoagulants for Thromboprophylaxis after Major Joint Surgery: a Network Meta-Analysis. ( Chen, X; Jin, Y; Wang, Z; Xiang, Y; Zhao, Y; Zheng, J, 2017) |
| "Studies have consistently demonstrated the need for venous thromboembolism (VTE) prophylaxis in patients with newly diagnosed multiple myeloma (NDMM) or relapsed refractory multiple myeloma (RRMM), receiving lenalidomide-based therapy." | 4.93 | Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review. ( Al-Ani, F; Bermejo, JM; Louzada, M; Mateos, MV, 2016) |
| "Aspirin, both alone and in multimodal approaches to thromboprophylaxis, confers a low rate of VTE, with a low risk of major bleeding complications." | 4.93 | Aspirin as Thromboprophylaxis in Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis. ( An, VV; Bruce, WJ; Levy, YD; Phan, K, 2016) |
| "To compare venous thromboembolism (VTE) and bleeding rates in adult patients receiving aspirin versus anticoagulants after major lower extremity orthopedic surgery." | 4.90 | Aspirin versus anticoagulation for prevention of venous thromboembolism major lower extremity orthopedic surgery: a systematic review and meta-analysis. ( Chiang, WH; Drescher, FS; Larson, RJ; Lee, A; Morrison, DH; Sirovich, BE, 2014) |
| "While there is conclusive evidence that aspirin plays a role in reducing the risk of clinically relevant venous thromboembolism (VTE) arising in a number of surgical and non-surgical situations at risk, little is known of the potential of aspirin for the long/term prevention of recurrent VTE." | 4.89 | Aspirin and recurrent venous thromboembolism. ( Milan, M; Noventa, F; Prandoni, P, 2013) |
| "To summarise and compare the efficacy and safety of various oral anticoagulants (dabigatran, rivaroxaban, apixaban, and vitamin K antagonists) and antiplatelet agents (acetylsalicylic acid) for the secondary prevention of venous thromboembolism." | 4.89 | Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. ( Cameron, C; Carrier, M; Castellucci, LA; Clifford, T; Coyle, D; Gandara, E; Le Gal, G; Rodger, MA; Wells, G; Wells, PS, 2013) |
| " The existence of a common pathophysiologic background is also suggested by the evidence that aspirin, low-molecular weight heparin (LMWH) and warfarin are recommended for the prevention and treatment of both venous and arterial thrombosis." | 4.88 | Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update. ( Ageno, W; Di Minno, G; Di Minno, MN; Prandoni, P; Tufano, A, 2012) |
| "Currently multiple antithrombotic agents are used for thalidomide thromboprophylaxis in multiple myeloma patients." | 4.88 | Thalidomide thromboprophylaxis in multiple myeloma: a review of current evidence. ( Alexander, M; Kirsa, S; Mellor, JD, 2012) |
| "In aspirin-treated patients with acute coronary syndromes without ST-segment elevation unfractionated heparin (UFH) or low molecular weight heparin (LMWH) treatment < 7 days significantly reduce the risk of acute myocardial infarction (AMI), and LMWH furthermore reduces revascularisation." | 4.86 | [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review]. ( Husted, SE; Nielsen, HK, 2010) |
| "The use of aspirin for venous thromboembolism (VTE) prophylaxis after major orthopaedic surgery is controversial." | 4.85 | Venous thromboembolism prophylaxis after major orthopaedic surgery: a pooled analysis of randomized controlled trials. ( Brown, GA, 2009) |
| " Clinical trials have demonstrated that patients with antiphospholipid antibodies and venous thromboembolism should be treated with vitamin K antagonists (warfarin); that ischemic stroke may be treated with aspirin or warfarin; and that women with recurrent pregnancy loss should receive prophylactic-dose heparin and aspirin." | 4.85 | Antiphospholipid antibody syndrome. ( Lim, W, 2009) |
| " The risk of VTE is higher in multiple myeloma (MM) patients who receive thalidomide or lenalidomide, especially in combination with dexamethasone or chemotherapy." | 4.84 | Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. ( Anderson, KC; Attal, M; Barlogie, B; Belch, A; Bladé, J; Boccadoro, M; Bringhen, S; Cavo, M; Dimopoulos, MA; Durie, BG; Harousseau, J; Hussein, MA; Joshua, D; Knop, S; Kyle, R; Lonial, S; Ludwig, H; Morgan, GJ; Niesvizky, R; Orlowski, RZ; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Shimizu, K; Sonneveld, P; Vesole, D; von Lilienfeld-Toal, M; Waage, A; Weber, D; Westin, J; Zangari, M; Zonder, JA, 2008) |
| "While there is good evidence for a protective effect of aspirin against occlusive vascular events in individuals with arterial disease, its role in preventing venous thromboembolism (VTE) is unclear." | 4.84 | Aspirin and other antiplatelet drugs in the prevention of venous thromboembolism. ( Chee, YL; Watson, HG, 2008) |
| " A tool for evaluating the risk of bleeding in patients with MN was proposed in the KDIGO 2021 guideline, and individuals with low risk of bleeding as well as high risk of VTE were suggested to use warfarin or low-molecular-weight heparin (LMWH) combined with aspirin, as an alternative regimen for warfarin." | 4.31 | Some Points for the KDIGO 2021 Guideline for Prophylactic Anticoagulation in Membranous Nephropathy: Is It Clear Enough for Us to Follow? ( Li, X; Shao, H; Wang, G; Xie, X; Zhang, X; Zhao, Y, 2023) |
| "Aspirin and enoxaparin are commonly used for venous thromboembolism (VTE) prophylaxis following total hip arthroplasty (THA) or total knee arthroplasty (TKA)." | 4.31 | Post-discharge patient-reported non-adherence to aspirin compared to enoxaparin for venous thromboembolism prophylaxis after hip or knee arthroplasty. ( Ackerman, I; Adie, S; Bastiras, D; Buchbinder, R; Harris, IA; Naylor, JM; Sidhu, V, 2023) |
| "While aspirin is acceptable for venous thromboembolism (VTE) prophylaxis following total joint arthroplasty in most patients, more potent agents are used in patients considered higher risk for VTE." | 4.31 | Comparison of 90-Day Adverse Events Associated With Aspirin and Potent Anticoagulation Use for Venous Thromboembolism Prophylaxis: A Cohort Study of 72,288 Total Knee and 35,142 Total Hip Arthroplasty Patients. ( Kroger, EW; Prentice, HA; Singh, G; Winston, BA, 2023) |
| "Rivaroxaban chemoprophylaxis following TKA and THA was associated with an increased risk of bleeding and prothrombotic complications compared to aspirin and enoxaparin." | 4.31 | Safety and Efficacy of Rivaroxaban in Primary Total Hip and Knee Arthroplasty. ( Christ, AB; Heckmann, ND; Kang, HP; Lieberman, JR; Mayfield, CK; Mills, ES; Piple, AS; Wang, JC, 2023) |
| "Aspirin may be effective at preventing venous thromboembolism following total knee arthroplasty (TKA) or total hip arthroplasty (THA)." | 4.31 | Aspirin for Venous Thromboembolic Prophylaxis Following Total Hip and Total Knee Arthroplasty: An Analysis of Safety and Efficacy Accounting for Surgeon Selection Bias. ( Christ, AB; Heckmann, ND; Lieberman, JR; Mayfield, CK; Oakes, DA; Piple, AS; Richardson, MK; Wang, JC, 2023) |
| " In this context, the effectiveness of the new direct oral anticoagulants in antiphospholipid syndrome is debated, as well as that of low-dose aspirin for primary thromboprophylaxis." | 4.31 | Controversies in the Management of Antiphospholipid Syndrome. ( Alba Moreyra, P; de Andrade, DCO; Erkan, D; Gómez-Puerta, JA; Jara, LJ; Pons-Estel, GJ; Porta, SV, 2023) |
| "Administration of aspirin for VTE prophylaxis, compared to other chemoprophylaxis agents may have an association with lower risk of major bleeding following TJA." | 4.12 | Aspirin Thromboprophylaxis Is Associated With Less Major Bleeding Events Following Total Joint Arthroplasty. ( Chisari, E; Goh, GS; Ludwick, L; Parvizi, J; Shohat, N; Streicher, S, 2022) |
| "Patient-reported allergies to aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) may preclude certain patients from receiving aspirin as venous thromboembolism (VTE) prophylaxis after total joint arthroplasty (TJA)." | 4.12 | Patients Who Do Not Receive Aspirin Because of Allergy Have an Increased Risk of Venous Thromboembolism Following Total Joint Arthroplasty. ( Goh, GS; Kozaily, E; Parvizi, J; Tan, TL, 2022) |
| "Aspirin has become the main agent for venous thromboembolism (VTE) prophylaxis following total knee arthroplasty (TKA)." | 4.12 | Aspirin Administered for Venous Thromboembolism Prophylaxis May Protect Against Stiffness Following Total Knee Arthroplasty. ( Chisari, E; Ludwick, L; Parvizi, J; Shohat, N; Sutton, R, 2022) |
| "The attitude and approach of orthopedic community for minimizing venous thromboembolism (VTE) has evolved over the last decade with the trend toward use of aspirin (and mechanical modalities) in lieu of aggressive anticoagulation." | 4.12 | Time to Venous Thromboembolism Events Following Total Hip Arthroplasty: A Comparison Between Aspirin and Warfarin. ( Goel, R; Ludwick, L; Parvizi, J; Shohat, N, 2022) |
| "(1) To assess the clinical utility of the adjusted global antiphospholipid syndrome score (aGAPSS) to predict new obstetric events during follow-up in primary obstetric antiphospholipid syndrome (POAPS) patients under standard-of-care treatment (SC) based on the use of low-dose aspirin (LDA) + heparin and (2) to study the risk of a first thrombotic event and to evaluate whether stratification according to this score could help to identify POAPS patients who would benefit from long-term thromboprophylaxis." | 4.12 | Clinical and therapeutic value of the adjusted Global Antiphospholipid Syndrome Score in primary obstetric antiphospholipid syndrome. ( Alijotas-Reig, J; Aranda, F; Belizna, C; de Larrañaga, G; Esteve-Valverde, E; Fernández-Romero, DS; Latino, JO; Peréz, SM; Udry, S; Wingeyer, SP, 2022) |
| "In recent years, aspirin has become a popular agent for venous thromboembolism (VTE) prophylaxis following total joint arthroplasty (TJA)." | 4.12 | Aspirin May Be a Suitable Prophylaxis for Patients with a History of Venous Thromboembolism Undergoing Total Joint Arthroplasty. ( Ledesma, J; Ludwick, L; Paladino, J; Parvizi, J; Shohat, N; Van Nest, D, 2022) |
| " The incidence of VTE and hematoma formation was evaluated and compared between patients who received aspirin versus enoxaparin or heparin." | 4.12 | Does Aspirin Provide Adequate Chemoprophylaxis for Venous Thromboembolic Events in Operative Pelvic and Acetabular Fractures? ( Du, JY; Metcalf, KB; Ochenjele, G, 2022) |
| "Aspirin as a venous thromboembolism (VTE) prophylactic agent has been shown to have antistaphylococcal and antibiofilm roles." | 4.12 | Low-Dose Aspirin for Venous Thromboembolism Prophylaxis is Associated With Lower Rates of Periprosthetic Joint Infection After Total Joint Arthroplasty. ( Bernthal, NM; Ciesielka, KA; Kendal, JK; Najafi, F; Parvizi, J; Peterson, NV; Restrepo, C, 2022) |
| "For some patients receiving warfarin, adding aspirin (acetylsalicylic acid) increases bleeding risk with unclear treatment benefit." | 4.12 | Assessment of an Intervention to Reduce Aspirin Prescribing for Patients Receiving Warfarin for Anticoagulation. ( Alexandris-Souphis, T; Ali, MA; Barnes, GD; Errickson, J; Froehlich, JB; Gu, X; Haymart, B; Kaatz, S; Kline-Rogers, E; Kozlowski, JH; Krol, GD; Schaefer, JK; Shah, V; Sood, SL, 2022) |
| "The primary aim was to assess the incidence of venous thromboembolism (VTE) following total hip replacements (THR) in a low-risk patient group when using 150 mg aspirin as the pharmacological component of VTE prophylaxis on discharge." | 4.12 | Incidence and risk factors associated with venous thromboembolism following primary total hip arthroplasty in low-risk patients when using aspirin for prophylaxis. ( Clement, ND; Howard, TA; Judd, CS; Lambert, RJ; Snowden, GT, 2022) |
| "Background Increasing evidence for the use of the aspirin in patients undergoing an orthopaedic surgery for venous thromboembolism prophylaxis has led to a change in the national guidelines substituting anticoagulants with aspirin." | 4.02 | Venous thromboembolism prophylaxis in patients undergoing knee replacements: comparison of real-world outcomes. ( Ahmed, N; Dawoud, D; Hasan, SS; Sunter, W; Zaidi, STR, 2021) |
| " The purpose of this study is to examine if aspirin (ASA), when used as venous thromboembolism (VTE) prophylaxis, influenced the rate of HO formation following TJA." | 4.02 | Low-Dose Aspirin Administered for Venous Thromboembolism Prophylaxis Reduces the Incidence of Heterotopic Ossification in Total Joint Arthroplasty. ( Chisari, E; Clarkson, S; Parvizi, J; Sherman, MB; Van Nest, DS, 2021) |
| "Uncertainty remains surrounding the use of aspirin as a sole chemoprophylactic agent to reduce the risk of venous thromboembolism (deep vein thrombosis or pulmonary embolism) and bleeding after primary total hip arthroplasty." | 4.02 | Non-Inferiority of Aspirin for Venous Thromboembolism Prophylaxis After Hip Arthroplasty in a Statewide Registry. ( Cowen, ME; Hallstrom, BR; Hughes, RE; Muscatelli, SR; Zheng, H, 2021) |
| "Consensus on whether low-dose (81 mg) or regular-dose (325 mg) aspirin (ASA) is more effective for venous thromboembolism (VTE) chemoprophylaxis in primary total joint arthroplasties (TJAs) is not reached." | 4.02 | Low-Dose vs Regular-Dose Aspirin for Venous Thromboembolism Prophylaxis in Primary Total Joint Arthroplasty. ( Abdel, MP; Mabry, TM; Perry, KI; Siljander, MP; Taunton, MJ; Uvodich, ME, 2021) |
| "Previous studies have shown that aspirin is noninferior to other anticoagulation therapies in preventing postoperative venous thromboembolism following lower extremity arthroplasty or revision; however, its optimal dosing for this indication is less clear." | 4.02 | A Retrospective Analysis Comparing Post-Operative Bleeding with Various Doses of Aspirin after Lower Extremity Joint Arthroplasty or Revision. ( Cornett, B; Dziadkowiec, O; Harkness, W; Hassan, S; Hicks, ME; Jenkins, P; Kopstein, M; Scherbak, D; Watts, PJ, 2021) |
| "The optimal length of aspirin prophylaxis to minimize venous thromboembolism (VTE) following total knee arthroplasty (TKA) remains unknown." | 4.02 | Thirty Days of Aspirin for Venous Thromboembolism Prophylaxis Is Adequate Following Total Knee Arthroplasty, Regardless of the Dose Used. ( Goel, R; Ledesma, J; Ludwick, L; Parvizi, J; Shohat, N; Streicher, S, 2021) |
| " The purpose of this study is to evaluate a weight-based aspirin dosing regimen for prevention of venous thromboembolism (VTE) following TJA." | 4.02 | Weight-Based Aspirin Dosing May Further Reduce the Incidence of Venous Thromboembolism Following Primary Total Joint Arthroplasty. ( Brown, TS; Gulbrandsen, TR; Halbur, CR; Noiseux, NO; West, CR, 2021) |
| "Among older patients with cancer, aspirin was associated with lower VTE incidence and overall inhospital mortality without significantly increased bleeding." | 3.96 | Aspirin Is Associated With Reduced Rates of Venous Thromboembolism in Older Patients With Cancer. ( Cai, P; Dixon, RAF; Hadley, M; Li, M; Li, P; Liu, EY; Liu, Q; Ning, Y; Pan, S; Siddiqui, AD; Wu, F, 2020) |
| "Few studies have compared aspirin with direct oral anticoagulants (DOACs) (DOACs = direct thrombin inhibitors and factor Xa inhibitors) for venous thromboembolism (VTE) prophylaxis after total hip arthroplasty (THA) and total knee arthroplasty (TKA)." | 3.96 | Is Aspirin as Effective as the Newer Direct Oral Anticoagulants for Venous Thromboembolism Prophylaxis After Total Hip and Knee Arthroplasty? An Analysis From the National Joint Registry for England, Wales, Northern Ireland, and the Isle of Man. ( Garriga, C; Judge, A; Matharu, GS; Rangan, A; Whitehouse, MR, 2020) |
| " The aim of this study is to identify the rates of PWD among THA and TKA patients who received aspirin (ASA) or Coumadin for postoperative venous thromboembolism (VTE) prophylaxis." | 3.96 | Persistent Wound Drainage among Total Joint Arthroplasty Patients Receiving Aspirin vs Coumadin. ( Oliashirazi, A; Saleh, U; Shahi, A; Singh, V; Tarabichi, S, 2020) |
| "The purpose of this meta-analysis is to compare the efficacy and safety of aspirin and rivaroxaban in the prevention of venous thromboembolism (VTE) following either total knee arthroplasty or total hip arthroplasty." | 3.96 | Efficacy and safety of aspirin and rivaroxaban for venous thromboembolism prophylaxis after total hip or knee arthroplasty: A protocol for meta-analysis. ( Le, G; Luo, H; Tang, J; Xi, L; Yang, C; Zhang, M; Zhao, J, 2020) |
| "To determine using a simplified risk-stratified protocol to select candidates for aspirin therapy have similar death and postoperative complications as universal warfarin therapy in patients undergoing total joint replacement (TJR)." | 3.96 | Evaluation of a Simplified Risk Stratification Twice-Daily Aspirin Protocol for Venous Thromboembolism Prophylaxis After Total Joint Replacement. ( Adams, W; Davis, ES; Ng, C; Pinzur, MS; Zavala, S, 2020) |
| " Aspirin has been considered a safe and cost-effective prophylaxis for venous thromboembolism (VTE), and there have been some reports about the incidence of PTE (0%-0." | 3.96 | Clinical efficacy of risk-stratified prophylaxis with low-dose aspirin for the management of symptomatic venous thromboembolism after total hip arthroplasty. ( Hirakawa, K; Mihara, M; Nakura, N; Ochiai, S; Saito, A; Takayanagi, S; Tamaki, Y, 2020) |
| "Although several studies now support the use of aspirin for venous thromboembolism (VTE) prophylaxis in primary total hip arthroplasty (THA) and total knee arthroplasty (TKA), the optimal chemoprophylactic agent in revision THA and TKA is not clear." | 3.91 | Anticoagulation in Revision Total Joint Arthroplasty: A Retrospective Review of 1917 Cases. ( Batko, BD; Courtney, PM; Edmiston, TA; Hannon, CP; Levine, BR; Manista, GC; Sexton, AC, 2019) |
| "To compare the efficacy and safety of aspirin with rivaroxaban following treatment with enoxaparin for prevention of venous thromboembolism (VTE) after hip fracture surgery (HFS)." | 3.91 | Comparison of the Efficacy and Safety of Aspirin and Rivaroxaban Following Enoxaparin Treatment for Prevention of Venous Thromboembolism after Hip Fracture Surgery. ( Huang, Q; Shen, B; Si, HB; Xing, SX; Zeng, Y; Zhou, ZK, 2019) |
| "The incidence of overall venous thromboembolism (VTE) within 90-day postsurgery was significantly higher in the aspirin cohort than it was in the rivaroxaban cohorts." | 3.91 | Clinical outcomes and risk factors of thromboprophylaxis with rivaroxaban versus aspirin in patients undergoing hip arthroplasty in low-incidence population: A nationwide study in Korea. ( Choi, KS; Kang, J; Kim, HA; Lee, JY; Park, SH; Rhie, SJ, 2019) |
| "The use of aspirin as prophylaxis against venous thromboembolism (VTE) following total joint arthroplasty (TJA) has increased in popularity; however, the potential cardioprotective effects of aspirin when administered as VTE prophylaxis remain unknown." | 3.91 | The Use of Aspirin for Prophylaxis Against Venous Thromboembolism Decreases Mortality Following Primary Total Joint Arthroplasty. ( Goswami, K; Huang, RC; Parvizi, J; Rondon, AJ; Shohat, N; Tan, TL, 2019) |
| "Aspirin prophylaxis demonstrated a lower rate of deep vein thrombosis, pulmonary embolism, and venous thromboembolism than warfarin and low-molecular-weight heparin alone throughout all risk scores." | 3.91 | Potent Anticoagulation Does Not Reduce Venous Thromboembolism in High-Risk Patients. ( Chen, AF; Foltz, C; Hansen, EN; Higuera, C; Huang, R; Parvizi, J; Sing, DC; Siqueira, M; Tan, TL, 2019) |
| "The results of this study clearly show that aspirin, as part of a multimodal thromboprophylactic regime, is an effective and safe regime in preventing venous thromboembolism with respect to risk of deep vein thrombosis or pulmonary embolism when compared to LMWH." | 3.91 | Clinical Effectiveness of Aspirin as Multimodal Thromboprophylaxis in Primary Total Hip and Knee Arthroplasty: A Review of 6078 Cases. ( Best, AJ; Chatterji, U; Ghosh, A; Rudge, SJ, 2019) |
| "The risks of venous thromboembolism (VTE) and bleeding with direct oral anticoagulants (DOACs) and aspirin for thromboprophylaxis after orthopedic surgery were studied." | 3.91 | Direct oral anticoagulants versus aspirin for venous thromboembolism prophylaxis after orthopedic surgery. ( Muntz, J; Murillo, M; Putney, D; Vadhariya, A; Wilson, A; Yang, T, 2019) |
| "Although guidelines now allow the use of aspirin as an alternative to anticoagulants for venous thromboembolism prophylaxis after knee or hip arthroplasty, there is limited data on contemporary use and outcomes with aspirin." | 3.91 | Aspirin Compared with Anticoagulation to Prevent Venous Thromboembolism After Knee or Hip Arthroplasty: a Large Retrospective Cohort Study. ( Auerbach, AD; Baumgartner, C; Fang, MC; Maselli, J, 2019) |
| ": There is a good rationale for the use of aspirin in venous thromboembolism prophylaxis in some orthopaedic procedures, as already proposed by the 9th American College of Chest Physicians' guidelines (Grade 1C)." | 3.88 | European guidelines on perioperative venous thromboembolism prophylaxis: Aspirin. ( Jenny, JY; Pabinger, I; Samama, CM, 2018) |
| "The aims of this study were to compare the efficacy of two agents, aspirin and warfarin, for the prevention of venous thromboembolism (VTE) after simultaneous bilateral total knee arthroplasty (SBTKA), and to elucidate the risk of VTE conferred by this procedure compared with unilateral TKA (UTKA)." | 3.88 | Venous thromboembolic prophylaxis after simultaneous bilateral total knee arthroplasty: aspirin ( Fleischman, AN; Goel, R; Higuera, C; Huang, R; Parvizi, J; Rothman, RH; Sterbis, E; Tan, T, 2018) |
| " The risk of readmission resulting from bleeding and venous thromboembolism (VTE) has also not been determined for patients undergoing THA or TKA when treated with low-molecular-weight heparin (LMWH) alone compared with mechanical prophylaxis plus aspirin (ASA)." | 3.88 | Mobile Compression Reduces Bleeding-related Readmissions and Wound Complications After THA and TKA. ( Arsoy, D; Giori, NJ; Woolson, ST, 2018) |
| "Aspirin and unfractionated heparin (UH) are accepted options for venous thromboembolism (VTE) prophylaxis after total joint arthroplasty (TJA)." | 3.88 | The Role of Aspirin and Unfractionated Heparin Combination Therapy Immediately After Total Hip and Knee Arthroplasty. ( Karadsheh, MS; Koueiter, DM; Mells, A; Siljander, MP; Sobh, AH, 2018) |
| "Aspirin is an effective prophylaxis for venous thromboembolism (VTE) after total knee arthroplasty (TKA)." | 3.88 | Low-Dose Aspirin Is Safe and Effective for Venous Thromboembolism Prophylaxis Following Total Knee Arthroplasty. ( Barsoum, WK; Brigati, DP; Faour, M; Higuera, CA; Klika, AK; Mont, MA; Piuzzi, NS, 2018) |
| "Full- or lower-dose anticoagulant therapy or aspirin can be used for extended therapy in patients with venous thromboembolism (VTE), but information on their relative benefit-risk profiles is limited." | 3.88 | Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. ( Bauersachs, R; Beyer-Westendorf, J; Bounameaux, H; Cohen, AT; Davidson, BL; Gebel, M; Homering, M; Lensing, AWA; Levitan, B; Pap, AF; Prandoni, P; Prins, MH; van Bellen, B; Verhamme, P; Weitz, JI; Wells, PS; Yuan, Z, 2018) |
| "Using data from the Reduced-Dose Rivaroxaban in the Long-Term Prevention of Recurrent Symptomatic Venous Thromboembolism (EINSTEIN-CHOICE) trial, this study assessed cost impact of continued anticoagulation therapy with rivaroxaban vs aspirin." | 3.88 | Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population. ( Ashton, V; Beyer-Westendorf, J; Crivera, C; Haskell, L; Laliberté, F; Lefebvre, P; Lejeune, D; Lensing, AWA; Levitan, B; Prandoni, P; Prins, MH; Schein, J; Wells, PS; Xiao, Y; Yuan, Z; Zhao, Q, 2018) |
| "Recent guidelines include aspirin as an option to prevent venous thromboembolism (VTE) in selected patients undergoing hip or knee replacement surgery." | 3.85 | The risk of venous thromboembolism with aspirin compared to anticoagulants after hip and knee arthroplasty. ( Auerbach, AD; Chu, JN; Fang, MC; Maselli, J, 2017) |
| "There was no evidence that fondaparinux, enoxaparin, or warfarin were superior to aspirin in the prevention of pulmonary embolism, deep vein thrombosis, or venous thromboembolism or that aspirin was safer than these alternatives." | 3.85 | Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty. ( Bini, SA; Cafri, G; Cheetham, CT; Chen, Y; Gould, MK; Khatod, M; Paxton, EW; Sluggett, J, 2017) |
| "Aspirin is a safe and effective prophylaxis for the prevention of venous thromboembolism following total joint arthroplasty." | 3.85 | Low-Dose Aspirin Is Effective Chemoprophylaxis Against Clinically Important Venous Thromboembolism Following Total Joint Arthroplasty: A Preliminary Analysis. ( Austin, MS; Chen, AF; Hozack, WJ; Huang, R; Lonner, JH; Parvizi, J; Restrepo, C, 2017) |
| "ESSENTIALS: We audited venous thromboembolism (VTE) in Achilles injuries after the use of prophylactic aspirin." | 3.83 | Venous thromboembolism rates in patients with lower limb immobilization after Achilles tendon injury are unchanged after the introduction of prophylactic aspirin: audit. ( Beasley, R; Braithwaite, I; Dunbar, L; Eathorne, A; Weatherall, M, 2016) |
| "This study's purpose was to present our institution's experience with the use of a risk stratification protocol for venous thromboembolism (VTE) prophylaxis in joint arthroplasty in which "routine" risk patients receive a mobile compression device in conjunction with aspirin and "high"-risk patients receive warfarin for thromboprophylaxis." | 3.83 | The Effectiveness of a Risk Stratification Protocol for Thromboembolism Prophylaxis After Hip and Knee Arthroplasty. ( Barrack, RL; Clohisy, JC; Johnson, SR; Keeney, JA; Nam, D; Nunley, RM, 2016) |
| "2% of dabigatran-treated patients had renal insufficiency requiring a dose reduction." | 3.83 | Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. ( Barra, ME; Connors, JM; Fanikos, J; Goldhaber, SZ; Piazza, G; Sylvester, KW, 2016) |
| "01) the rate of transfusion, units of packed red blood cells, hemoglobin drop, and hematocrit drop compared to aspirin in both unilateral and bilateral TKA patients, without significantly decreasing venous thromboembolism events (aspirin: 3 pulmonary embolisms and 4 deep venous thrombosis; Lovenox: 3 pulmonary embolisms and 2 deep venous thrombosis)." | 3.83 | Rate of Transfusions After Total Knee Arthroplasty in Patients Receiving Lovenox or High-Dose Aspirin. ( Hall, KE; Nakasone, CK; Radzak, KN; Wages, JJ, 2016) |
| "This study aims to compare rates of venous thromboembolism (VTE), gastro-intestinal (GI) bleeding and mortality events, with use of new oral anticoagulants (NOAC) or low-molecular-weight heparins (LMWHs) compared with aspirin in patients undergoing total joint replacement." | 3.83 | Safety and efficacy of new oral anticoagulants and low-molecular-weight heparins compared with aspirin in patients undergoing total knee and hip replacements. ( Boonen, AE; Dagnelie, PC; de Vries, F; Emans, PJ; Lalmohamed, A; Nielen, JT; van den Bemt, BJ; van Staa, TP; Veldhorst-Janssen, N, 2016) |
| " This study's purpose was to assess if the addition of aspirin to MCDs improves venous thromboembolism (VTE) prevention following simultaneous bilateral TKA." | 3.81 | Mobile compression devices and aspirin for VTE prophylaxis following simultaneous bilateral total knee arthroplasty. ( Barrack, RL; Johnson, SR; Keeney, JA; Nam, D; Nunley, RM, 2015) |
| "Although recent guidelines suggest aspirin for venous thromboembolism (VTE) prophylaxis in low risk patients following total hip arthroplasty (THA) and total knee arthroplasty (TKA), there are no cost-effectiveness studies comparing aspirin and warfarin." | 3.81 | Cost-effective prophylaxis against venous thromboembolism after total joint arthroplasty: warfarin versus aspirin. ( Maltenfort, MG; Mostafavi Tabatabaee, R; Parvizi, J; Rasouli, MR, 2015) |
| "Interest in aspirin as an alternative strategy for venous thromboembolism prophylaxis after arthroplasty has grown, as studies have suggested improved clinical efficacy and lower complication rates with aspirin compared to warfarin." | 3.81 | Direct Costs of Aspirin versus Warfarin for Venous Thromboembolism Prophylaxis after Total Knee or Hip Arthroplasty. ( Gutowski, CJ; Lonner, JH; Parvizi, J; Purtill, JJ; Zmistowski, BM, 2015) |
| "The efficacy and safety of aspirin (ASA) for prevention of venous thromboembolism (VTE) following total joint arthroplasty (TJA) have been demonstrated." | 3.81 | Administration of Aspirin as a Prophylaxis Agent Against Venous Thromboembolism Results in Lower Incidence of Periprosthetic Joint Infection. ( Buckley, PS; Huang, R; Parvizi, J; Purtill, JJ; Scott, B, 2015) |
| "Combined anticoagulant and aspirin therapy is associated with increased bleeding risk in patients with atrial fibrillation, but the bleeding risk of combined use of anticoagulant and nonsteroidal anti-inflammatory drugs (NSAIDs) is poorly documented." | 3.80 | Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. ( Brighton, TA; Davidson, BL; Gebel, M; Lensing, AW; Lyons, RM; Prins, MH; Rehm, J; Verheijen, S, 2014) |
| "We used a Markov cohort model with health states of healthy after surgery, no postphlebitic syndrome after venous thromboembolism, postphlebitic syndrome after venous thromboembolism, and survival after intracranial hemorrhage to compare treatment with low-molecular-weight heparin or aspirin (160 mg) for fourteen days after total knee arthroplasty or total hip arthroplasty in patients with an age of fifty-five, sixty, sixty-five, seventy, seventy-five, eighty, or eighty-five years." | 3.79 | Cost-effectiveness of low-molecular-weight heparin compared with aspirin for prophylaxis against venous thromboembolism after total joint arthroplasty. ( Brown, GA; Schousboe, JT, 2013) |
| "Rather than extend oral anticoagulation therapy for patients at high risk for recurrence of venous thromboembolism, advise them to take an aspirin a day." | 3.78 | PURLs: a safer way to prevent VTE recurrence. ( Kaiseruddin, A; Oyola, S; Rao, G, 2012) |
| "In this relatively small, nonrandomized study comparing endovenous thermal ablation in patients with and without warfarin, no differences were found in periprocedural risk of major bleeding or closure rate of the treated venous segments." | 3.77 | Effect of anticoagulation on endothermal ablation of the great saphenous vein. ( Bay, C; Emrani, F; Mehdipour, M; Sharifi, J; Sharifi, M, 2011) |
| "The objectives of this study were to compare the risk of venous thromboembolism (VTE), bleeding, surgical site infection, and mortality in patients receiving aspirin or guideline-approved VTE prophylactic therapies (warfarin, low-molecular-weight heparins, synthetic pentasaccharides) in total knee arthroplasty (TKA)." | 3.76 | Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? ( Auerbach, AD; Bozic, KJ; Lindenauer, PK; Maselli, JH; Pekow, PS; Vail, TP, 2010) |
| " A scoring system for VTE risk in pregnant women was developed, each score being associated with a specific treatment: graduated elastic compression stockings, aspirin, prophylactic Low Molecular Weight Heparin (LMWH: variable durations), or adjusted-dose of LMWH through pregnancy and postpartum." | 3.76 | Use of the Delphi method to facilitate antithrombotics prescription during pregnancy. ( Chauleur, C; Decousus, H; Gris, JC; Laporte, S; Mismetti, P; Rancon, F; Varlet, MN, 2010) |
| "To determine whether arterial cardiovascular events, use of statins and low-dose aspirin were associated with the risk of venous thromboembolism." | 3.75 | Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. ( Baron, JA; Christensen, S; Horvath-Puho, E; Johnsen, SP; Prandoni, P; Søgaard, KK; Sørensen, HT; Thomsen, RW, 2009) |
| " This is a case of a 79-year-old female with newly diagnosed atrial fibrillation who was inappropriately started on aspirin for anticoagulation despite her high risk for stroke." | 3.75 | Prevention and treatment of cardioembolic stroke: a case study. ( Brophy, GM; Glick, JA, 2009) |
| "In a monocentric prospective study, patients with stage II-IV breast cancer, who underwent CVC insertion for continuous infusional chemotherapy, were assigned to receive low-dose aspirin (100 mg daily)." | 3.74 | Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter. ( Balduzzi, A; Cardillo, A; Colleoni, M; Curigliano, G; Dellapasqua, S; Ghisini, R; Goldhirsch, A; Lunghi, L; Orlando, L; Peruzzotti, G; Torrisi, R, 2007) |
| "Patients with multiple myeloma are at increased risk of vascular thromboembolic events (VTEs)." | 3.11 | Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study. ( Anderson, LD; Baljevic, M; Bartlett, JB; Chari, A; Cortoos, A; Costa, LJ; Efebera, YA; Holstein, SA; Kaufman, JL; Laubach, J; Lin, TS; Patel, S; Pei, H; Reeves, B; Richardson, PG; Rodriguez, C; Sborov, DW; Shah, N; Silbermann, R; Vermeulen, J; Voorhees, PM, 2022) |
| " The UNIVERSE Study evaluated the efficacy and safety of a novel liquid rivaroxaban formulation, using a body weight-adjusted dosing regimen, versus acetylsalicylic acid (ASA) in children post-Fontan." | 3.01 | Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study. ( Harris, KC; Jefferies, JL; Justino, H; Li, JS; Lu, W; McCrindle, BW; Michelson, AD; Miriam Pina, L; Nessel, K; Pablo Sandoval, J; Peluso, C; Suzana Horowitz, E; Van Bergen, AH, 2021) |
| "Aspirin has been shown to be effective at reducing rates of VTE." | 3.01 | Aspirin Thromboprophylaxis Following Primary Total Knee Arthroplasty Is Associated With a Lower Rate of Early Prosthetic Joint Infection Compared With Other Agents. ( Aggarwal, VK; Anil, U; Kirschner, N; Long, WJ; Lygrisse, KA; Schwarzkopf, R; Sicat, CS; Teo, GM, 2023) |
| "With unprovoked VTE, rates of recurrence in the 1173 patients given rivaroxaban, the 468 given aspirin, and the 243 given placebo were 2." | 2.87 | Risk of recurrent venous thromboembolism according to baseline risk factor profiles. ( Bauersachs, R; Beyer-Westendorf, J; Bounameaux, H; Brighton, TA; Cohen, AT; Davidson, BL; Decousus, H; Homering, M; Kakkar, AK; Lensing, AWA; Pap, AF; Prandoni, P; Prins, MH; Tamm, M; van Bellen, B; Verhamme, P; Weitz, JI; Wells, PS, 2018) |
| "Although venous thromboembolism is one of the leading causes of morbidity after knee arthroplasty, little data exist on the risk of deep venous thrombosis (DVT) after unicompartmental knee arthroplasty (UKA)." | 2.84 | Deep Venous Thrombosis Prophylaxis After Unicompartmental Knee Arthroplasty: A Prospective Study on the Safety of Aspirin. ( Boettner, F; Mayman, DJ; Pearle, AD; Schmidt-Braekling, T; Waldstein, W; Westrich, GH, 2017) |
| "Our primary outcomes were pulmonary embolism (PE), symptomatic DVT, asymptomatic DVT, and all-cause mortality." | 2.82 | Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy. ( Badariotti, G; Chahla, J; Perrotta, C; Ramos, J, 2022) |
| "However, more recently, the rate of deep vein thrombosis (DVT) has been reported to be approximately 10%." | 2.80 | Prevention of Venous Thromboembolism after Arthroscopic Knee Surgery in a Low-Risk Population with the Use of Aspirin. A Randomized Trial. ( Alaia, MJ; Garofolo, G; Jazrawi, LM; Kaye, ID; Martinez, A; Patel, DN; Strauss, EJ, 2015) |
| " The purpose of this study was to evaluate the role of aspirin combined with mechanical measures in the prevention of VTE after total knee arthroplasty (TKA)." | 2.79 | Aspirin combined with mechanical measures to prevent venous thromboembolism after total knee arthroplasty: a randomized controlled trial. ( Du, H; Jiang, Y; Liu, J; Zhou, Y, 2014) |
| "Venous thromboembolism is a common complication of patients with hematologic malignancies, due both to release of procoagulant factors by tumor cells and to external factors, such us drugs." | 2.72 | Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going? ( Chistolini, A; Fazio, F; Lapietra, G; Petrucci, MT; Serrao, A, 2021) |
| " Laboratory studies suggest that a twice-daily dosing regimen or evening intake may lead to more efficient platelet inhibition, and the potential clinical benefit of such strategies is currently being explored in ongoing clinical trials." | 2.72 | Contemporary Clinical Use of Aspirin: Mechanisms of Action, Current Concepts, Unresolved Questions, and Future Perspectives. ( Christiansen, M; Grove, EL; Hvas, AM, 2021) |
| "Tranexamic acid is a safe and effective treatment modality, and consideration should be given to use multiple doses and combine different modes of administration." | 2.66 | Controversial Topics in Total Knee Arthroplasty: A Five-Year Update (Part 2). ( Mastel, MS; van der Merwe, JM, 2020) |
| "Aspirin has long been an inexpensive cornerstone of arterial vascular disease therapy, but its role in the primary or secondary prophylaxis of VTE has been debated." | 2.66 | Does aspirin prevent venous thromboembolism? ( Diep, R; Garcia, D, 2020) |
| "Dabigatran was shown to be safer than vitamin K antagonists and similarly effective for the prevention of recurrent VTE." | 2.66 | Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study. ( Imberti, D; Mastroiacovo, D; Pomero, F, 2020) |
| " Regarding antithrombotic prophylaxis, data are lacking on DOAC use in general surgical patients, while DOACs appear to be more effective than and as safe as LMWHs in VTE prophylaxis for major orthopedic surgical patients." | 2.61 | Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism. ( Agnelli, G; Becattini, C; Franco, L; Giustozzi, M; Vedovati, MC, 2019) |
| "A symptomatic pulmonary embolism (PE) after total joint arthroplasty has been described as a "never event." | 2.55 | Pulmonary Embolism Rates Following Total Hip Arthroplasty With Prophylactic Anticoagulation: Some Pulmonary Emboli Cannot Be Avoided. ( Cheng, V; Cote, MP; Lieberman, JR, 2017) |
| "Venous thromboembolic disease (VTED) (deep venous thrombosis and pulmonary embolism) is a considerable source of morbidity and mortality following lower extremity total joint arthroplasty." | 2.52 | What's New in Venous Thromboembolic Prophylaxis Following Total Knee and Total Hip Arthroplasty? An Update. ( Cherian, JJ; Elmallah, RK; Jauregui, JJ; Mont, MA; Pierce, TP, 2015) |
| "Pregnancy is a specific state of heightened coagulability related to the increase in procoagulant agents and to the reduced fibrinolysis." | 2.50 | Anticoagulant therapy in pregnant patients with metabolic syndrome: a review. ( Kimber-Trojnar, Z; Leszczynska-Gorzelak, B; Mierzynski, R; Oleszczuk, J; Poniedzialek-Czajkowska, E, 2014) |
| "Hence active cancer and a history of cancer are both strongly related to VTE in medical (non-surgical) patients." | 2.46 | VTE prophylaxis for the medical patient: where do we stand? - a focus on cancer patients. ( Cohen, AT; Nandini, B; Ota, S; Wills, JO, 2010) |
| " The optimal drug therapies and dosing strategies for reducing VTE risk are not well defined for many clinical situations, despite the availability of evidence-based guidelines from authoritative sources." | 2.46 | Issues in assessing and reducing the risk for venous thromboembolism. ( Dager, WE, 2010) |
| "The diagnosis of multiple myeloma (MM) has been associated to an increased risk of venous thromboembolic events (VTE)." | 2.45 | Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. ( Dahdaleh, FS; Musallam, KM; Shamseddine, AI; Taher, AT, 2009) |
| "After the procedure, deep vein thrombosis (DVT) was a commonly diagnosed complication (3." | 1.91 | Incidence of venous thromboembolism in patients with peripheral arterial disease after endovascular intervention. ( Agala, C; Caruso, DM; Duchesneau, E; Farber, M; Kindell, DG; Marston, WA; Marulanda, K; McGinigle, KL, 2023) |
| "The Total Thrombus-formation Analysis System (T-TAS) was developed for the quantitative analysis of thrombus formation using microchips with thrombogenic surfaces." | 1.91 | Utility of the Total Thrombus-Formation Analysis System as a Tool for Evaluating Thrombogenicity and Monitoring Antithrombotic Therapy in Pediatric Fontan Patients. ( Ishii, M; Kaikita, K; Matsumoto, S; Matsuo, O; Miyamura, F; Morinaga, J; Nakamura, K; Tsujita, K, 2023) |
| "Aspirin duration was not associated with cardiovascular events, blood transfusion, graft thrombosis, graft dysfunction, rejection, or mortality." | 1.91 | Incidence of Thromboembolic Complications Following Kidney Transplantation with Short and Extended Aspirin Prophylaxis: A Retrospective Single-Center Study. ( Cho, Y; Gately, RP; Harfield, ME; Hawley, CM; Hegerty, K; Isbel, NM; Jegatheesan, DK; Johnson, DW; McCann, AB; Pegler, AH, 2023) |
| "The incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) after total joint arthroplasty (TJA) procedures are lower in Asian populations than in Caucasian populations." | 1.91 | Combination of enoxaparin and low-dose aspirin for thromboprophylaxis in selective patients after primary total joint arthroplasty in a Taiwanese population. ( Chang, WL; Chen, CF; Chen, WM; Chou, TA; Pai, FY; Tsai, SW; Wu, PK, 2023) |
| "A history of postoperative hemorrhage (OR 1." | 1.91 | Risk Factors for Thromboembolic and Bleeding Events in Patients After the Fontan Operation (Insights from the National Database of Health Insurance Claims of Japan). ( Fujii, T; Hosoi, M; Kise, H; Kogo, M; Miyahara, Y; Ohbayashi, M, 2023) |
| "Aspirin 81 mg was cost-effective if the initial symptomatic VTE rates decreased by an absolute risk reduction (ARR) of 0." | 1.72 | Cost-Effective Modeling of Thromboembolic Chemoprophylaxis for Total Ankle Arthroplasty. ( Aynardi, MC; Bonaddio, V; Kirchner, GJ; Koroneos, Z; Lorenz, FJ; Manto, KM; Martinazzi, BJ; Stauch, CM, 2022) |
| "Aspirin was cost-effective at all 3 rates if the initial rate decreased by 0." | 1.72 | Venous Thromboembolism Chemoprophylaxis in Knee Arthroscopy: A Break-Even Analysis of Cost. ( Bonaddio, V; Gallo, RA; Hines, S; Kim, RY; Kirchner, GJ; Lorenz, FJ; Martinazzi, BJ, 2022) |
| " The aim of this study was to determine whether a protocol of 81-mg aspirin (ASA) bis in die (BID) is safe and/or sufficient in preventing VTE in patients undergoing rTKAs versus 325-mg ASA BID." | 1.72 | Low-Dose Aspirin is Safe and Effective for Venous Thromboembolism Prevention in Patients Undergoing Revision Total Knee Arthroplasty: A Retrospective Cohort Study. ( Bosco, JA; Iorio, R; Schwarzkopf, R; Slover, JD; Tang, A; Waren, D; Zak, SG, 2022) |
| " The aim of this study is to determine if discontinued use of outpatient IPCDs is safe and does not increase the rate of VTE or any other related complications in patients following TKA." | 1.72 | Discontinued Use of Outpatient Portable Intermittent Pneumatic Compression Devices May Be Safe for Venous Thromboembolism Prophylaxis in Primary Total Knee Arthroplasty Using Low-Dose Aspirin. ( Lajam, C; Lygrisse, K; Macaulay, W; Meftah, M; Schwarzkopf, R; Slover, J; Tang, A; Zak, S, 2022) |
| "Rates of hemorrhage were similar for aspirin in combination with warfarin or direct-acting oral anticoagulants." | 1.72 | Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study. ( Colucci, PM; Grunwald, MR; Lessen, DS; Paranagama, D; Zwicker, JI, 2022) |
| "Among women with endometrial cancer, aspirin use exerted a modest effect on VTE prophylaxis, whereas statin use was associated with a decreased prevalence of VTE, especially in women with obesity and type II cancer, compared with those in non-users." | 1.72 | Effects of aspirin and statin use on venous thromboembolism prophylaxis and survival in patients with endometrial cancer. ( Klar, M; Matsuo, K; Matsuzaki, S; Miller, H; Takiuchi, T, 2022) |
| "ASA is safe for VTE prophylaxis after total joint arthroplasty in patients with history of GI issues and is not associated with an increased risk of postoperative GI bleeds." | 1.62 | Aspirin Is Safe for Venous Thromboembolism Prophylaxis for Patients With a History of Gastrointestinal Issues. ( Austin, MS; Grosso, MJ; Kozaily, E; Parvizi, J, 2021) |
| "Odds of venous thromboembolism were not statistically significant between all three study medications." | 1.62 | A retrospective analysis of bleeding risk with rivaroxaban, enoxaparin, and aspirin following total joint arthroplasty or revision. ( Cornett, B; Dziadkowiec, O; Harkness, W; Hassan, S; Hicks, ME; Kopstein, M; Scherbak, D; Watts, PJ, 2021) |
| "The aspirin group was older (73 ± 7." | 1.62 | No Increased Risk of Venous Thromboembolism in High-Risk Patients Continuing Their Dose of 75 mg Aspirin Compared to Healthier Patients Given Low-Molecular-Weight Heparin. ( Amlie, EJ; Hovik, O; Jenssen, KK, 2021) |
| " Concomitant administration of single-dose DS-1040 with multiple-dose aspirin, multiple-dose clopidogrel, or single-dose enoxaparin, consistent with clinically relevant dose regimens, was safe and well tolerated with no serious treatment-emergent adverse events (TEAEs), TEAEs leading to discontinuation, bleeding-related TEAEs, and no significant changes in coagulation parameters." | 1.56 | Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin. ( Dishy, V; Kobayashi, F; Kochan, J; Limsakun, T; McPhillips, P; Mendell, J; Orihashi, Y; Pav, J; Pizzagalli, F; Rambaran, C; Vandell, AG; Warren, V; Zhou, J, 2020) |
| "The current rates of deep vein thrombosis (DVT) and pulmonary embolism (PE) at our institution following hip or knee arthroplasty or hip fracture surgery are 1." | 1.56 | Incidence of venous thromboembolism after total hip, total knee and hip fracture surgery at Waitemata District Health Board following a peer-reviewed audit. ( Andrew, P; Farrington, B; Lawes, CM; Merriman, E; Millar, JS; Misur, P; Walker, M, 2020) |
| " The aim of this study is to determine whether a protocol of 81-mg aspirin (ASA) bis in die (BID) is safe and/or effective in preventing VTE in patients undergoing rTHAs vs 325-mg ASA BID." | 1.56 | Low-Dose Aspirin Is Safe and Effective for Venous Thromboembolism Prevention in Patients Undergoing Revision Total Hip Arthroplasty: A Retrospective Cohort Study. ( Bosco, J; Iorio, R; Schwarzkopf, R; Slover, J; Tang, A; Zak, S, 2020) |
| "Aspirin was administered to all patients once a day." | 1.56 | Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action. ( Frigieri, FC; Gianesello, L; Meconi, T; Pavoni, V; Pazzi, M; Stera, C, 2020) |
| "Incidence of postoperative deep venous thrombosis (DVT), pulmonary embolism (PE), bleeding-related complications, postoperative anaemia, and transfusion were identified at 2 weeks, 30 days, 6 weeks, and 90 days." | 1.56 | Venous thromboprophylaxis after total hip arthroplasty: aspirin, warfarin, enoxaparin, or factor Xa inhibitors? ( Amanatullah, DF; Bala, A; Burk, DR; Goodman, SB; Huddleston, JI; Maloney, WJ; Murasko, MJ, 2020) |
| "Geographic region, patient age, gender, deep vein thrombosis prophylaxis strategy, and complications were obtained." | 1.51 | Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates. ( Gottschalk, MB; Pour, AE; Roberson, JR; Runner, RP; Staley, CA, 2019) |
| "Aspirin has been shown to be a safe and cost-effective thromboprophylaxis agent with equivalent preventive efficacy to warfarin and fewer side-effects." | 1.51 | Aspirin Thromboprophylaxis Confers No Increased Risk for Aseptic Loosening Following Cementless Primary Hip Arthroplasty. ( Courtney, PM; Goswami, K; Rondon, AJ; Schlitt, PK; Shohat, N; Tan, TL; Yayac, M, 2019) |
| " Direct oral anticoagulants (DOACs): For long-term secondary prevention, a reduced dosing regimen of DOACs was found to be effective with a low bleeding risk." | 1.48 | [Prolonged Secondary Prevention After Venous Thromboembolism]. ( Bauersachs, R, 2018) |
| "Funded studies reported less pulmonary embolisms, fewer events of major bleeding, and significantly less 90-day mortality compared with nonfunded studies." | 1.48 | Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty. ( Azboy, I; Groff, H; Parvizi, J, 2018) |
| "The rate of postoperative complications has significantly increased annually only in HFS: VTE (P=0." | 1.46 | Trends of thromboprophylaxis and complications after major lower limb orthopaedic surgeries in Korea: National Health Insurance Claim Data. ( Ahn, H; Kim, S; Park, JH; Shin, SA; Won, CW, 2017) |
| "The incidence of symptomatic deep vein thrombosis and pulmonary embolism was evaluated." | 1.43 | Tranexamic Acid Can Be Administered to Arthroplasty Patients Who Receive Aspirin for Venous Thromboembolic Prophylaxis. ( Chen, AF; Heller, S; Parvizi, J; Secrist, E; Shahi, A, 2016) |
| "The rate of surgical site infection was similar between the aspirin group and the warfarin group (1." | 1.43 | Aspirin Can Be Used as Prophylaxis for Prevention of Venous Thromboembolism After Revision Hip and Knee Arthroplasty. ( Chen, AF; Deirmengian, GK; Heller, S; Maltenfort, M; Parvizi, J; Smith, EB, 2016) |
| " In conclusion, DOACs are effective and safe for the extended treatment of VTE, and may reduce the risk of all-cause mortality." | 1.43 | Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism. ( Benedetti, R; Fenoglio, L; Imberti, D; Pomero, F, 2016) |
| "Most hospitalized patients with active cancer require thromboprophylaxis throughout hospitalization." | 1.42 | Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. ( Arcelus, JI; Balaban, EP; Bohlke, K; Clarke, JM; Falanga, A; Flowers, CR; Francis, CW; Gates, LE; Kakkar, AK; Key, NS; Khorana, AA; Kuderer, NM; Lee, AY; Levine, MN; Liebman, HA; Lyman, GH; Somerfield, MR; Tempero, MA; Wong, SL, 2015) |
| "Aspirin was prescribed from discharge until 6 weeks following surgery." | 1.42 | Staged venous thromboemolic events prophylaxis with low-molecular-weight heparin followed by aspirin is safe and effective after arthroplasty. ( Asopa, V; Bauze, A; Cobain, W; Keene, G; Martin, D, 2015) |
| "Rivaroxaban has a higher incidence of bleeding complication and further clinical trials are required to be conducted to assess the safety of rivaroxaban in clinical." | 1.42 | [Case-control study on three antithrombotic agents for the prevention of venous thromboembolism after unilateral total knee arthroplasty]. ( Lu, JH; Lu, N; Miao, SG; Yang, Y; Zhang, XG, 2015) |
| "Aspirin use was associated with a marginally significant reduction in incidence of VTEs within 2 years of diagnosis, HR 0." | 1.40 | Statins, aspirin and risk of thromboembolic events in ovarian cancer patients. ( Lavie, O; Leviov, M; Rennert, G; Rennert, HS; Sagi, S; Shai, A, 2014) |
| "Among hematologic malignancies, multiple myeloma (MM) confers a high risk of developing such complications, with a VTE rate of nearly 10%." | 1.37 | Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. ( Brioli, A; Cavo, M; Pantani, L; Tacchetti, P; Zamagni, E; Zannetti, B, 2011) |
| "The rate of pulmonary embolism was 0." | 1.37 | The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after hip replacement: a non-randomised comparison from information in the National Joint Registry. ( Charman, SC; Gregg, PJ; Jameson, SS; Reed, MR; van der Meulen, JH, 2011) |
| "Aspirin was a viable alternative to LDUH, saving $123 compared with no prophylaxis." | 1.36 | Cost-effectiveness of prolonged thromboprophylaxis after cancer surgery. ( Bradley, CT; Brasel, KJ; Miller, JJ; Pappas, SG, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 23 (5.71) | 29.6817 |
| 2010's | 234 (58.06) | 24.3611 |
| 2020's | 146 (36.23) | 2.80 |
| Authors | Studies |
|---|---|
| McCrindle, BW | 2 |
| Michelson, AD | 1 |
| Van Bergen, AH | 1 |
| Suzana Horowitz, E | 1 |
| Pablo Sandoval, J | 1 |
| Justino, H | 1 |
| Harris, KC | 1 |
| Jefferies, JL | 1 |
| Miriam Pina, L | 1 |
| Peluso, C | 1 |
| Nessel, K | 1 |
| Lu, W | 1 |
| Li, JS | 1 |
| Shohat, N | 7 |
| Ludwick, L | 5 |
| Goh, GS | 2 |
| Streicher, S | 2 |
| Chisari, E | 3 |
| Parvizi, J | 26 |
| Louie, PK | 1 |
| Urakawa, H | 1 |
| Manzur, MK | 1 |
| Craig, CM | 1 |
| Qureshi, SA | 1 |
| Cai, JY | 1 |
| Cui, CM | 1 |
| Min, JK | 1 |
| Cao, YQ | 1 |
| Zhang, LY | 1 |
| Kozaily, E | 2 |
| Tan, TL | 4 |
| Sutton, R | 1 |
| Goel, R | 3 |
| Udry, S | 1 |
| Peréz, SM | 1 |
| Belizna, C | 1 |
| Aranda, F | 1 |
| Esteve-Valverde, E | 1 |
| Wingeyer, SP | 1 |
| Fernández-Romero, DS | 1 |
| Latino, JO | 1 |
| de Larrañaga, G | 1 |
| Alijotas-Reig, J | 1 |
| McLoughlin, J | 1 |
| Farrow, L | 1 |
| Ashcroft, GP | 1 |
| Kirchner, VA | 1 |
| O'Farrell, B | 1 |
| Imber, C | 1 |
| McCormack, L | 1 |
| Northup, PG | 1 |
| Song, GW | 1 |
| Spiro, M | 1 |
| Raptis, DA | 1 |
| Durand, F | 1 |
| Leeds, IL | 1 |
| Sklow, B | 1 |
| Gorgun, E | 1 |
| Liska, D | 1 |
| Lightner, AL | 1 |
| Hull, TL | 1 |
| Steele, SR | 1 |
| Holubar, SD | 1 |
| Jenny, JY | 2 |
| Didier, A | 1 |
| De Ladoucette, A | 1 |
| Bradbury, CA | 1 |
| Lawler, PR | 1 |
| Stanworth, SJ | 1 |
| McVerry, BJ | 1 |
| McQuilten, Z | 1 |
| Higgins, AM | 1 |
| Mouncey, PR | 1 |
| Al-Beidh, F | 1 |
| Rowan, KM | 1 |
| Berry, LR | 1 |
| Lorenzi, E | 1 |
| Zarychanski, R | 1 |
| Arabi, YM | 1 |
| Annane, D | 1 |
| Beane, A | 1 |
| van Bentum-Puijk, W | 1 |
| Bhimani, Z | 1 |
| Bihari, S | 1 |
| Bonten, MJM | 1 |
| Brunkhorst, FM | 1 |
| Buzgau, A | 1 |
| Buxton, M | 1 |
| Carrier, M | 5 |
| Cheng, AC | 1 |
| Cove, M | 1 |
| Detry, MA | 1 |
| Estcourt, LJ | 1 |
| Fitzgerald, M | 1 |
| Girard, TD | 1 |
| Goligher, EC | 1 |
| Goossens, H | 1 |
| Haniffa, R | 1 |
| Hills, T | 1 |
| Huang, DT | 1 |
| Horvat, CM | 1 |
| Hunt, BJ | 1 |
| Ichihara, N | 1 |
| Lamontagne, F | 1 |
| Leavis, HL | 1 |
| Linstrum, KM | 1 |
| Litton, E | 1 |
| Marshall, JC | 1 |
| McAuley, DF | 1 |
| McGlothlin, A | 1 |
| McGuinness, SP | 1 |
| Middeldorp, S | 2 |
| Montgomery, SK | 1 |
| Morpeth, SC | 1 |
| Murthy, S | 1 |
| Neal, MD | 1 |
| Nichol, AD | 1 |
| Parke, RL | 1 |
| Parker, JC | 1 |
| Reyes, LF | 1 |
| Saito, H | 1 |
| Santos, MS | 1 |
| Saunders, CT | 1 |
| Serpa-Neto, A | 1 |
| Seymour, CW | 1 |
| Shankar-Hari, M | 1 |
| Singh, V | 2 |
| Tolppa, T | 1 |
| Turgeon, AF | 1 |
| Turner, AM | 1 |
| van de Veerdonk, FL | 1 |
| Green, C | 1 |
| Lewis, RJ | 1 |
| Angus, DC | 1 |
| McArthur, CJ | 1 |
| Berry, S | 1 |
| Derde, LPG | 1 |
| Webb, SA | 1 |
| Gordon, AC | 1 |
| Van Nest, D | 1 |
| Paladino, J | 1 |
| Ledesma, J | 2 |
| Pogosova, N | 1 |
| Bosch, J | 1 |
| Bhatt, DL | 2 |
| Fox, KAA | 1 |
| Connolly, SJ | 1 |
| Alings, M | 1 |
| Verhamme, P | 5 |
| Muehlhofer, E | 2 |
| Shestakovska, O | 1 |
| Yusuf, S | 2 |
| Eikelboom, JW | 6 |
| Hess, CN | 1 |
| Szarek, M | 1 |
| Anand, SS | 1 |
| Bauersachs, RM | 1 |
| Patel, MR | 1 |
| Debus, ES | 1 |
| Nehler, MR | 1 |
| Capell, WH | 1 |
| Beckman, JA | 1 |
| Piazza, G | 3 |
| Henkin, S | 1 |
| Bura-Rivière, A | 1 |
| Lawall, H | 2 |
| Roztocil, K | 1 |
| Hsia, J | 1 |
| Berkowitz, SD | 2 |
| Haskell, LP | 1 |
| Bonaca, MP | 2 |
| Metcalf, KB | 1 |
| Du, JY | 1 |
| Ochenjele, G | 1 |
| Eman, A | 1 |
| Balaban, O | 1 |
| Süner, KÖ | 1 |
| Cırdı, Y | 1 |
| Şahin, F | 1 |
| Demir, G | 1 |
| Pekşen, Ö | 1 |
| Musmul, A | 1 |
| Erdem, AF | 1 |
| Najafi, F | 1 |
| Kendal, JK | 1 |
| Peterson, NV | 1 |
| Ciesielka, KA | 1 |
| Restrepo, C | 2 |
| Bernthal, NM | 1 |
| Zhang, Y | 1 |
| Song, Y | 1 |
| Xia, X | 1 |
| Wang, J | 1 |
| Qian, Y | 1 |
| Yuan, C | 1 |
| Mao, Y | 1 |
| Diao, F | 1 |
| Liu, J | 3 |
| Ma, X | 1 |
| Martinazzi, BJ | 2 |
| Kirchner, GJ | 2 |
| Stauch, CM | 1 |
| Lorenz, FJ | 2 |
| Manto, KM | 1 |
| Bonaddio, V | 2 |
| Koroneos, Z | 1 |
| Aynardi, MC | 1 |
| Li, X | 2 |
| Xie, X | 2 |
| Zhao, Y | 2 |
| Wang, G | 1 |
| Shao, H | 1 |
| Zhang, X | 1 |
| Hernigou, P | 1 |
| Perrotta, C | 1 |
| Chahla, J | 1 |
| Badariotti, G | 1 |
| Ramos, J | 1 |
| Sidhu, VS | 6 |
| Kelly, TL | 4 |
| Pratt, N | 3 |
| Graves, SE | 3 |
| Buchbinder, R | 5 |
| Adie, S | 7 |
| Cashman, K | 3 |
| Ackerman, I | 3 |
| Bastiras, D | 4 |
| Brighton, R | 2 |
| Burns, AWR | 2 |
| Chong, BH | 3 |
| Clavisi, O | 3 |
| Cripps, M | 3 |
| Dekkers, M | 2 |
| de Steiger, R | 3 |
| Dixon, M | 2 |
| Ellis, A | 2 |
| Griffith, EC | 3 |
| Hale, D | 2 |
| Hansen, A | 3 |
| Harris, A | 4 |
| Hau, R | 2 |
| Horsley, M | 3 |
| James, D | 2 |
| Khorshid, O | 2 |
| Kuo, L | 2 |
| Lewis, P | 1 |
| Lieu, D | 3 |
| Lorimer, M | 4 |
| MacDessi, S | 1 |
| McCombe, P | 2 |
| McDougall, C | 2 |
| Mulford, J | 2 |
| Naylor, JM | 5 |
| Page, RS | 2 |
| Radovanovic, J | 2 |
| Solomon, M | 2 |
| Sorial, R | 2 |
| Summersell, P | 2 |
| Tran, P | 2 |
| Walter, WL | 2 |
| Webb, S | 3 |
| Wilson, C | 2 |
| Wysocki, D | 2 |
| Harris, IA | 10 |
| Sborov, DW | 1 |
| Baljevic, M | 1 |
| Reeves, B | 1 |
| Laubach, J | 1 |
| Efebera, YA | 1 |
| Rodriguez, C | 1 |
| Costa, LJ | 1 |
| Chari, A | 1 |
| Silbermann, R | 1 |
| Holstein, SA | 1 |
| Anderson, LD | 1 |
| Kaufman, JL | 1 |
| Shah, N | 1 |
| Pei, H | 1 |
| Patel, S | 1 |
| Cortoos, A | 1 |
| Bartlett, JB | 1 |
| Vermeulen, J | 1 |
| Lin, TS | 1 |
| Voorhees, PM | 1 |
| Richardson, PG | 2 |
| Schaefer, JK | 2 |
| Errickson, J | 2 |
| Gu, X | 1 |
| Alexandris-Souphis, T | 2 |
| Ali, MA | 2 |
| Haymart, B | 2 |
| Kaatz, S | 2 |
| Kline-Rogers, E | 2 |
| Kozlowski, JH | 2 |
| Krol, GD | 2 |
| Shah, V | 1 |
| Sood, SL | 2 |
| Froehlich, JB | 2 |
| Barnes, GD | 2 |
| Gris, JC | 2 |
| Bourguignon, C | 1 |
| Bouvier, S | 1 |
| Nouvellon, É | 1 |
| Laurent, J | 1 |
| Perez-Martin, A | 1 |
| Mousty, È | 1 |
| Nikolaeva, MG | 1 |
| Khizroeva, J | 1 |
| Bitsadze, V | 1 |
| Makatsariya, A | 1 |
| Kindell, DG | 1 |
| Marulanda, K | 1 |
| Caruso, DM | 1 |
| Duchesneau, E | 1 |
| Agala, C | 1 |
| Farber, M | 1 |
| Marston, WA | 1 |
| McGinigle, KL | 1 |
| Dietz, MJ | 1 |
| Moushmoush, O | 1 |
| Frye, BM | 1 |
| Lindsey, BA | 1 |
| Murphy, TR | 1 |
| Klein, AE | 1 |
| Hines, S | 1 |
| Kim, RY | 1 |
| Gallo, RA | 1 |
| Whipple, MO | 3 |
| Engler, ID | 3 |
| Garcia, D | 3 |
| Matsuo, O | 1 |
| Ishii, M | 1 |
| Kaikita, K | 1 |
| Morinaga, J | 1 |
| Miyamura, F | 1 |
| Matsumoto, S | 1 |
| Tsujita, K | 1 |
| Nakamura, K | 1 |
| Maximiliano, CL | 1 |
| Jaime, GC | 1 |
| Erika, MH | 1 |
| Hsu, CH | 1 |
| Chen, CH | 1 |
| Hsu, NC | 1 |
| Hsu, CC | 1 |
| Hsu, CJ | 1 |
| Wei, JC | 1 |
| DeMik, DE | 1 |
| Mont, MA | 4 |
| Dunbar, M | 2 |
| Walker, R | 1 |
| Kim, RG | 1 |
| O'Toole, RV | 5 |
| Stein, DM | 5 |
| O'Hara, NN | 5 |
| Frey, KP | 2 |
| Taylor, TJ | 2 |
| Scharfstein, DO | 2 |
| Carlini, AR | 2 |
| Sudini, K | 2 |
| Degani, Y | 2 |
| Slobogean, GP | 4 |
| Haut, ER | 3 |
| Obremskey, W | 1 |
| Firoozabadi, R | 2 |
| Bosse, MJ | 2 |
| Goldhaber, SZ | 5 |
| Marvel, D | 2 |
| Castillo, RC | 3 |
| Costa, M | 1 |
| Sidhu, V | 4 |
| Lin, J | 2 |
| Lluri, G | 1 |
| Agarwal, AR | 1 |
| Das, A | 1 |
| Campbell, JC | 1 |
| Golladay, GJ | 1 |
| Thakkar, SC | 1 |
| Kulkarni, NS | 1 |
| Singh, G | 1 |
| Prentice, HA | 1 |
| Winston, BA | 1 |
| Kroger, EW | 1 |
| Piple, AS | 2 |
| Wang, JC | 2 |
| Kang, HP | 1 |
| Mills, ES | 1 |
| Mayfield, CK | 2 |
| Lieberman, JR | 5 |
| Christ, AB | 2 |
| Heckmann, ND | 2 |
| Stengel, D | 1 |
| Renkawitz, T | 1 |
| Anil, U | 1 |
| Kirschner, N | 1 |
| Teo, GM | 1 |
| Lygrisse, KA | 1 |
| Sicat, CS | 1 |
| Schwarzkopf, R | 4 |
| Aggarwal, VK | 1 |
| Long, WJ | 1 |
| Vergallo, R | 1 |
| Patrono, C | 1 |
| Richardson, MK | 1 |
| Oakes, DA | 1 |
| Sourmelis, S | 1 |
| Zagoreos, N | 1 |
| Wu, XD | 1 |
| Min, J | 1 |
| Yoshino, T | 1 |
| Yamada, Y | 1 |
| Tamura, Y | 1 |
| Ahuja, T | 1 |
| Green, D | 1 |
| van Twist, DJL | 1 |
| Luu, IHY | 1 |
| Ten Cate, H | 1 |
| Griffin, M | 1 |
| Lip, GYH | 2 |
| Rosenberg, K | 2 |
| Suarez Ferreira, SP | 1 |
| Hall, RP | 1 |
| Majumdar, M | 1 |
| Goudot, G | 1 |
| Jessula, S | 1 |
| Bellomo, T | 1 |
| Lee, I | 1 |
| Kukreja, N | 1 |
| Parmar, G | 1 |
| Boada, AE | 1 |
| Dua, A | 1 |
| Ackerman, IN | 2 |
| Lewis, PL | 1 |
| MacDessi, SJ | 1 |
| Pegler, AH | 1 |
| Hegerty, K | 1 |
| Gately, RP | 1 |
| Hawley, CM | 1 |
| Johnson, DW | 1 |
| Cho, Y | 1 |
| Jegatheesan, DK | 1 |
| McCann, AB | 1 |
| Harfield, ME | 1 |
| Isbel, NM | 1 |
| Poacher, AT | 1 |
| Hoskins, HC | 1 |
| Protty, MB | 1 |
| Pettit, R | 1 |
| Johansen, A | 1 |
| Ebell, MH | 1 |
| Porta, SV | 1 |
| de Andrade, DCO | 1 |
| Erkan, D | 1 |
| Gómez-Puerta, JA | 1 |
| Jara, LJ | 1 |
| Alba Moreyra, P | 1 |
| Pons-Estel, GJ | 1 |
| Badge, H | 1 |
| Churches, T | 1 |
| Maree Naylor, J | 1 |
| A Harris, I | 1 |
| Tsai, SW | 1 |
| Chang, WL | 1 |
| Pai, FY | 1 |
| Chou, TA | 1 |
| Chen, CF | 1 |
| Wu, PK | 1 |
| Chen, WM | 1 |
| Meng, J | 1 |
| Liu, W | 1 |
| Xiao, Y | 2 |
| Tang, H | 2 |
| Wu, Y | 1 |
| Gao, S | 1 |
| Santos, BC | 1 |
| Flumignan, RL | 1 |
| Civile, VT | 1 |
| Atallah, ÁN | 1 |
| Nakano, LC | 1 |
| Hosoi, M | 1 |
| Ohbayashi, M | 1 |
| Miyahara, Y | 1 |
| Fujii, T | 1 |
| Kise, H | 1 |
| Kogo, M | 1 |
| Liu, HZ | 1 |
| Liang, J | 2 |
| Hu, AX | 1 |
| Barrett, CD | 1 |
| Moore, HB | 1 |
| Moore, EE | 1 |
| Chandler, J | 1 |
| Sauaia, A | 1 |
| Rose, M | 1 |
| Pang, N | 1 |
| Conway, S | 1 |
| Simon, SJ | 1 |
| Patell, R | 1 |
| Zwicker, JI | 2 |
| Kazi, DS | 1 |
| Hollenbeck, BL | 1 |
| Misky, GJ | 1 |
| Lewis, S | 1 |
| Glen, J | 1 |
| Dawoud, D | 2 |
| Dias, S | 1 |
| Cobb, J | 1 |
| Griffin, X | 1 |
| Reed, M | 1 |
| Sharpin, C | 1 |
| Stansby, G | 1 |
| Barry, P | 1 |
| Samama, CM | 3 |
| Fan, KL | 1 |
| Black, CK | 1 |
| Abbate, O | 1 |
| Lu, K | 1 |
| Camden, RC | 1 |
| Evans, KK | 1 |
| Manista, GC | 1 |
| Batko, BD | 1 |
| Sexton, AC | 1 |
| Edmiston, TA | 1 |
| Courtney, PM | 2 |
| Hannon, CP | 1 |
| Levine, BR | 1 |
| Seagrave, KG | 1 |
| Fletcher, JP | 1 |
| Hitos, K | 1 |
| Chalayer, E | 1 |
| Teste, A | 1 |
| Guyotat, D | 1 |
| Elalamy, I | 1 |
| Leleu, X | 1 |
| Tardy, B | 1 |
| Huang, Q | 1 |
| Xing, SX | 1 |
| Zeng, Y | 1 |
| Si, HB | 1 |
| Zhou, ZK | 1 |
| Shen, B | 1 |
| Jacobson, B | 1 |
| Rambiritch, V | 1 |
| Paek, D | 1 |
| Sayre, T | 1 |
| Naidoo, P | 1 |
| Shan, J | 1 |
| Leisegang, R | 1 |
| Pratt, NL | 1 |
| de Steiger, RS | 1 |
| Anandan, D | 1 |
| O'Donohue, G | 1 |
| Azboy, I | 4 |
| Groff, H | 3 |
| Goswami, K | 3 |
| Vahedian, M | 1 |
| Pellegrini, VD | 3 |
| Eikelboom, J | 2 |
| McCollister Evarts, C | 1 |
| Franklin, PD | 1 |
| Iorio, R | 4 |
| Lambourne, CA | 1 |
| Magaziner, JS | 1 |
| Magder, LS | 1 |
| Murphy, RF | 1 |
| Williams, D | 1 |
| Hogue, GD | 1 |
| Spence, DD | 1 |
| Epps, H | 1 |
| Chambers, HG | 1 |
| Shore, BJ | 1 |
| Matharu, GS | 2 |
| Kunutsor, SK | 1 |
| Judge, A | 2 |
| Blom, AW | 2 |
| Whitehouse, MR | 3 |
| Limsakun, T | 1 |
| Dishy, V | 1 |
| Mendell, J | 1 |
| Pizzagalli, F | 1 |
| Pav, J | 1 |
| Kochan, J | 1 |
| Vandell, AG | 1 |
| Rambaran, C | 1 |
| Kobayashi, F | 1 |
| Orihashi, Y | 1 |
| Warren, V | 1 |
| McPhillips, P | 1 |
| Zhou, J | 1 |
| van der Merwe, JM | 1 |
| Mastel, MS | 1 |
| Millar, JS | 1 |
| Lawes, CM | 1 |
| Farrington, B | 1 |
| Andrew, P | 1 |
| Misur, P | 1 |
| Merriman, E | 1 |
| Walker, M | 1 |
| Parhofer, KG | 1 |
| Kubicek, P | 1 |
| Boughalem, E | 1 |
| Frere, C | 1 |
| Kang, G | 1 |
| Zhang, H | 1 |
| Ní Cheallaigh, S | 1 |
| Fleming, A | 1 |
| Dahly, D | 1 |
| Kehoe, E | 1 |
| O'Byrne, JM | 1 |
| McGrath, B | 1 |
| O'Connell, C | 1 |
| Sahm, LJ | 1 |
| Tang, A | 3 |
| Zak, S | 2 |
| Slover, J | 2 |
| Bosco, J | 2 |
| Dorr, LD | 1 |
| Li, P | 1 |
| Ning, Y | 1 |
| Li, M | 1 |
| Cai, P | 1 |
| Siddiqui, AD | 1 |
| Liu, EY | 1 |
| Hadley, M | 1 |
| Wu, F | 1 |
| Pan, S | 1 |
| Dixon, RAF | 1 |
| Liu, Q | 1 |
| Sagris, D | 1 |
| Leventis, I | 1 |
| Georgiopoulos, G | 1 |
| Korompoki, E | 1 |
| Makaritsis, K | 1 |
| Vemmos, K | 1 |
| Milionis, H | 1 |
| Ntaios, G | 1 |
| Ramlakhan, KP | 1 |
| Johnson, MR | 1 |
| Roos-Hesselink, JW | 1 |
| Garriga, C | 1 |
| Rangan, A | 1 |
| Gonzalez Della Valle, A | 1 |
| Shanaghan, KA | 1 |
| Nguyen, J | 1 |
| Memtsoudis, S | 1 |
| Sharrock, NE | 1 |
| Salvati, EA | 2 |
| Farey, JE | 1 |
| An, VVG | 1 |
| Karunaratne, S | 1 |
| Haac, BE | 3 |
| Manson, TT | 3 |
| Shahi, A | 2 |
| Saleh, U | 1 |
| Tarabichi, S | 1 |
| Oliashirazi, A | 1 |
| Santana, DC | 1 |
| Emara, AK | 1 |
| Orr, MN | 1 |
| Klika, AK | 3 |
| Higuera, CA | 3 |
| Krebs, VE | 1 |
| Molloy, RM | 1 |
| Piuzzi, NS | 3 |
| Zak, SG | 1 |
| Waren, D | 1 |
| Slover, JD | 1 |
| Bosco, JA | 1 |
| Qin, C | 1 |
| Qin, MM | 1 |
| Baker, H | 1 |
| Shi, LL | 1 |
| Strelzow, J | 1 |
| Athiviraham, A | 1 |
| Pavoni, V | 1 |
| Gianesello, L | 1 |
| Pazzi, M | 1 |
| Stera, C | 1 |
| Meconi, T | 1 |
| Frigieri, FC | 1 |
| van Oosterom, N | 1 |
| Barras, M | 1 |
| Bird, R | 1 |
| Nusem, I | 1 |
| Cottrell, N | 1 |
| Hasan, SS | 1 |
| Sunter, W | 1 |
| Ahmed, N | 1 |
| Zaidi, STR | 1 |
| Chan, NC | 2 |
| Weitz, JI | 6 |
| Hood, B | 1 |
| Springer, B | 1 |
| Odum, S | 1 |
| Curtin, BM | 1 |
| Lygrisse, K | 1 |
| Meftah, M | 1 |
| Lajam, C | 1 |
| Macaulay, W | 1 |
| Diep, R | 1 |
| Le, G | 1 |
| Yang, C | 1 |
| Zhang, M | 1 |
| Xi, L | 1 |
| Luo, H | 1 |
| Tang, J | 1 |
| Zhao, J | 1 |
| Ren, Y | 1 |
| Cao, SL | 1 |
| Li, Z | 1 |
| Luo, T | 1 |
| Feng, B | 2 |
| Weng, XS | 2 |
| Lapietra, G | 1 |
| Serrao, A | 1 |
| Fazio, F | 1 |
| Petrucci, MT | 2 |
| Chistolini, A | 1 |
| Osborne, J | 1 |
| Friedman, K | 1 |
| Runeckles, K | 1 |
| Choueiter, NF | 1 |
| Giglia, TM | 1 |
| Dallaire, F | 1 |
| Newburger, JW | 1 |
| Low, T | 1 |
| Mathew, M | 1 |
| Mackie, AS | 1 |
| Dahdah, N | 1 |
| Yetman, AT | 1 |
| Harahsheh, AS | 1 |
| Raghuveer, G | 1 |
| Norozi, K | 1 |
| Burns, JC | 1 |
| Jain, S | 1 |
| Mondal, T | 1 |
| Portman, MA | 1 |
| Szmuszkovicz, JR | 1 |
| Crean, A | 1 |
| Peng, HM | 1 |
| Chen, X | 2 |
| Wang, YO | 1 |
| Bian, YY | 1 |
| Wang, W | 1 |
| Qian, WW | 1 |
| Van Nest, DS | 1 |
| Clarkson, S | 1 |
| Sherman, MB | 1 |
| Kirsch, JM | 1 |
| Gutman, M | 1 |
| Patel, M | 1 |
| Rondon, A | 1 |
| Ramsey, ML | 1 |
| Abboud, JA | 1 |
| Williams, GR | 1 |
| Namdari, S | 1 |
| Hu, B | 1 |
| Jiang, L | 1 |
| Hu, M | 1 |
| Yu, J | 1 |
| Dai, Z | 1 |
| Muscatelli, SR | 1 |
| Zheng, H | 1 |
| Hughes, RE | 2 |
| Cowen, ME | 2 |
| Hallstrom, BR | 2 |
| Howard, TA | 1 |
| Judd, CS | 1 |
| Snowden, GT | 1 |
| Lambert, RJ | 1 |
| Clement, ND | 1 |
| Borton, ZM | 1 |
| Bhangoo, NS | 1 |
| Quah, CS | 1 |
| Stephen, AB | 1 |
| Howard, PW | 2 |
| Grosso, MJ | 1 |
| Austin, MS | 3 |
| Uvodich, ME | 1 |
| Siljander, MP | 2 |
| Taunton, MJ | 1 |
| Mabry, TM | 1 |
| Perry, KI | 1 |
| Abdel, MP | 1 |
| Bravo-Perez, C | 1 |
| Fernández-Caballero, M | 1 |
| Soler-Espejo, E | 1 |
| Garcia-Torralba, E | 1 |
| Sorigue, M | 1 |
| García-Malo, MD | 1 |
| Jerez, A | 1 |
| Vicente, V | 1 |
| Roldán, V | 1 |
| de Arriba, F | 1 |
| Mullins, CD | 1 |
| Wegener, ST | 1 |
| Seymour, RB | 1 |
| Holden, MB | 1 |
| Gitajn, IL | 1 |
| Eastman, AL | 1 |
| Jurkovich, GJ | 1 |
| Vallier, HA | 1 |
| Gary, JL | 1 |
| Kleweno, CP | 1 |
| Cuschieri, J | 1 |
| Li, Y | 1 |
| Kong, X | 1 |
| Decamillo, D | 1 |
| Shankar, SR | 1 |
| Watts, PJ | 2 |
| Kopstein, M | 2 |
| Harkness, W | 2 |
| Cornett, B | 2 |
| Dziadkowiec, O | 2 |
| Hicks, ME | 2 |
| Hassan, S | 2 |
| Scherbak, D | 2 |
| Jenkins, P | 1 |
| Omari, AM | 1 |
| Parcells, BW | 1 |
| Levine, HB | 1 |
| Seidenstein, A | 1 |
| Klein, GR | 1 |
| Dizon, K | 1 |
| Ng, PCK | 1 |
| Battistella, M | 1 |
| Christiansen, M | 1 |
| Grove, EL | 1 |
| Hvas, AM | 1 |
| Paranagama, D | 1 |
| Lessen, DS | 1 |
| Colucci, PM | 1 |
| Grunwald, MR | 1 |
| Hovik, O | 1 |
| Amlie, EJ | 1 |
| Jenssen, KK | 1 |
| Bahrani, S | 1 |
| Teimouri-Jervekani, Z | 1 |
| Sadeghi, M | 1 |
| Halbur, CR | 1 |
| Gulbrandsen, TR | 1 |
| West, CR | 1 |
| Brown, TS | 1 |
| Noiseux, NO | 1 |
| Piedra, K | 1 |
| Peterson, T | 1 |
| Tan, C | 1 |
| Orozco, J | 1 |
| Hultcrantz, M | 1 |
| Hassoun, H | 1 |
| Mailankody, S | 1 |
| Lesokhin, A | 1 |
| Shah, U | 1 |
| Lu, S | 1 |
| Patel, D | 1 |
| Derkach, A | 1 |
| Wilkins, CR | 1 |
| Korde, N | 1 |
| Graves, S | 1 |
| Naylor, J | 1 |
| Harris, I | 1 |
| Matsuzaki, S | 1 |
| Miller, H | 1 |
| Takiuchi, T | 1 |
| Klar, M | 1 |
| Matsuo, K | 2 |
| Johnson, SA | 1 |
| Jones, AE | 1 |
| Young, E | 1 |
| Jennings, C | 1 |
| Simon, K | 1 |
| Fleming, RP | 1 |
| Witt, DM | 1 |
| Lensing, AWA | 4 |
| Prins, MH | 5 |
| Bauersachs, R | 6 |
| Beyer-Westendorf, J | 5 |
| Bounameaux, H | 5 |
| Brighton, TA | 7 |
| Cohen, AT | 10 |
| Davidson, BL | 6 |
| Decousus, H | 4 |
| Freitas, MCS | 1 |
| Holberg, G | 2 |
| Kakkar, AK | 4 |
| Haskell, L | 3 |
| van Bellen, B | 4 |
| Pap, AF | 3 |
| Wells, PS | 7 |
| Prandoni, P | 12 |
| Huynh, K | 1 |
| Kim, S | 1 |
| Ahn, H | 1 |
| Shin, SA | 1 |
| Park, JH | 1 |
| Won, CW | 1 |
| Chu, JN | 1 |
| Maselli, J | 2 |
| Auerbach, AD | 3 |
| Fang, MC | 2 |
| Suen, K | 1 |
| Westh, RN | 1 |
| Churilov, L | 1 |
| Hardidge, AJ | 1 |
| Yhim, HY | 1 |
| Lee, J | 1 |
| Lee, JY | 2 |
| Lee, JO | 1 |
| Bang, SM | 1 |
| Bala, A | 2 |
| Huddleston, JI | 2 |
| Goodman, SB | 2 |
| Maloney, WJ | 2 |
| Amanatullah, DF | 2 |
| Ceylan, HH | 1 |
| Kucukdurmaz, F | 1 |
| Merli, G | 1 |
| Tuncay, I | 1 |
| Beverland, D | 2 |
| Bartlett, M | 1 |
| Mauck, KF | 1 |
| Bierle, DM | 1 |
| Saadiq, RA | 1 |
| Daniels, PR | 1 |
| Dunn, A | 2 |
| Cafri, G | 1 |
| Paxton, EW | 1 |
| Chen, Y | 1 |
| Cheetham, CT | 1 |
| Gould, MK | 1 |
| Sluggett, J | 1 |
| Bini, SA | 1 |
| Khatod, M | 1 |
| Steurer, J | 3 |
| Gordon, RJ | 2 |
| Lombard, FW | 1 |
| Whiting, DR | 1 |
| Iriye, BK | 1 |
| Gregory, KD | 1 |
| Saade, GR | 1 |
| Grobman, WA | 1 |
| Brown, HL | 1 |
| Wang, Z | 1 |
| Zheng, J | 1 |
| Xiang, Y | 1 |
| Jin, Y | 1 |
| Klok, FA | 1 |
| Huisman, MV | 1 |
| Agnelli, G | 5 |
| Becattini, C | 5 |
| Giustozzi, M | 2 |
| Imberti, D | 3 |
| Benedetti, R | 2 |
| Fontana, M | 1 |
| Chang, R | 1 |
| Scerbo, MH | 1 |
| Schmitt, KM | 1 |
| Adams, SD | 1 |
| Choi, TJ | 1 |
| Wade, CE | 1 |
| Holcomb, JB | 1 |
| Bichell, D | 1 |
| Raees, MA | 1 |
| Garfinkel, JH | 1 |
| Gladnick, BP | 1 |
| Roland, N | 1 |
| Romness, DW | 1 |
| Kaymaz, C | 1 |
| Cavallari, I | 1 |
| Morrow, DA | 1 |
| Creager, MA | 1 |
| Olin, J | 1 |
| Steg, PG | 1 |
| Storey, RF | 1 |
| Cohen, M | 1 |
| Scirica, BS | 1 |
| Goodrich, EL | 1 |
| Braunwald, E | 1 |
| Sabatine, MS | 1 |
| Barrack, R | 1 |
| Thomas, AM | 1 |
| Haddad, FS | 1 |
| Llau, JV | 1 |
| Kamphuisen, P | 1 |
| Albaladejo, P | 1 |
| Pabinger, I | 2 |
| Afshari, A | 1 |
| Ageno, W | 3 |
| Ahmed, A | 1 |
| Duranteau, J | 1 |
| Faraoni, D | 1 |
| Kozek-Langenecker, S | 1 |
| Llau, J | 1 |
| Nizard, J | 1 |
| Solca, M | 1 |
| Stensballe, J | 1 |
| Thienpont, E | 1 |
| Tsiridis, E | 1 |
| Venclauskas, L | 1 |
| Mendez, GM | 1 |
| Patel, YM | 1 |
| Ricketti, DA | 1 |
| Gaughan, JP | 1 |
| Lackman, RD | 1 |
| Kim, TWB | 1 |
| Damron, TA | 1 |
| Sultan, SM | 1 |
| Jackson, DS | 1 |
| Erhard, HA | 1 |
| Greenspun, DT | 1 |
| Benacquista, T | 1 |
| Garfein, ES | 1 |
| Weichman, KE | 1 |
| Robertson, L | 1 |
| Yeoh, SE | 1 |
| Ramli, A | 1 |
| Van Besien, R | 1 |
| Johal, H | 1 |
| Berger, PZ | 1 |
| Reahl, GB | 1 |
| Marinos, D | 1 |
| Mascarenhas, D | 1 |
| Connelly, D | 1 |
| Scalea, TM | 1 |
| Fleischman, AN | 1 |
| Tan, T | 1 |
| Sterbis, E | 1 |
| Huang, R | 4 |
| Higuera, C | 2 |
| Rothman, RH | 1 |
| Anderson, DR | 3 |
| Murnaghan, J | 1 |
| Kahn, SR | 3 |
| Gross, P | 2 |
| Forsythe, M | 1 |
| Pelet, S | 2 |
| Fisher, W | 2 |
| Belzile, E | 2 |
| Dolan, S | 1 |
| Crowther, M | 2 |
| Bohm, E | 1 |
| MacDonald, SJ | 1 |
| Gofton, W | 2 |
| Kim, P | 2 |
| Zukor, D | 2 |
| Pleasance, S | 2 |
| Andreou, P | 2 |
| Doucette, S | 1 |
| Theriault, C | 1 |
| Abianui, A | 1 |
| Kovacs, MJ | 1 |
| Rodger, MA | 3 |
| Coyle, D | 2 |
| Vendittoli, PA | 2 |
| Box, HN | 1 |
| Shahrestani, S | 1 |
| Huo, MH | 1 |
| Arsoy, D | 1 |
| Giori, NJ | 1 |
| Woolson, ST | 1 |
| Sobh, AH | 1 |
| Koueiter, DM | 1 |
| Mells, A | 1 |
| Karadsheh, MS | 1 |
| Homering, M | 3 |
| Tamm, M | 1 |
| Lippi, G | 1 |
| Cervellin, G | 1 |
| Faour, M | 2 |
| Brigati, DP | 2 |
| Barsoum, WK | 2 |
| De Stefano, V | 2 |
| Finazzi, G | 1 |
| Barbui, T | 1 |
| Cervi, A | 1 |
| Douketis, JD | 2 |
| Gebel, M | 2 |
| Yuan, Z | 2 |
| Levitan, B | 2 |
| Kahlenberg, CA | 1 |
| Richardson, SS | 2 |
| Schairer, WW | 2 |
| Sculco, PK | 2 |
| Laliberté, F | 1 |
| Ashton, V | 1 |
| Lejeune, D | 1 |
| Crivera, C | 1 |
| Lefebvre, P | 1 |
| Zhao, Q | 1 |
| Schein, J | 1 |
| Palareti, G | 2 |
| Poli, D | 1 |
| Hunt, LP | 1 |
| Ben-Shlomo, Y | 1 |
| Wang, KL | 1 |
| van Es, N | 1 |
| Cameron, C | 2 |
| Castellucci, LA | 2 |
| Büller, HR | 1 |
| Sterling, RS | 1 |
| Hood, BR | 1 |
| Zheng, HT | 1 |
| Singal, B | 1 |
| Zoppellaro, G | 1 |
| Veronese, N | 1 |
| Granziera, S | 3 |
| Gobbi, L | 1 |
| Stubbs, B | 1 |
| Ng, C | 1 |
| Zavala, S | 1 |
| Davis, ES | 1 |
| Adams, W | 1 |
| Pinzur, MS | 1 |
| Alyea, E | 1 |
| Gaston, T | 1 |
| Austin, LS | 1 |
| Wowkanech, C | 1 |
| Cypel, B | 1 |
| Pontes, M | 1 |
| Williams, G | 1 |
| Hom, MS | 1 |
| Yabuno, A | 1 |
| Shida, M | 1 |
| Kakuda, M | 1 |
| Adachi, S | 1 |
| Mandelbaum, RS | 1 |
| Ueda, Y | 1 |
| Hasegawa, K | 1 |
| Enomoto, T | 1 |
| Mikami, M | 1 |
| Roman, LD | 1 |
| Yuenyongviwat, V | 1 |
| Tuntarattanapong, P | 1 |
| Chuaychoosakoon, C | 1 |
| Iemsaengchairat, C | 1 |
| Iamthanaporn, K | 1 |
| Hongnaparak, T | 1 |
| Runner, RP | 1 |
| Gottschalk, MB | 1 |
| Staley, CA | 1 |
| Pour, AE | 1 |
| Roberson, JR | 1 |
| Bostrom, MP | 1 |
| Mirkazemi, C | 1 |
| Bereznicki, LR | 1 |
| Peterson, GM | 1 |
| Gnecchi-Ruscone, T | 1 |
| Restifo Pecorella, D | 1 |
| Hallstrom, B | 1 |
| Kim, HA | 1 |
| Park, SH | 1 |
| Kang, J | 1 |
| Choi, KS | 1 |
| Rhie, SJ | 1 |
| Rondon, AJ | 2 |
| Huang, RC | 2 |
| Herman, A | 1 |
| Mihara, M | 1 |
| Tamaki, Y | 1 |
| Nakura, N | 1 |
| Takayanagi, S | 1 |
| Saito, A | 1 |
| Ochiai, S | 1 |
| Hirakawa, K | 1 |
| Mai, V | 1 |
| Bertoletti, L | 1 |
| Cucherat, M | 1 |
| Jardel, S | 1 |
| Grange, C | 1 |
| Provencher, S | 1 |
| Lega, JC | 1 |
| Foltz, C | 1 |
| Chen, AF | 5 |
| Siqueira, M | 1 |
| Hansen, EN | 1 |
| Sing, DC | 1 |
| Ghosh, A | 1 |
| Best, AJ | 2 |
| Rudge, SJ | 1 |
| Chatterji, U | 1 |
| Nadi, S | 1 |
| Vreugdenburg, TD | 1 |
| Atukorale, Y | 1 |
| Ma, N | 1 |
| Maddern, G | 1 |
| Rovers, M | 1 |
| Murasko, MJ | 1 |
| Burk, DR | 1 |
| Yang, T | 1 |
| Murillo, M | 1 |
| Vadhariya, A | 1 |
| Wilson, A | 1 |
| Putney, D | 1 |
| Muntz, J | 1 |
| Alavinia, SM | 1 |
| Kumbhare, D | 1 |
| Franco, L | 1 |
| Vedovati, MC | 1 |
| Sayar, Z | 1 |
| Czuprynska, J | 1 |
| Patel, JP | 1 |
| Benjamin, R | 1 |
| Roberts, LN | 1 |
| Patel, RK | 1 |
| Cornelius, V | 1 |
| Arya, R | 1 |
| Pomero, F | 2 |
| Mastroiacovo, D | 1 |
| Tomkowski, WZ | 1 |
| Kerr, DL | 1 |
| Butler, S | 1 |
| Read, AC | 1 |
| Baumgartner, C | 1 |
| Zou, P | 1 |
| Li, H | 1 |
| Cai, J | 1 |
| Li, C | 1 |
| Chen, Z | 1 |
| Morris, MC | 1 |
| Kassam, F | 1 |
| Bercz, A | 1 |
| Beckmann, N | 1 |
| Schumacher, F | 1 |
| Gulbins, E | 1 |
| Makley, AT | 1 |
| Goodman, MD | 1 |
| Xie, J | 1 |
| Jiang, M | 1 |
| Lin, Y | 1 |
| Deng, H | 1 |
| Li, L | 1 |
| Yayac, M | 1 |
| Schlitt, PK | 1 |
| Simes, J | 3 |
| Čulić, V | 1 |
| Paraskevas, KI | 1 |
| Noventa, F | 2 |
| Milan, M | 3 |
| Schellong, S | 1 |
| Dunbar, MJ | 2 |
| Bohm, ER | 1 |
| MacDonald, S | 1 |
| Davis, N | 1 |
| Wells, P | 1 |
| Kovacs, M | 1 |
| Ramsay, T | 1 |
| Wolzt, M | 1 |
| Gouya, G | 1 |
| Kapiotis, S | 1 |
| Becka, M | 1 |
| Mueck, W | 1 |
| Kubitza, D | 1 |
| El-Daly, I | 1 |
| Reidy, J | 1 |
| Culpan, P | 1 |
| Bates, P | 1 |
| Schousboe, JT | 1 |
| Brown, GA | 2 |
| Yates, AJ | 1 |
| Kansal, AR | 1 |
| Zheng, Y | 1 |
| Pokora, T | 1 |
| Sorensen, SV | 1 |
| Le Gal, G | 2 |
| Clifford, T | 1 |
| Gandara, E | 1 |
| Wells, G | 1 |
| Steinberg, DI | 1 |
| Duerschmied, D | 1 |
| Nitschmann, S | 1 |
| Bode, C | 1 |
| Barbar, S | 1 |
| Vedovetto, V | 2 |
| Pesavento, R | 1 |
| Markun, S | 1 |
| Allan, GM | 1 |
| Banh, HL | 1 |
| Ference, J | 1 |
| Medjeral-Thomas, N | 1 |
| Ziaj, S | 1 |
| Condon, M | 1 |
| Galliford, J | 1 |
| Levy, J | 1 |
| Cairns, T | 1 |
| Griffith, M | 1 |
| Bloch, BV | 1 |
| Patel, V | 1 |
| Shai, A | 1 |
| Rennert, HS | 1 |
| Rennert, G | 1 |
| Sagi, S | 1 |
| Leviov, M | 1 |
| Lavie, O | 1 |
| Yi, X | 1 |
| Wang, C | 1 |
| Zhang, B | 1 |
| Chi, W | 1 |
| Mierzynski, R | 1 |
| Poniedzialek-Czajkowska, E | 1 |
| Kimber-Trojnar, Z | 1 |
| Leszczynska-Gorzelak, B | 1 |
| Oleszczuk, J | 1 |
| Verheijen, S | 1 |
| Lensing, AW | 2 |
| Lyons, RM | 1 |
| Rehm, J | 1 |
| Jiang, Y | 1 |
| Du, H | 1 |
| Zhou, Y | 1 |
| Oberacker, R | 1 |
| Zemmrich, C | 1 |
| Bramlage, P | 1 |
| Diehm, C | 1 |
| Schellong, SM | 1 |
| Drescher, FS | 1 |
| Sirovich, BE | 1 |
| Lee, A | 1 |
| Morrison, DH | 1 |
| Chiang, WH | 1 |
| Larson, RJ | 1 |
| Lussana, F | 1 |
| Squizzato, A | 1 |
| Permunian, ET | 1 |
| Cattaneo, M | 1 |
| Kirby, AC | 1 |
| Mister, R | 2 |
| Wakefield, TW | 1 |
| Obi, AT | 1 |
| Henke, PK | 1 |
| Torjesen, I | 1 |
| Undas, A | 1 |
| Brummel-Ziedins, K | 1 |
| Mann, KG | 1 |
| Barmparas, G | 1 |
| Jain, M | 1 |
| Mehrzadi, D | 1 |
| Melo, N | 1 |
| Chung, R | 1 |
| Bloom, M | 1 |
| Ley, EJ | 1 |
| Margulies, DR | 1 |
| Stiefelhagen, P | 1 |
| Rosendaal, FR | 1 |
| Reitsma, PH | 1 |
| Nam, D | 4 |
| Nunley, RM | 3 |
| Johnson, SR | 3 |
| Keeney, JA | 3 |
| Barrack, RL | 4 |
| Wu, C | 1 |
| Alotaibi, GS | 1 |
| Alsaleh, K | 1 |
| Linkins, LA | 1 |
| McMurtry, MS | 1 |
| Mostafavi Tabatabaee, R | 1 |
| Rasouli, MR | 1 |
| Maltenfort, MG | 1 |
| Imfeld, S | 1 |
| Markham, J | 1 |
| Lyman, GH | 1 |
| Bohlke, K | 1 |
| Khorana, AA | 1 |
| Kuderer, NM | 1 |
| Lee, AY | 1 |
| Arcelus, JI | 1 |
| Balaban, EP | 1 |
| Clarke, JM | 1 |
| Flowers, CR | 1 |
| Francis, CW | 1 |
| Gates, LE | 1 |
| Key, NS | 1 |
| Levine, MN | 1 |
| Liebman, HA | 1 |
| Tempero, MA | 1 |
| Wong, SL | 1 |
| Somerfield, MR | 1 |
| Falanga, A | 2 |
| Dalury, D | 1 |
| Lonner, J | 1 |
| Boonyawat, K | 1 |
| Crowther, MA | 1 |
| Sobieraj, DM | 1 |
| Coleman, CI | 1 |
| Pasupuleti, V | 1 |
| Deshpande, A | 1 |
| Kaw, R | 1 |
| Hernandez, AV | 1 |
| Kakkar, A | 1 |
| Prins, M | 1 |
| Asopa, V | 1 |
| Cobain, W | 1 |
| Martin, D | 1 |
| Keene, G | 1 |
| Bauze, A | 1 |
| Pierce, TP | 1 |
| Elmallah, RK | 1 |
| Jauregui, JJ | 1 |
| Cherian, JJ | 1 |
| Sahebally, SM | 1 |
| Healy, D | 1 |
| Walsh, SR | 1 |
| Gutowski, CJ | 1 |
| Zmistowski, BM | 1 |
| Lonner, JH | 3 |
| Purtill, JJ | 2 |
| Grandone, E | 3 |
| Villani, M | 1 |
| Tiscia, GL | 2 |
| Clohisy, JC | 2 |
| Buckley, PS | 1 |
| Scott, B | 1 |
| Yokoyama, K | 1 |
| Thompson, R | 1 |
| Thachil, J | 1 |
| Kaye, ID | 1 |
| Patel, DN | 1 |
| Strauss, EJ | 1 |
| Alaia, MJ | 1 |
| Garofolo, G | 1 |
| Martinez, A | 1 |
| Jazrawi, LM | 1 |
| Braithwaite, I | 1 |
| Dunbar, L | 1 |
| Eathorne, A | 1 |
| Weatherall, M | 1 |
| Beasley, R | 1 |
| Miao, SG | 1 |
| Zhang, XG | 1 |
| Lu, JH | 1 |
| Yang, Y | 1 |
| Lu, N | 2 |
| Borgdorff, P | 1 |
| Tangelder, GJ | 1 |
| Ogonda, L | 1 |
| Hill, J | 1 |
| Doran, E | 1 |
| Dennison, J | 1 |
| Stevenson, M | 1 |
| Al-Ani, F | 1 |
| Bermejo, JM | 1 |
| Mateos, MV | 1 |
| Louzada, M | 1 |
| Heller, S | 2 |
| Secrist, E | 1 |
| Suarez, JC | 1 |
| McNamara, CA | 1 |
| Barksdale, LC | 1 |
| Calvo, C | 1 |
| Szubski, CR | 1 |
| Patel, PD | 1 |
| Bonilla, GA | 1 |
| Bautista, MP | 1 |
| Odeh, K | 1 |
| Doran, J | 1 |
| Yu, S | 1 |
| Bolz, N | 1 |
| Hozack, WJ | 2 |
| Deirmengian, GK | 1 |
| Smith, EB | 1 |
| Maltenfort, M | 1 |
| Riaz, H | 1 |
| Alansari, SA | 1 |
| Khan, MS | 1 |
| Riaz, T | 1 |
| Raza, S | 1 |
| Luni, FK | 1 |
| Khan, AR | 1 |
| Riaz, IB | 1 |
| Krasuski, RA | 1 |
| An, VV | 1 |
| Phan, K | 1 |
| Levy, YD | 1 |
| Bruce, WJ | 1 |
| Barra, ME | 1 |
| Fanikos, J | 1 |
| Connors, JM | 1 |
| Sylvester, KW | 1 |
| Wilson, DG | 1 |
| Poole, WE | 1 |
| Chauhan, SK | 1 |
| Rogers, BA | 1 |
| Fenoglio, L | 1 |
| Radzak, KN | 1 |
| Wages, JJ | 1 |
| Hall, KE | 1 |
| Nakasone, CK | 1 |
| Nielen, JT | 1 |
| Dagnelie, PC | 1 |
| Emans, PJ | 1 |
| Veldhorst-Janssen, N | 1 |
| Lalmohamed, A | 1 |
| van Staa, TP | 1 |
| Boonen, AE | 1 |
| van den Bemt, BJ | 1 |
| de Vries, F | 1 |
| Kearon, C | 1 |
| Guyatt, G | 1 |
| Sessler, DI | 1 |
| Cook, D | 1 |
| Douketis, J | 1 |
| Patel, A | 1 |
| Kurz, A | 1 |
| Allard, R | 1 |
| Jones, PM | 1 |
| Dennis, RJ | 1 |
| Painter, TW | 1 |
| Bergese, SD | 1 |
| Leslie, K | 1 |
| Wijeysundera, DN | 1 |
| Balasubramanian, K | 1 |
| Duceppe, E | 1 |
| Miller, S | 1 |
| Diedericks, J | 1 |
| Devereaux, PJ | 1 |
| Cosmi, B | 1 |
| Shah, SS | 1 |
| Satin, AM | 1 |
| Mullen, JR | 1 |
| Merwin, S | 1 |
| Goldin, M | 1 |
| Sgaglione, NA | 1 |
| Schmidt-Braekling, T | 1 |
| Pearle, AD | 1 |
| Mayman, DJ | 1 |
| Westrich, GH | 1 |
| Waldstein, W | 1 |
| Boettner, F | 1 |
| Cheng, V | 1 |
| Cote, MP | 1 |
| Lim, W | 2 |
| Haynes, J | 1 |
| Shaw, JA | 1 |
| Snyder, MA | 1 |
| Sympson, AN | 1 |
| Scheuerman, CM | 1 |
| Gregg, JL | 1 |
| Hussain, LR | 1 |
| Kwak, HS | 1 |
| Cho, JH | 1 |
| Kim, JT | 1 |
| Yoo, JJ | 1 |
| Kim, HJ | 1 |
| Mackenzie, DG | 1 |
| Elders, A | 1 |
| Wild, S | 1 |
| Muir, R | 1 |
| Bates, SM | 1 |
| Greer, IA | 1 |
| Sofaer, S | 1 |
| Hirsh, J | 2 |
| Lacut, K | 3 |
| van der Maaten, J | 1 |
| Cornily, G | 1 |
| Mottier, D | 3 |
| Oger, E | 1 |
| Fishmann, A | 1 |
| Boyd, HS | 1 |
| Skrzypczak, J | 1 |
| Millar, JA | 1 |
| Musallam, KM | 1 |
| Dahdaleh, FS | 1 |
| Shamseddine, AI | 1 |
| Taher, AT | 1 |
| Pottier, P | 1 |
| Sørensen, HT | 1 |
| Horvath-Puho, E | 1 |
| Søgaard, KK | 1 |
| Christensen, S | 1 |
| Johnsen, SP | 1 |
| Thomsen, RW | 1 |
| Baron, JA | 1 |
| Barnes, CL | 1 |
| Lachiewicz, PF | 1 |
| Hanssen, AD | 1 |
| Clarke, HD | 1 |
| Grant, PJ | 1 |
| Brotman, DJ | 1 |
| Jaffer, AK | 1 |
| Bozic, KJ | 1 |
| Vail, TP | 1 |
| Pekow, PS | 1 |
| Maselli, JH | 1 |
| Lindenauer, PK | 1 |
| Bradley, CT | 1 |
| Brasel, KJ | 1 |
| Miller, JJ | 1 |
| Pappas, SG | 1 |
| Mathias, JM | 1 |
| Sobieraj-Teague, M | 1 |
| White, RH | 1 |
| Meehan, JP | 1 |
| Romano, PS | 1 |
| Chauleur, C | 2 |
| Laporte, S | 2 |
| Rancon, F | 1 |
| Varlet, MN | 2 |
| Mismetti, P | 2 |
| Glick, JA | 1 |
| Brophy, GM | 1 |
| Nandini, B | 1 |
| Wills, JO | 1 |
| Ota, S | 1 |
| Dager, WE | 1 |
| Duvernoy, CS | 1 |
| Yeo, AA | 1 |
| Wong, M | 1 |
| Cox, DA | 1 |
| Kim, HM | 1 |
| Tadros, R | 1 |
| Shakib, S | 1 |
| Patel, AR | 1 |
| Crist, MK | 1 |
| Nemitz, J | 1 |
| Mayerson, JL | 1 |
| Husted, SE | 1 |
| Nielsen, HK | 1 |
| Garcia, DA | 1 |
| Sharifi, M | 1 |
| Mehdipour, M | 1 |
| Bay, C | 1 |
| Emrani, F | 1 |
| Sharifi, J | 1 |
| Anderson, FA | 2 |
| Tapson, VF | 1 |
| Bergmann, JF | 1 |
| Deslandes, B | 1 |
| Huang, W | 2 |
| Zamagni, E | 1 |
| Brioli, A | 1 |
| Tacchetti, P | 1 |
| Zannetti, B | 1 |
| Pantani, L | 1 |
| Cavo, M | 3 |
| Di Minno, MN | 1 |
| Tufano, A | 1 |
| Di Minno, G | 1 |
| Molnar, RB | 1 |
| Jenkin, DE | 1 |
| Millar, MJ | 1 |
| Campbell, D | 1 |
| Khemasuwan, D | 1 |
| Chae, YK | 1 |
| Gupta, S | 1 |
| Carpio, A | 1 |
| Yun, JH | 1 |
| Neagu, S | 1 |
| Lucca, AB | 1 |
| Valsecchi, ME | 1 |
| Mora, JI | 1 |
| Larocca, A | 1 |
| Cavallo, F | 1 |
| Bringhen, S | 2 |
| Di Raimondo, F | 1 |
| Evangelista, A | 1 |
| Cavalli, M | 1 |
| Stanevsky, A | 1 |
| Corradini, P | 1 |
| Pezzatti, S | 1 |
| Patriarca, F | 1 |
| Peccatori, J | 1 |
| Catalano, L | 1 |
| Carella, AM | 1 |
| Cafro, AM | 1 |
| Siniscalchi, A | 1 |
| Crippa, C | 1 |
| Yehuda, DB | 1 |
| Beggiato, E | 1 |
| Di Toritto, TC | 1 |
| Boccadoro, M | 2 |
| Nagler, A | 1 |
| Palumbo, A | 2 |
| Friedman, RJ | 2 |
| Kwong, LM | 1 |
| Jameson, SS | 2 |
| Charman, SC | 2 |
| Gregg, PJ | 2 |
| Reed, MR | 2 |
| van der Meulen, JH | 2 |
| Ji, HM | 1 |
| Lee, YK | 1 |
| Ha, YC | 1 |
| Kim, KC | 1 |
| Koo, KH | 1 |
| de Jong, PG | 1 |
| Goddijn, M | 1 |
| Eriksson, BI | 1 |
| Rosencher, N | 1 |
| Dahl, OE | 1 |
| Tormene, D | 1 |
| Tosetto, A | 1 |
| Margaglione, M | 1 |
| Castaman, G | 1 |
| Rossi, E | 1 |
| Ciminello, A | 1 |
| Valdrè, L | 1 |
| Legnani, C | 1 |
| Bafunno, V | 1 |
| Carraro, S | 1 |
| Rodeghiero, F | 1 |
| Simioni, P | 1 |
| Griffiths, JT | 1 |
| Matthews, L | 1 |
| Pearce, CJ | 1 |
| Calder, JD | 1 |
| Kristinsson, SY | 1 |
| Landgren, O | 1 |
| DeDea, L | 1 |
| Schenone, A | 1 |
| Eichinger, S | 1 |
| Bucherini, E | 1 |
| Silingardi, M | 1 |
| Bianchi, M | 1 |
| Moia, M | 1 |
| Vandelli, MR | 1 |
| Becker, RC | 1 |
| Alsayegh, F | 1 |
| Kamaliddin, H | 1 |
| Sheshah, E | 1 |
| Bukhamseen, N | 1 |
| Alkhuwaitir, T | 1 |
| Elhoufi, A | 1 |
| Baker, PN | 1 |
| Deehan, DJ | 1 |
| Ghirarduzzi, A | 1 |
| Pengo, V | 1 |
| Filippi, L | 1 |
| Campello, E | 1 |
| Alexander, M | 1 |
| Kirsa, S | 1 |
| Mellor, JD | 1 |
| Edwards, C | 1 |
| Taylor, S | 1 |
| van de Meerendonk, HW | 1 |
| Heit, JA | 1 |
| Warkentin, TE | 1 |
| Mann, K | 1 |
| Gallus, A | 1 |
| Ockelford, P | 1 |
| Gibbs, H | 1 |
| Hague, W | 1 |
| Xavier, D | 1 |
| Diaz, R | 1 |
| Kirby, A | 1 |
| Fontana, P | 1 |
| Delluc, A | 1 |
| Watson, HG | 2 |
| Kato, A | 1 |
| Takano, H | 1 |
| Ichikawa, A | 1 |
| Koshino, M | 1 |
| Igarashi, A | 1 |
| Hattori, K | 1 |
| Nagata, K | 1 |
| Kaiseruddin, A | 1 |
| Oyola, S | 1 |
| Rao, G | 1 |
| Ferrières, C | 1 |
| Conard, J | 1 |
| Blacher, J | 1 |
| Stewart, DW | 1 |
| Freshour, JE | 1 |
| Pernod, G | 1 |
| Lazareth, I | 1 |
| Levack, A | 1 |
| Kamath, AF | 1 |
| Curigliano, G | 1 |
| Balduzzi, A | 1 |
| Cardillo, A | 1 |
| Ghisini, R | 1 |
| Peruzzotti, G | 1 |
| Orlando, L | 1 |
| Torrisi, R | 1 |
| Dellapasqua, S | 1 |
| Lunghi, L | 1 |
| Goldhirsch, A | 1 |
| Colleoni, M | 1 |
| Rajkumar, SV | 1 |
| Dimopoulos, MA | 1 |
| San Miguel, J | 1 |
| Barlogie, B | 1 |
| Harousseau, J | 1 |
| Zonder, JA | 1 |
| Zangari, M | 1 |
| Attal, M | 1 |
| Belch, A | 1 |
| Knop, S | 1 |
| Joshua, D | 1 |
| Sezer, O | 1 |
| Ludwig, H | 1 |
| Vesole, D | 1 |
| Bladé, J | 1 |
| Kyle, R | 1 |
| Westin, J | 1 |
| Weber, D | 1 |
| Niesvizky, R | 1 |
| Waage, A | 1 |
| von Lilienfeld-Toal, M | 1 |
| Lonial, S | 1 |
| Morgan, GJ | 1 |
| Orlowski, RZ | 1 |
| Shimizu, K | 1 |
| Anderson, KC | 1 |
| Durie, BG | 1 |
| Sonneveld, P | 1 |
| Hussein, MA | 1 |
| Tassinari, D | 1 |
| Santelmo, C | 1 |
| Tombesi, P | 1 |
| Sartori, S | 1 |
| Chee, YL | 1 |
| Quenet, S | 1 |
| Seffert, P | 1 |
| Daniel, J | 1 |
| Pradhan, A | 1 |
| Pradhan, C | 1 |
| Ziaee, H | 1 |
| Moss, M | 1 |
| Freeman, J | 1 |
| McMinn, DJ | 1 |
| Tian, H | 1 |
| Song, F | 1 |
| Zhang, K | 1 |
| Liu, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Open-Label, Active-Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Rivaroxaban for Thromboprophylaxis in Pediatric Subjects 2 to 8 Years of Age After the Fontan Procedure[NCT02846532] | Phase 3 | 112 participants (Actual) | Interventional | 2016-11-16 | Completed | ||
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia[NCT02735707] | Phase 3 | 10,000 participants (Anticipated) | Interventional | 2016-04-11 | Recruiting | ||
| Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy[NCT02874742] | Phase 2 | 224 participants (Actual) | Interventional | 2016-08-29 | Completed | ||
| Efficacy of Different Doses of Pregabalin as a Multimodal Analgesic Agent in Postoperative Pain Control After Total Knee Arthroplasty - A Randomized Controlled Trial[NCT05447364] | Phase 4 | 82 participants (Anticipated) | Interventional | 2021-07-01 | Recruiting | ||
| Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement: Balancing Safety and Effectiveness[NCT02810704] | Phase 4 | 20,000 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| Low Molecular Weight hEparin vs. Aspirin Post-partum[NCT05058924] | 50 participants (Anticipated) | Interventional | 2021-08-29 | Recruiting | |||
| A Phase 1, Open-label, 2-period, Fixed-sequence Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion Coadministered With Clopidogrel in Healthy Subjects[NCT02560688] | Phase 1 | 22 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| A PHASE 1, OPEN LABEL, SINGLE DOSE STUDY, TO ASSESS THE SAFETY AND TOLERABILITY OF A SINGLE IV DOSE OF DS-1040B AFTER 5 DAYS OF ASPIRIN TREATMENT IN HEALTHY SUBJECTS[NCT02071004] | Phase 1 | 18 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Pneumatic Compression Versus Anti-thromboembolic Exercises: Effects on Edema of the Lower Limbs and the Outcomes of Patients Undergoing Total Hip Arthroplasty: Randomized Controlled Clinical Trial[NCT05312060] | 48 participants (Anticipated) | Interventional | 2022-04-11 | Enrolling by invitation | |||
| PREVENTion of Clot in Orthopaedic Trauma (PREVENT CLOT): A Randomized Pragmatic Trial Comparing the Complications and Safety of Blood Clot Prevention Medicines Used in Orthopaedic Trauma Patients[NCT02984384] | Phase 3 | 12,211 participants (Actual) | Interventional | 2017-04-24 | Completed | ||
| Prospective, Non-interventional Study of Disease Progression and Treatment of Patients With Polycythemia Vera in United States Academic or Community Clinical Practices[NCT02252159] | 2,544 participants (Actual) | Observational | 2014-07-31 | Completed | |||
| Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism[NCT02064439] | Phase 3 | 3,365 participants (Actual) | Interventional | 2014-03-05 | Completed | ||
| A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myoca[NCT01225562] | Phase 3 | 21,379 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Clinical Investigation of a Novel Approach for the Prevention of Deep Venous Thrombosis After Total Knee Replacement[NCT04979026] | 90 participants (Actual) | Interventional | 2019-10-17 | Completed | |||
| Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty[NCT01720108] | Phase 3 | 3,426 participants (Actual) | Interventional | 2013-02-24 | Completed | ||
| Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy[NCT04352439] | Phase 4 | 19 participants (Actual) | Interventional | 2020-08-08 | Completed | ||
| A Different Approach to Preventing Thrombosis (ADAPT): A Randomized Controlled Trial Comparing Low Molecular Weight Heparin to Acetylsalicylic Acid in Orthopedic Trauma Patients[NCT02774265] | Phase 3 | 329 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| Prasugrel in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients[NCT04445623] | Phase 3 | 128 participants (Anticipated) | Interventional | 2020-07-31 | Not yet recruiting | ||
| Multicenter Randomized, Double-blind, Placebo-controlled, Clinical Trial of Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients (Asperum)[NCT04808895] | Phase 3 | 204 participants (Anticipated) | Interventional | 2021-04-01 | Not yet recruiting | ||
| Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria: A Feasibility Study[NCT05185505] | Phase 4 | 24 participants (Anticipated) | Interventional | 2023-01-30 | Recruiting | ||
| "Study on Indications of Bard PowerPort Isp Implantable Port: Image Accuracy in Resectable Esophageal Cancer Patients"[NCT02887261] | 100 participants (Actual) | Interventional | 2016-05-31 | Completed | |||
| Rivaroxaban for Improvement of Thromboembolism Outcomes in Patients With Multiple Myeloma on Lenalidomide-based Therapy: RithMM Trial[NCT03428373] | Phase 2/Phase 3 | 86 participants (Anticipated) | Interventional | 2023-07-30 | Recruiting | ||
| Swelling Management After Total Knee Arthroplasty[NCT04841356] | 21 participants (Actual) | Interventional | 2021-04-01 | Completed | |||
| Efficacy of Prolonged Distal Calf Compression as Part of a Multimodal DVT Protocol in Tourniquet-less Total Knee Arthroplasty: a Randomized Clinical Trial in 100 Patients[NCT02102828] | 100 participants (Actual) | Interventional | 2014-03-31 | Completed | |||
| Thromboelastography to Assess Age-Related Coagulation Differences in Patients Undergoing Elective Cesarean Delivery.[NCT01416454] | 46 participants (Actual) | Observational | 2010-10-31 | Completed | |||
| Prospective Multicentric Evaluation of an Antithrombotic Therapeutic Strategy in Pregnant Women With a Risk of Thromboembolism and/or a Risk of Placental Vascular Complication, Strategy Determined With a Risk Score.[NCT00745212] | 2,280 participants (Actual) | Observational | 2008-06-30 | Completed | |||
| Thrombosis in Newly Diagnosed Multiple Myeloma Patients: a Clinical Audit of Intermediate Dose Low Molecular Weight Heparin[NCT05541978] | 140 participants (Actual) | Observational | 2022-09-01 | Completed | |||
| A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS[NCT00551928] | Phase 3 | 402 participants (Actual) | Interventional | 2007-06-30 | Active, not recruiting | ||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| Prospective Study of the Assessment of the Dental Protocol for Tooth Extraction in Patients With Atrial Fibrillation in Continuous Use of New Oral Anticoagulants: A Pilot Study[NCT03181386] | Phase 3 | 60 participants (Actual) | Interventional | 2017-05-03 | Completed | ||
| Aspirin After Six Months or One Year of Oral Anticoagulants for the Prevention of Recurrent Venous Thromboembolism in Patients With Idiopathic Venous Thromboembolism. The WARFASA Study.[NCT00222677] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2004-05-31 | Active, not recruiting | ||
| An Open Label, Multicenter, Phase 2, Pilot Study, Evaluating Early Treatment With Bispecific T-cell Redirectors (Teclistamab and Talquetamab) in the Frontline Therapy of Newly Diagnosed High-risk Multiple Myeloma[NCT05849610] | Phase 2 | 30 participants (Anticipated) | Interventional | 2023-11-30 | Recruiting | ||
| A Phase I/II Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, (BdL) for the Treatment of Patients With Relapsed Myeloma.[NCT01686386] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2010-02-28 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Absolute prothrombin time was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 0.5-1.5 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 15.46 |
| Rivaroxaban (Part B) | 18.02 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 1.5-4 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 16.58 |
| Rivaroxaban (Part B) | 18.76 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 0.5-1.5 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 17.95 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 1.5-4 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 18.73 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 6-8 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 16.13 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: Up to 3 hours predose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 15.21 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 0.5-1.5 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 20.13 |
| Rivaroxaban (Part B) | 18.89 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 2.5-4 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 19.14 |
| Rivaroxaban (Part B) | 19.69 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: Up to 3 hours predose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 17.59 |
| Rivaroxaban (Part B) | 16.45 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 0.5-1.5 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 31.4 |
| Rivaroxaban (Part B) | 30.69 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 0.5-1.5 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 66.93 |
| Rivaroxaban (Part B) | 99.46 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 1.5-4 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 74.06 |
| Rivaroxaban (Part B) | 104.57 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 6-8 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 74.21 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 0.5-1.5 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part B) | 110.90 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 2.5-4 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part B) | 93.48 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: Up to 3 hours predose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 60.51 |
| Rivaroxaban (Part B) | 53.41 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 1.5-4 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 32.83 |
| Rivaroxaban (Part B) | 30.25 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 0.5-1.5 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 36.17 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average for the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 1.5-4 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 37.58 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 6-8 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 32.83 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: Up to 3 hours predose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 33.08 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 0.5-1.5 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 26.60 |
| Rivaroxaban (Part B) | 31.15 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 2.5-4 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 26.74 |
| Rivaroxaban (Part B) | 31.67 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: Up to 3 hours predose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 25.36 |
| Rivaroxaban (Part B) | 28.70 |
TEAEs were defined as those adverse events (AEs) that occurred from the first day of study drug to the last day of study drug + 2 days inclusive. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. (NCT02846532)
Timeframe: Up to 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban (Part A) | 91.7 |
| Rivaroxaban (Part B) | 85.9 |
| Aspirin (Part B) | 85.3 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 0.5-1.5 hours postdose
| Intervention | micrograms per liter (mcg/L) (Mean) |
|---|---|
| Rivaroxaban (Part A) | 46.69 |
| Rivaroxaban (Part B) | 92.86 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 1.5-4 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 86.62 |
| Rivaroxaban (Part B) | 103.61 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 0.5-1.5 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 107.58 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 1.5-4 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 147.18 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 6-8 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 66.81 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: Up to 3 hours predose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 36.58 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 0.5-1.5 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 86.25 |
| Rivaroxaban (Part B) | 94.12 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 2.5-4 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 96.67 |
| Rivaroxaban (Part B) | 102.99 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: Up to 3 hours predose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 38.23 |
| Rivaroxaban (Part B) | 29.41 |
Thrombotic event was defined as the appearance of a new thrombotic burden within the cardiovascular system on either routine surveillance or clinically indicated imaging, or the occurrence of a clinical event known to be strongly associated with thrombus (such as cardioembolic stroke, pulmonary embolism). The event included ischemic stroke, pulmonary embolism, venous thrombosis, arterial/intracardiac thrombosis, and other thrombosis. (NCT02846532)
Timeframe: Up to 12 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any thrombotic event | Ischemic stroke | Pulmonary embolism | Venous thrombosis | Arterial/intracardiac thrombosis | Other thrombosis | |
| Aspirin (Part B) | 8.8 | 2.9 | 0 | 5.9 | 0 | 0 |
| Rivaroxaban (Part A) | 8.3 | 0 | 0 | 8.3 | 0 | 0 |
| Rivaroxaban (Part B) | 1.6 | 0 | 1.6 | 0 | 0 | 0 |
Bleeding events were categorized into major, clinically relevant non-major bleeding (CRNM), and trivial bleeding events. Major bleeding: overt bleeding and associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more; or leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults; or occurring in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; or contributing to death. CRNM bleeding: overt bleeding not meeting the criteria for major bleeding but associated with: Medical intervention, or Unscheduled contact with a physician, cessation of study treatment, or Discomfort for the subject such as pain, or Impairment of activities of daily life. Trivial bleeding: any other overt bleeding event that does not meet criteria for CRNM bleeding. (NCT02846532)
Timeframe: Up to 12 months
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Any bleeding event | Major Bleeding | Clinically relevant non-major bleeding | Trivial bleeding | |
| Aspirin (Part B) | 41.2 | 0 | 8.8 | 35.3 |
| Rivaroxaban (Part A) | 33.3 | 0 | 8.3 | 25.0 |
| Rivaroxaban (Part B) | 35.9 | 1.6 | 6.3 | 32.8 |
Duration of CR or better is the duration from the date of initial documentation of a CR or sCR response, according to the IMWG criteria, to the date of first documented evidence of progressive disease (PR), or relapse from CR. PD is defined as an increase of 25 % from the lowest response value in one of the following: serum and urine M-component (absolute increase must be greater than or equal to [>=] 0.5 gram per deciliter [g/dL] and >=200 milligrams [mg]/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be > 10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium >11.5 mg/dL) that can be attributed solely to plasma cells (PCs) proliferative disorder. (NCT02874742)
Timeframe: From randomization to the date of first documented evidence of progressive disease or relapse from CR (up to 5 years)
| Intervention | Months (Median) |
|---|---|
| Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | NA |
| Randomized: Daratumumab+RVd (D-RVd) | NA |
| Safety Run-in: D-RVd | NA |
Duration of response is defined as the duration from the date of initial documentation of a response (PR or better) according to the IMWG criteria to the date of first documented evidence of progressive disease according to the IMWG criteria. PD is defined as an increase of 25 % from the lowest response value in one of the following: serum and urine M-component (absolute increase must be >= 0.5 g/dL and >=200 mg/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be > 10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium >11.5 mg/dL) that can be attributed solely to PC proliferative disorder. (NCT02874742)
Timeframe: From the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive (up to 5 years)
| Intervention | Months (Median) |
|---|---|
| Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | NA |
| Randomized: Daratumumab+RVd (D-RVd) | NA |
| Safety Run-in: D-RVd | NA |
Duration of sCR is the duration from the date of initial documentation of a sCR response, according to the IMWG criteria, to the date of first documented evidence of progressive disease, or relapse from sCR. PD is defined as an increase of 25 % from the lowest response value in one of the following: serum and urine M component (absolute increase must be >= 0.5 g/dL and >=200 mg/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be > 10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium >11.5 mg/dL) that can be attributed solely to PC proliferative disorder. (NCT02874742)
Timeframe: From randomization to the date of first documented evidence of progressive disease or relapse from sCR (up to 5 years)
| Intervention | Months (Median) |
|---|---|
| Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | NA |
| Randomized: Daratumumab+RVd (D-RVd) | NA |
| Safety Run-in: D-RVd | NA |
OS is measured from the date of randomization to the date of the participant's death. (NCT02874742)
Timeframe: From randomization to the date of initial documentation of participant's death (up to 5 years)
| Intervention | Months (Median) |
|---|---|
| Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | NA |
| Randomized: Daratumumab+RVd (D-RVd) | NA |
| Safety Run-in: D-RVd | NA |
Percentage of participants who had achieved sCR as determined by the validated computer algorithm according to the International Myeloma Working Group (IMWG) criteria, by the end of post-autologous stem cell transplantation (post-ASCT) consolidation treatment were reported. Complete response (CR) is defined as negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and less than (<) 5 percent (%) PCs in bone marrow. sCR is defined as in addition to CR a normal FLC ratio, and absence of clonal plasma cells (PCs) by immunohistochemistry or immunofluorescence or 2 to 4-color flow cytometry. (NCT02874742)
Timeframe: From randomization to post-ASCT consolidation (after Cycle 6) before maintenance treatment (up to 10 months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | 32.0 |
| Randomized: Daratumumab+RVd (D-RVd) | 42.4 |
PFS is defined as the duration from the date of randomization to the date of first documented evidence of progressive disease or death, whichever comes first. PD is defined as an increase of 25 % from the lowest response value in one of the following: serum and urine M-component (absolute increase must be >= 0.5 g/dL and >=200 mg/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be > 10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium >11.5 mg/dL) that can be attributed solely to PC proliferative disorder. (NCT02874742)
Timeframe: From randomization to the date of first documented evidence of progressive disease or death (up to 5 years)
| Intervention | Months (Median) |
|---|---|
| Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | NA |
| Randomized: Daratumumab+RVd (D-RVd) | NA |
| Safety Run-in: D-RVd | NA |
Time to CR or better is the duration from the date of randomization to the date of initial documentation of CR or better, which was confirmed by a repeated measurement as required by the IMWG criteria. (NCT02874742)
Timeframe: From randomization to the date of initial documentation of CR (up to 5 years)
| Intervention | Months (Median) |
|---|---|
| Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | 9.6 |
| Randomized: Daratumumab+RVd (D-RVd) | 8.9 |
| Safety Run-in: D-RVd | 7.7 |
Time to PR or better is the duration from the date of randomization to the date of initial documentation of PR or better, which was confirmed by a repeated measurement as required by the IMWG criteria. (NCT02874742)
Timeframe: From randomization to the date of initial documentation of PR or better (up to 5 years)
| Intervention | Months (Median) |
|---|---|
| Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | 0.8 |
| Randomized: Daratumumab+RVd (D-RVd) | 0.8 |
| Safety Run-in: D-RVd | 0.8 |
TTP is defined as the duration from the date of randomization to the date of first documented evidence of progressive disease according to the IMWG criteria. (NCT02874742)
Timeframe: From randomization to the date of first documented evidence of progressive disease (up to 5 years)
| Intervention | Months (Median) |
|---|---|
| Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | NA |
| Randomized: Daratumumab+RVd (D-RVd) | NA |
| Safety Run-in: D-RVd | NA |
Time to sCR is the duration from the date of randomization to the date of initial documentation of sCR, which was confirmed by a repeated measurement as required by the IMWG criteria. (NCT02874742)
Timeframe: From randomization to the date of initial documentation of sCR (up to 5 years)
| Intervention | Months (Median) |
|---|---|
| Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | 14.3 |
| Randomized: Daratumumab+RVd (D-RVd) | 10.2 |
| Safety Run-in: D-RVd | 8.4 |
Time to VGPR or better is the duration from the date of randomization to the date of initial documentation of VGPR or better, which was confirmed by a repeated measurement as required by the IMWG criteria. (NCT02874742)
Timeframe: From randomization to the date of initial documentation of VGPR or better (up to 5 years)
| Intervention | Months (Median) |
|---|---|
| Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | 3.0 |
| Randomized: Daratumumab+RVd (D-RVd) | 2.2 |
| Safety Run-in: D-RVd | 2.1 |
VGPR or better rate is defined as the percentage of participants who achieved VGPR or better, according to the IMWG criteria. VGPR is defined as serum and urine M-component detectable by immunofixation but not on electrophoresis, or >= 90% reduction in serum M-protein plus urine M-protein <100 mg/24 hours. (NCT02874742)
Timeframe: From randomization to end of following: induction treatment, ASCT, post-ASCT consolidation (after Cycle 6) and at the end of maintenance period of 24 months (overall duration up to 34 months)
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| At the end of induction prior to ASCT | At the end of ASCT prior to consolidation | At the end of post-ASCT consolidation | At the End of Maintenance Period (up to 24 Months) | |
| Randomized: Daratumumab+RVd (D-RVd) | 71.7 | 86.9 | 90.9 | 96.0 |
| Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | 56.7 | 66.0 | 73.2 | 77.6 |
| Safety Run-in: D-RVd | 68.8 | 100 | 100 | 100.0 |
CR or better rate is defined as the percentage of participants who achieve CR or sCR, according to the IMWG criteria. CR is negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and < 5% PCs in bone marrow. sCR is defined as in addition to CR a normal FLC ratio, and absence of clonal plasma cells (PCs) by immunohistochemistry or immunofluorescence or 2 to 4-color flow cytometry. For 2 participants (1 in each randomized treatment group), data were updated by the study sites which resulted in their inclusion to the response-evaluable analysis set after the primary analysis. (NCT02874742)
Timeframe: From randomization to end of following: induction treatment, ASCT, post-ASCT consolidation (after Cycle 6) and at the end of maintenance period of 24 months (overall duration up to 34 months)
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| At the end of induction prior to ASCT | At the end of ASCT prior to consolidation | At the end of post-ASCT consolidation | At the end of maintenance period (up to 24 Months) | |
| Randomized: Daratumumab+RVd (D-RVd) | 19.2 | 27.3 | 51.5 | 83.0 |
| Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | 13.4 | 19.6 | 42.3 | 60.2 |
| Safety Run-in: D-RVd | 12.5 | 56.3 | 68.8 | 93.8 |
Minimal residual disease negative rate is defined as the percentage of participants who achieve MRD negative status by the respective time point. Minimal residual disease was evaluated in participants who achieved CR or sCR (including participants with VGPR or better and suspected daratumumab interference) using next-generation sequencing which utilizes multiple myeloma cell DNA from bone marrow aspirates at a threshold of less than (<) 10^5. (NCT02874742)
Timeframe: From randomization to end of following: induction treatment, post-ASCT consolidation (after Cycle 6) (up to 4.5 months), and at the end of maintenance period of 24 months (overall duration up to 34 months)
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| MRD from randomization to prior to ASCT (10^5) | Post ASCT consolidation (10^5) | At the End of Maintenance Period (up to 24 Months) (10^5) | |
| Randomized: Daratumumab+RVd (D-RVd) | 22.1 | 50.0 | 64.4 |
| Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | 7.8 | 20.4 | 30.1 |
| Safety Run-in: D-RVd | 18.8 | 50.0 | 81.3 |
ORR- percentage of participants who achieved partial response (PR) or better (PR, Very Good Partial Response [VGPR], CR or sCR) based on computerized algorithm as per IMWG criteria. PR -greater than or equal to (>=) 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by >=90% or to <200 mg//24 hours. If serum and urine M-protein are not measurable, a decrease of >=50% in the difference between involved and uninvolved FLC levels is required. A >=50% reduction in the size of soft tissue plasmacytomas is also required; VGPR-serum and urine M-component detectable by immunofixation but not on electrophoresis, or >= 90% reduction in serum M-protein plus urine M-protein <100 mg/24 hours; CR-negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and <5% PCs in bone marrow. sCR- in addition to CR a normal FLC ratio, and absence of clonal PCs by immunohistochemistry or immunofluorescence or 2 to 4-color flow cytometry. (NCT02874742)
Timeframe: From randomization to end of following: induction treatment, ASCT, post-ASCT consolidation (after Cycle 6) and at the end of maintenance treatment of 24 months (overall duration up to 34 months)
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| At the end of induction prior to ASCT | At the end of ASCT prior to consolidation | At the end of post-ASCT consolidation | At the End of Maintenance Treatment (up to 24 Months) | |
| Randomized: Daratumumab+RVd (D-RVd) | 98.0 | 99.0 | 99.0 | 99.0 |
| Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | 91.8 | 91.8 | 91.8 | 91.8 |
| Safety Run-in: D-RVd | 100 | 100 | 100 | 100.0 |
Overall sCR rate is defined as the percentage of participants who achieved sCR, according to the IMWG criteria. CR is defined as negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and < 5 % PCs in bone marrow. sCR is defined as in addition to CR a normal FLC ratio, and absence of clonal PCs by immunohistochemistry or immunofluorescence or 2 to 4-color flow cytometry. (NCT02874742)
Timeframe: From randomization to end of following: induction treatment, ASCT, post-ASCT consolidation (after Cycle 6) and at the end of maintenance treatment of 24 months (overall duration up to 34 months)
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| At the end of induction prior to ASCT | At the end of ASCT prior to consolidation | At the end of post-ASCT consolidation | At the end of Maintenance Treatment (up to 24 Months) | |
| Randomized: Daratumumab+RVd (D-RVd) | 12.1 | 21.2 | 42.4 | 67.0 |
| Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | 7.2 | 14.4 | 32.0 | 48.0 |
| Safety Run-in: D-RVd | 0 | 43.8 | 56.3 | 93.8 |
The secondary safety outcome was clinically relevant non-major (CRNM) bleeding, which was adjudicated by the CIAC using the ASA criteria: the bleeding was non-major and the bleeding was associated with a study medication interruption of more than 14 days. (NCT02064439)
Timeframe: Up to 12 months, at least 6 months
| Intervention | participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD | 12 |
| Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD | 17 |
| Acetylsalicylic (ASA) 100 mg, OD | 12 |
"The principal safety outcome was major bleeding which was defined according to the criteria of the International Society on Thrombosis and Hemostasis (ISTH) as clinically overt bleeding and associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or whole blood, or occurring in a critical site, e.g. intracranial, intraspinal, intraocular, pericardial, intra articular, intramuscular with compartment syndrome, retroperitoneal, or contributing to death.~Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant." (NCT02064439)
Timeframe: Up to 12 months, at least 6 months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Any major bleeding | Fatal bleeding | Non-fatal critical organ bleed | Non-fatal non-critical organ bleeding | |
| Acetylsalicylic (ASA) 100 mg, OD | 3 | 1 | 1 | 1 |
| Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD | 5 | 0 | 2 | 3 |
| Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD | 6 | 1 | 4 | 1 |
"The primary efficacy outcomes (i.e., recurrent venous thromboembolism [VTE] defined as composite of fatal or non-fatal symptomatic recurrent VTE, including unexplained death for which pulmonary embolism [PE] could not be ruled out) as confirmed by the central independent adjudication committee (CIAC) were considered up to the end of the individual intended duration of treatment.~Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant." (NCT02064439)
Timeframe: Up to 12 months, at least 6 months
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Composite | Symptomatic recurrent Deep vein thrombosis (DVT) | Symptomatic recurrent PE | Death (PE) | Death (unexplained and PE cannot be ruled out) | |
| Acetylsalicylic (ASA) 100 mg, OD | 50 | 29 | 19 | 1 | 1 |
| Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD | 13 | 8 | 5 | 0 | 0 |
| Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD | 17 | 9 | 6 | 0 | 2 |
The secondary efficacy outcome is the composite of the primary efficacy outcome, myocardial infarction (MI), ischemic stroke or non-central nervous system (CNS) systemic embolism. Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant. (NCT02064439)
Timeframe: Up to 12 months, at least 6 months
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Composite | Ischemic stroke | Non-CNS systemic embolism | Myocardial infarction | Symptomatic recurrent DVT | Symptomatic recurrent PE | Death (PE) | Death (unexplained and PE cannot be ruled out) | Death (cardiovascular: myocardial infarction) | Death (cardiovascular: ischemic stroke) | |
| Acetylsalicylic (ASA) 100 mg, OD | 56 | 2 | 1 | 4 | 29 | 18 | 1 | 1 | 0 | 0 |
| Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD | 18 | 4 | 1 | 0 | 8 | 5 | 0 | 0 | 0 | 0 |
| Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD | 19 | 2 | 0 | 1 | 9 | 6 | 0 | 1 | 0 | 0 |
Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 5.1 |
| Ticagrelor 60 mg | 4.7 |
| Placebo | 5.2 |
A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of >= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug (NCT01225562)
Timeframe: First dosing up to 48 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.6 |
| Ticagrelor 60 mg | 2.3 |
| Placebo | 1.1 |
Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.9 |
| Ticagrelor 60 mg | 2.9 |
| Placebo | 3.4 |
Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 7.8 |
| Ticagrelor 60 mg | 7.8 |
| Placebo | 9.0 |
(NCT04352439)
Timeframe: Up to six months
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 4 |
Adverse events will only include those that are determined to be related to the study drug. (NCT04352439)
Timeframe: Up to six months
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 0 |
DVT and how the diagnosis was made will be recorded. The number of events in participants in each arm will be compared to evaluate efficacy. (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 5 |
| VTE Prophylaxis With Aspirin 81mg BID | 9 |
Bases on imaging obtained for symptoms. (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 6 |
| VTE Prophylaxis With Aspirin 81mg BID | 2 |
Includes a greater than 2g/dL drop in hemoglobin, blood transfusion, hematoma evacuation, re-operation for a deep surgical site infection or minor procedure for bleeding and GI bleed (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 52 |
| VTE Prophylaxis With Aspirin 81mg BID | 53 |
94 reviews available for aspirin and Thromboembolism, Venous
| Article | Year |
|---|---|
Narrative Review of Antiplatelet and Anticoagulant Medications for Venous Thromboembolism Prevention in Spine Surgery.
Topics: Anticoagulants; Aspirin; Humans; Risk Factors; Spine; Venous Thromboembolism; Warfarin | 2022 |
Comparison between use of direct oral anticoagulants and aspirin for risk of thromboembolism complications in patients undergoing total knee and hip arthroplasty: a systematic review and meta-analysis.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Factor Xa Inhibitors | 2021 |
What is the optimal management of thromboprophylaxis after liver transplantation regarding prevention of bleeding, hepatic artery, or portal vein thrombosis? A systematic review of the literature and expert panel recommendations.
Topics: Anticoagulants; Aspirin; Hemorrhage; Hepatic Artery; Humans; Liver Diseases; Liver Transplantation; | 2022 |
Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy.
Topics: Adult; Anticoagulants; Arthroscopy; Aspirin; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Huma | 2022 |
Aspirin Thromboprophylaxis Following Primary Total Knee Arthroplasty Is Associated With a Lower Rate of Early Prosthetic Joint Infection Compared With Other Agents.
Topics: Anticoagulants; Arthritis, Infectious; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kn | 2023 |
The role of aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis after total knee arthroplasty: a meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Heparin; Heparin, Low-Molecular-Weight; Hu | 2023 |
Prophylactic anticoagulants for non-hospitalised people with COVID-19.
Topics: Anticoagulants; Aspirin; COVID-19; Humans; Platelet Aggregation Inhibitors; Pulmonary Embolism; Veno | 2023 |
The efficacy and safety of aspirin in preventing venous thrombosis in major orthopedic surgery: An updated meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Aspirin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Orthopedic Procedures; P | 2023 |
Venous Thromboembolism Prophylaxis Strategies for People Undergoing Elective Total Hip Replacement: A Systematic Review and Network Meta-Analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Bayes Theorem; Cost-Benefit Analysis; Elect | 2019 |
Postoperative Venous Thromboembolism Prophylaxis: Changes in the Daily Clinical Practice, Modified Guidelines.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Humans; Po | 2020 |
Venous thromboembolism in plastic surgery: the current state of evidence in risk assessment and chemoprophylactic options.
Topics: Administration, Oral; Anticoagulants; Aspirin; Chemoprevention; Heparin, Low-Molecular-Weight; Human | 2019 |
Aspirin for prevention of venous thromboembolism in recipients of major lower-limb orthopedic surgery: a systematic review of Level I evidence.
Topics: Anticoagulants; Aspirin; Evidence-Based Medicine; Hemorrhage; Humans; Lower Extremity; Orthopedic Pr | 2019 |
Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Aspirin; Enoxaparin; Female; Hemorrhage; Humans; Pregnancy; Pregnancy Complications; | 2020 |
Low-Dose Aspirin Is Adequate for Venous Thromboembolism Prevention Following Total Joint Arthroplasty: A Systematic Review.
Topics: Anticoagulants; Arthroplasty; Aspirin; Humans; Joints; Pulmonary Embolism; Venous Thromboembolism | 2020 |
Clinical Effectiveness and Safety of Aspirin for Venous Thromboembolism Prophylaxis After Total Hip and Knee Replacement: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Fibrinolytic Agents; Human | 2020 |
Controversial Topics in Total Knee Arthroplasty: A Five-Year Update (Part 2).
Topics: Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Aspirin; Blood Loss, Surgi | 2020 |
Topics: Aspirin; Humans; Pyrazines; Randomized Controlled Trials as Topic; Thrombosis; Treatment Outcome; Ve | 2020 |
Aspirin For VTE Prevention After Joint Replacement.
Topics: Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; Aspirin; Heparin; Humans; | 2020 |
Bleeding risk comparison between direct oral anticoagulants at doses approved for atrial fibrillation and aspirin: systematic review, meta-analysis and meta-regression.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Stroke; Venous Thromboem | 2020 |
Pregnancy and cardiovascular disease.
Topics: Acute Coronary Syndrome; Antihypertensive Agents; Aortic Dissection; Arrhythmias, Cardiac; Aspirin; | 2020 |
Aspirin versus enoxaparin for the initial prevention of venous thromboembolism following elective arthroplasty of the hip or knee: A systematic review and meta-analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Enoxaparin; Heparin, Low-Molecular-Weight; | 2021 |
An Update on Venous Thromboembolism Rates and Prophylaxis in Hip and Knee Arthroplasty in 2020.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Fibrinolytic Agents; Hemor | 2020 |
A Narrative Review of Aspirin Resistance in VTE Prophylaxis for Orthopaedic Surgery.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Drug Resistance; Humans; O | 2020 |
Recent advances in understanding, diagnosing and treating venous thrombosis.
Topics: Anticoagulants; Aspirin; Humans; Venous Thromboembolism; Venous Thrombosis | 2020 |
Does aspirin prevent venous thromboembolism?
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Hemorrhage; Humans; Male; Venous Thromboembolis | 2020 |
Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going?
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Humans; Leprostatic Agents; Multiple Myeloma; Ph | 2021 |
Rivaroxaban versus aspirin in prevention of venous thromboembolism following total joint arthroplasty or hip fracture surgery: a meta-analysis.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Female; Fracture Fix | 2021 |
Aspirin monotherapy is a suitable standard thromboprophylactic agent following total hip arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Heparin, Low-Molecular-Weight; Humans; Post | 2022 |
Contemporary Clinical Use of Aspirin: Mechanisms of Action, Current Concepts, Unresolved Questions, and Future Perspectives.
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Female; Humans; Platelet Aggregation; Platelet Ag | 2021 |
Thrombotic Events and Anticoagulants in Beta-thalassemia Patients with Focus on Anticoagulants for Atrial Fibrillation: A Brief Review.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; beta-Thalassemia; Hemorrhage; Hu | 2022 |
Low-Molecular-Weight Heparin and the Relative Risk of Surgical Site Bleeding Complications: Results of a Systematic Review and Meta-Analysis of Randomized Controlled Trials of Venous Thromboprophylaxis in Patients After Total Joint Arthroplasty.
Topics: Anticoagulants; Arthroplasty; Arthroplasty, Replacement, Knee; Aspirin; Dabigatran; Hemorrhage; Hepa | 2017 |
Venous Thromboembolism Following Hip and Knee Arthroplasty: The Role of Aspirin.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Drug Administration Schedu | 2017 |
Updates in venous thromboembolism management: evidence published in 2016.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Factor Xa | 2017 |
Perioperative Venous Thromboembolism: A Review.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductas | 2017 |
Effectiveness and Tolerability of Anticoagulants for Thromboprophylaxis after Major Joint Surgery: a Network Meta-Analysis.
Topics: Anticoagulants; Aspirin; Databases, Factual; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Join | 2017 |
Aspirin and the prevention of venous thromboembolism following total joint arthroplasty: commonly asked questions.
Topics: Anticoagulants; Arthroplasty, Replacement; Aspirin; Drug Administration Schedule; Humans; Postoperat | 2017 |
Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Aspirin; Hemorrhage; Humans; Myocardial Infarction; Randomized | 2017 |
Venous Thromboembolism Prophylaxis after Total Knee Arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Chemoprevention; Early Ambulation; Hemorrh | 2018 |
Landmark trials in thrombotic vascular disease: a critical appraisal of potential practice-changing trials in 2016-2017.
Topics: Anticoagulants; Aspirin; Endovascular Procedures; Humans; Neoplasms; Platelet Aggregation Inhibitors | 2019 |
The prevention of venous thromboembolism recurrence in the elderly: a still open issue.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clinical Trials as Topic; Humans; Inc | 2018 |
Extended treatment of venous thromboembolism: a systematic review and network meta-analysis.
Topics: Anticoagulants; Aspirin; Humans; Network Meta-Analysis; Platelet Aggregation Inhibitors; Pulmonary E | 2019 |
Primary thromboembolic prevention in multiple myeloma patients: An exploratory meta-analysis on aspirin use.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Multiple Myeloma; Retrospective Studies; V | 2018 |
Long-Term Management of Venous Thromboembolism: Lessons from EINSTEIN CHOICE and Other Extension Trials.
Topics: Anticoagulants; Aspirin; Canada; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Rea | 2019 |
Rivaroxaban and the EINSTEIN clinical trial programme.
Topics: Adult; Aspirin; Child; Clinical Trials as Topic; Humans; Precision Medicine; Pulmonary Embolism; Riv | 2019 |
Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Coagulation; Female; Hemorrhage; Heparin, Low-M | 2019 |
Safety and effectiveness of aspirin and enoxaparin for venous thromboembolism prophylaxis after total hip and knee arthroplasty: a systematic review.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Asp | 2019 |
Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism.
Topics: Anticoagulants; Aspirin; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Ne | 2019 |
Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Dabigatran; Glycosaminoglycans; Hemorrhage; Hum | 2020 |
Does the form of venous thromboembolism prophylaxis following primary total knee arthroplasty alter the rate of early reoperation or revision surgery?
Topics: Arthroplasty, Replacement, Knee; Aspirin; Australia; Case-Control Studies; Clinical Decision-Making; | 2019 |
Rivaroxaban versus Aspirin in Prevention of Venous Thromboembolism: A Meta-Analysis of 9 Randomized Controlled Trials comprising 7,656 Patients.
Topics: Administration, Oral; Anticoagulants; Aspirin; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage | 2019 |
Aspirin and recurrent venous thromboembolism.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Patient Selection; Risk Assessment | 2013 |
Thromboprophylaxis in patients with pelvic and acetabular fractures: A short review and recommendations.
Topics: Acetabulum; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Fondaparin | 2013 |
Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Cost-Benef | 2013 |
Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis.
Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; | 2013 |
The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
Topics: Age Factors; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Disease Management; | 2014 |
Anticoagulant therapy in pregnant patients with metabolic syndrome: a review.
Topics: Animals; Anticoagulants; Aspirin; Female; Fondaparinux; Heparin; Humans; Metabolic Syndrome; Polysac | 2014 |
Aspirin for prevention and treatment of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Aspirin; Double-Blind Method; Humans; Randomized Controlled Tr | 2014 |
Aspirin versus anticoagulation for prevention of venous thromboembolism major lower extremity orthopedic surgery: a systematic review and meta-analysis.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Fema | 2014 |
A systematic review on the effect of aspirin in the prevention of post-operative arterial thrombosis in patients undergoing total hip and total knee arthroplasty.
Topics: Anticoagulants; Arterial Occlusive Diseases; Arthroplasty, Replacement, Hip; Arthroplasty, Replaceme | 2014 |
Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid.
Topics: Animals; Aspirin; Blood Coagulation; Blood Platelets; Fibrin; Fibrinolytic Agents; Humans; Platelet | 2014 |
The use of aspirin for primary and secondary prevention in venous thromboembolism and other cardiovascular disorders.
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Primary P | 2015 |
Aspirin in secondary prevention of recurrent venous thromboembolism.
Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recurrence; | 2015 |
Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: A network meta-analysis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Female; Hemorrhage; Humans; Male; Mi | 2015 |
What's New in Venous Thromboembolic Prophylaxis Following Total Knee and Total Hip Arthroplasty? An Update.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Heparin; H | 2015 |
Aspirin in the primary prophylaxis of venous thromboembolism in surgical patients.
Topics: Aspirin; Fibrinolytic Agents; Global Health; Humans; Incidence; Postoperative Complications; Primary | 2015 |
Aspirin and heparin in pregnancy.
Topics: Anticoagulants; Aspirin; Female; Fibrinolytic Agents; Heparin; Humans; Pregnancy; Pregnancy Complica | 2015 |
Thrombosis in Lymphoma Patients and in Myeloma Patients.
Topics: Anticoagulants; Aspirin; Female; Humans; Incidence; Lymphoma; Male; Multiple Myeloma; Retrospective | 2015 |
Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review.
Topics: Anti-Inflammatory Agents; Anticoagulants; Aspirin; Dexamethasone; Fibrinolytic Agents; Heparin, Low- | 2016 |
Safety and Use of Anticoagulation After Aortic Valve Replacement With Bioprostheses: A Meta-Analysis.
Topics: Anticoagulants; Aortic Valve; Aspirin; Bioprosthesis; Drug Administration Schedule; Heart Valve Dise | 2016 |
Aspirin as Thromboprophylaxis in Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Fibrinolytic Agents; Hemor | 2016 |
Systematic review of aspirin for thromboprophylaxis in modern elective total hip and knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Clinical P | 2016 |
Management of idiopathic venous thromboembolism.
Topics: Anticoagulants; Aspirin; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Hemorrhage; Hu | 2016 |
The 2016 American College of Chest Physicians treatment guidelines for venous thromboembolism: a review and critical appraisal.
Topics: Anticoagulants; Aspirin; Guidelines as Topic; Humans; Thoracic Surgery; Venous Thromboembolism; Veno | 2016 |
Pulmonary Embolism Rates Following Total Hip Arthroplasty With Prophylactic Anticoagulation: Some Pulmonary Emboli Cannot Be Avoided.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Aspirin; Factor Xa Inhibitors; Health | 2017 |
Prevention of thrombosis in antiphospholipid syndrome.
Topics: Antiphospholipid Syndrome; Aspirin; Female; Fibrinolytic Agents; Humans; Male; Pregnancy; Pregnancy | 2016 |
[The management of pregnant women with antiphospholipid syndrome].
Topics: Abortion, Habitual; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Fibrinolytic Agents; | 2007 |
Rational thromboprophylaxis in medical inpatients: not quite there yet.
Topics: Anticoagulants; Aspirin; Australia; Clinical Trials as Topic; Cost-Benefit Analysis; Evidence-Based | 2008 |
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
Topics: Arsenic Trioxide; Arsenicals; Aspirin; Boronic Acids; Bortezomib; Heparin, Low-Molecular-Weight; Hum | 2009 |
[Drugs and venous thromboembolism].
Topics: Angiogenesis Inhibitors; Aspirin; Estrogen Replacement Therapy; Humans; Hydroxymethylglutaryl-CoA Re | 2008 |
Venous thromboembolism prophylaxis after major orthopaedic surgery: a pooled analysis of randomized controlled trials.
Topics: Anticoagulants; Aspirin; Heparin, Low-Molecular-Weight; Humans; Orthopedic Procedures; Randomized Co | 2009 |
Antiphospholipid antibody syndrome.
Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Blood Transfus | 2009 |
VTE prophylaxis for the medical patient: where do we stand? - a focus on cancer patients.
Topics: Anticoagulants; Aspirin; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Morpholines; | 2010 |
Issues in assessing and reducing the risk for venous thromboembolism.
Topics: Anticoagulants; Aspirin; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Polysaccharides; Risk | 2010 |
Clot prevention--common questions about medications.
Topics: Anticoagulants; Aspirin; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Huma | 2010 |
[Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review].
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Evidence-Based Medicine; Fibrinolytic Agents; Hepa | 2010 |
Current therapeutic strategies and future perspectives for the treatment of venous thromboembolism.
Topics: Anticoagulants; Aspirin; Drugs, Investigational; Embolectomy; Embolic Protection Devices; Fibrinolyt | 2010 |
Multimodal prophylaxis for venous thromboembolic disease after total hip and knee arthroplasty: current perspectives.
Topics: Anesthesia, Epidural; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Fact | 2010 |
Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update.
Topics: Arterial Occlusive Diseases; Aspirin; Cardiovascular Diseases; Comorbidity; Female; Humans; Incidenc | 2012 |
Testing for inherited thrombophilia in recurrent miscarriage.
Topics: Abortion, Habitual; Aspirin; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Preg | 2011 |
Thalidomide thromboprophylaxis in multiple myeloma: a review of current evidence.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Multiple Myelom | 2012 |
[Aspirin for secondary prevention of venous thromboembolism. WARFASA: far from being conclusive].
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Pulmonary Embolism; Randomized Controlled Trials as Top | 2013 |
Aspirin for the prophylaxis of venous thromboembolic events in orthopedic surgery patients: a comparison of the AAOS and ACCP guidelines with review of the evidence.
Topics: Aspirin; Evidence-Based Medicine; Humans; Orthopedic Procedures; Platelet Aggregation Inhibitors; Pr | 2013 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Rati | 2008 |
Aspirin and other antiplatelet drugs in the prevention of venous thromboembolism.
Topics: Aspirin; Clinical Trials as Topic; Humans; Platelet Aggregation Inhibitors; Venous Thromboembolism; | 2008 |
49 trials available for aspirin and Thromboembolism, Venous
| Article | Year |
|---|---|
Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study.
Topics: Anticoagulants; Aspirin; Child; Factor Xa Inhibitors; Hemorrhage; Humans; Rivaroxaban; Stroke; Throm | 2021 |
Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
Topics: Adult; Anticoagulants; Aspirin; Bayes Theorem; COVID-19; COVID-19 Drug Treatment; Critical Illness; | 2022 |
Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization.
Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Female; Humans; Lower Extremity; Male; Peripheral Arteri | 2022 |
Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Aust | 2022 |
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bortezomib; Dexamethasone; Hematopoietic St | 2022 |
Randomized Trial of Postoperative Venous Thromboembolism Prophylactic Compliance: Aspirin and Mobile Compression Pumps.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Humans; Postoperative Period; Venous Thromb | 2022 |
Review of Article: CRISTAL Study Group. Effect of aspirin vs. enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: The CRISTAL randomized trial. JAMA. 2022;328(8):719-727.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Humans; Venous Thromboembolism | 2022 |
Review of Article: CRISTAL Study Group. Effect of aspirin vs. enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: The CRISTAL randomized trial. JAMA. 2022;328(8):719-727.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Humans; Venous Thromboembolism | 2022 |
Review of Article: CRISTAL Study Group. Effect of aspirin vs. enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: The CRISTAL randomized trial. JAMA. 2022;328(8):719-727.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Humans; Venous Thromboembolism | 2022 |
Review of Article: CRISTAL Study Group. Effect of aspirin vs. enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: The CRISTAL randomized trial. JAMA. 2022;328(8):719-727.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Humans; Venous Thromboembolism | 2022 |
Review of Article: CRISTAL Study Group. Effect of aspirin vs. enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: The CRISTAL randomized trial. JAMA. 2022;328(8):719-727.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Humans; Venous Thromboembolism | 2022 |
Review of Article: CRISTAL Study Group. Effect of aspirin vs. enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: The CRISTAL randomized trial. JAMA. 2022;328(8):719-727.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Humans; Venous Thromboembolism | 2022 |
Review of Article: CRISTAL Study Group. Effect of aspirin vs. enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: The CRISTAL randomized trial. JAMA. 2022;328(8):719-727.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Humans; Venous Thromboembolism | 2022 |
Review of Article: CRISTAL Study Group. Effect of aspirin vs. enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: The CRISTAL randomized trial. JAMA. 2022;328(8):719-727.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Humans; Venous Thromboembolism | 2022 |
Review of Article: CRISTAL Study Group. Effect of aspirin vs. enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: The CRISTAL randomized trial. JAMA. 2022;328(8):719-727.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Humans; Venous Thromboembolism | 2022 |
Rivaroxaban plus aspirin versus acenocoumarol to manage recurrent venous thromboembolic events despite systemic anticoagulation with rivaroxaban.
Topics: Acenocoumarol; Anticoagulants; Aspirin; Hemorrhage; Humans; Ischemic Stroke; Pilot Projects; Pulmona | 2023 |
Is Enoxaparin Associated With a Higher Risk of Persistent Wound Drainage Than Aspirin? A Secondary Analysis of Data From the CRISTAL Randomized Trial.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Australia; Drainage; Enoxaparin; Huma | 2023 |
Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture.
Topics: Adult; Anticoagulants; Aspirin; Chemoprevention; Extremities; Fractures, Bone; Hemorrhage; Heparin, | 2023 |
Effect of Aspirin vs Enoxaparin on 90-Day Mortality in Patients Undergoing Hip or Knee Arthroplasty: A Secondary Analysis of the CRISTAL Cluster Randomized Trial.
Topics: Adolescent; Adult; Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; E | 2023 |
Comparative effectiveness of aspirin for symptomatic venous thromboembolism prophylaxis in patients undergoing total joint arthroplasty, a cohort study.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Cohort Studies; Heparin, Low-Molecular-Weig | 2023 |
Combination of aspirin and rosuvastatin for reduction of venous thromboembolism in severely injured patients: a double-blind, placebo-controlled, pragmatic randomized phase II clinical trial (The STAT Trial).
Topics: Adolescent; Adult; Aged; Anticoagulants; Aspirin; Heparin; Humans; Middle Aged; Pandemics; Rosuvasta | 2023 |
CRISTAL: protocol for a cluster randomised, crossover, non-inferiority trial of aspirin compared to low molecular weight heparin for venous thromboembolism prophylaxis in hip or knee arthroplasty, a registry nested study.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Australia; Cross-Over Stud | 2019 |
Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial.
Topics: Adult; Aged; Anticoagulants; Aspirin; Enoxaparin; Female; Fibrinolytic Agents; Fractures, Bone; Hemo | 2020 |
Comparable efficacy of 100 mg aspirin twice daily and rivaroxaban for venous thromboembolism prophylaxis following primary total hip arthroplasty: a randomized controlled trial.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Humans; Ri | 2021 |
PREVENTion of CLots in Orthopaedic Trauma (PREVENT CLOT): a randomised pragmatic trial protocol comparing aspirin versus low-molecular-weight heparin for blood clot prevention in orthopaedic trauma patients.
Topics: Adult; Anticoagulants; Aspirin; Heparin, Low-Molecular-Weight; Humans; Multicenter Studies as Topic; | 2021 |
CRISTAL (a cluster-randomised, crossover, non-inferiority trial of aspirin compared to low molecular weight heparin for venous thromboembolism prophylaxis in hip or knee arthroplasty, a registry nested study): statistical analysis plan.
Topics: Adult; Arthroplasty, Replacement, Knee; Aspirin; Australia; Heparin, Low-Molecular-Weight; Humans; R | 2021 |
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.
Topics: Adult; Aged; Aspirin; Double-Blind Method; Drug Administration Schedule; Factor Xa Inhibitors; Femal | 2017 |
Topics: Aspirin; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; R | 2017 |
[The EINSTEIN CHOICE study].
Topics: Aspirin; Double-Blind Method; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Rivaroxaban; Venous | 2017 |
[EINSTEIN CHOICE: Comparison of rivaroxaban treatment and prophylactic doses with aspirin in the extended treatment of patients with venous thromboembolism].
Topics: Adult; Aged; Anticoagulants; Aspirin; Female; Humans; Male; Middle Aged; Rivaroxaban; Treatment Outc | 2017 |
Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocar | 2018 |
Post-discharge adherence with venous thromboembolism prophylaxis after orthopedic trauma: Results from a randomized controlled trial of aspirin versus low molecular weight heparin.
Topics: Adult; Aspirin; Female; Fibrinolytic Agents; Follow-Up Studies; Fractures, Bone; Heparin, Low-Molecu | 2018 |
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Double-Blind Method; | 2018 |
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Double-Blind Method; | 2018 |
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Double-Blind Method; | 2018 |
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Double-Blind Method; | 2018 |
Risk of recurrent venous thromboembolism according to baseline risk factor profiles.
Topics: Adult; Aged; Aspirin; Drug Administration Schedule; Factor Xa Inhibitors; Female; Humans; Male; Midd | 2018 |
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Double-Blind Method; | 2018 |
Association of Aspirin With Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty Compared With Other Anticoagulants: A Noninferiority Analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Female; Humans | 2019 |
What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feas
Topics: Aged; Aspirin; Clinical Trial Protocols as Topic; Feasibility Studies; Female; Focus Groups; Heparin | 2019 |
Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Dalteparin; Drug Administration Sche | 2013 |
Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber.
Topics: Adolescent; Adult; Animals; Anticoagulants; Aspirin; Cross-Over Studies; Female; Humans; In Vitro Te | 2013 |
Low-molecular-weight heparin is more effective than aspirin in preventing early neurologic deterioration and improving six-month outcome.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Enoxaparin; Female; Humans; Male; | 2014 |
Aspirin combined with mechanical measures to prevent venous thromboembolism after total knee arthroplasty: a randomized controlled trial.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Female; Humans; Male; Middle Aged; V | 2014 |
Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration.
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; H | 2014 |
Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration.
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; H | 2014 |
Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration.
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; H | 2014 |
Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration.
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; H | 2014 |
Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study.
Topics: Aspirin; Clinical Protocols; Double-Blind Method; Drug Administration Schedule; Fibrinolytic Agents; | 2015 |
Thromboembolism Prophylaxis in Hip Arthroplasty: Routine and High Risk Patients.
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Female; Hemorrhage; Humans; In | 2015 |
Prevention of Venous Thromboembolism after Arthroscopic Knee Surgery in a Low-Risk Population with the Use of Aspirin. A Randomized Trial.
Topics: Adolescent; Adult; Aged; Arthroscopy; Aspirin; Drug Administration Schedule; Female; Fibrinolytic Ag | 2015 |
Closed Suction Drainage Has No Benefits in Anterior Hip Arthroplasty: A Prospective, Randomized Trial.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Aspirin; Bl | 2016 |
Perioperative Aspirin for Prevention of Venous Thromboembolism: The PeriOperative ISchemia Evaluation-2 Trial and a Pooled Analysis of the Randomized Trials.
Topics: Aged; Aspirin; Female; Fibrinolytic Agents; Humans; Male; Odds Ratio; Perioperative Care; Postoperat | 2016 |
Deep Venous Thrombosis Prophylaxis After Unicompartmental Knee Arthroplasty: A Prospective Study on the Safety of Aspirin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin | 2017 |
Mobile pump deep vein thrombosis prophylaxis: just say no to drugs.
Topics: Adult; Aged; Ambulatory Care; Anticoagulants; Arthroplasty, Replacement; Aspirin; Combined Modality | 2017 |
Efficacy in Deep Vein Thrombosis Prevention With Extended Mechanical Compression Device Therapy and Prophylactic Aspirin Following Total Knee Arthroplasty: A Randomized Control Trial.
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Humans; Intermittent Pneumatic Compression D | 2017 |
Efficacy in Deep Vein Thrombosis Prevention With Extended Mechanical Compression Device Therapy and Prophylactic Aspirin Following Total Knee Arthroplasty: A Randomized Control Trial.
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Humans; Intermittent Pneumatic Compression D | 2017 |
Efficacy in Deep Vein Thrombosis Prevention With Extended Mechanical Compression Device Therapy and Prophylactic Aspirin Following Total Knee Arthroplasty: A Randomized Control Trial.
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Humans; Intermittent Pneumatic Compression D | 2017 |
Efficacy in Deep Vein Thrombosis Prevention With Extended Mechanical Compression Device Therapy and Prophylactic Aspirin Following Total Knee Arthroplasty: A Randomized Control Trial.
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Humans; Intermittent Pneumatic Compression D | 2017 |
Antiplatelet therapy use and the risk of venous thromboembolic events in the Raloxifene Use for the Heart (RUTH) trial.
Topics: Aspirin; Cohort Studies; Coronary Disease; Double-Blind Method; Female; Humans; Middle Aged; Placebo | 2010 |
A prospective comparison of warfarin to aspirin for thromboprophylaxis in total hip and total knee arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Fema | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplasty, Replacement, Knee; Aspi | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Low-dose aspirin for preventing recurrent venous thromboembolism.
Topics: Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle | 2012 |
[Efficacy and safety of aspirin in prevention of venous thromboembolism after total joint arthroplasty].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplasty, Replacement, Hip; Arthr | 2007 |
260 other studies available for aspirin and Thromboembolism, Venous
| Article | Year |
|---|---|
Aspirin Thromboprophylaxis Is Associated With Less Major Bleeding Events Following Total Joint Arthroplasty.
Topics: Anticoagulants; Arthroplasty; Arthroplasty, Replacement, Hip; Aspirin; Hemorrhage; Humans; Retrospec | 2022 |
Patients Who Do Not Receive Aspirin Because of Allergy Have an Increased Risk of Venous Thromboembolism Following Total Joint Arthroplasty.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplasty, Replacement; Asp | 2022 |
Aspirin Administered for Venous Thromboembolism Prophylaxis May Protect Against Stiffness Following Total Knee Arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Hemorrhage | 2022 |
Time to Venous Thromboembolism Events Following Total Hip Arthroplasty: A Comparison Between Aspirin and Warfarin.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Humans; Pu | 2022 |
Clinical and therapeutic value of the adjusted Global Antiphospholipid Syndrome Score in primary obstetric antiphospholipid syndrome.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Humans; Lupus Erythematosus, Systemic; P | 2022 |
Prevalence of aspirin resistance among the arthroplasty population: A pilot study.
Topics: Anticoagulants; Arthroplasty; Arthroplasty, Replacement, Hip; Aspirin; Humans; Pilot Projects; Preva | 2022 |
Cost-Effectiveness of Aspirin for Extended Venous Thromboembolism Prophylaxis After Major Surgery for Inflammatory Bowel Disease.
Topics: Aftercare; Anticoagulants; Aspirin; Cost-Benefit Analysis; Enoxaparin; Humans; Inflammatory Bowel Di | 2022 |
Patient-specific prescription of aspirin after total joint replacement: a case control study with propensity score matching.
Topics: Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; Aspirin; Case-Control Stu | 2022 |
Aspirin May Be a Suitable Prophylaxis for Patients with a History of Venous Thromboembolism Undergoing Total Joint Arthroplasty.
Topics: Anticoagulants; Arthroplasty; Arthroplasty, Replacement, Hip; Aspirin; Humans; Postoperative Complic | 2022 |
Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis.
Topics: Aspirin; Atherosclerosis; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Peripheral Arteri | 2022 |
Does Aspirin Provide Adequate Chemoprophylaxis for Venous Thromboembolic Events in Operative Pelvic and Acetabular Fractures?
Topics: Anticoagulants; Aspirin; Chemoprevention; Enoxaparin; Hematoma; Heparin; Hip Fractures; Humans; Pelv | 2022 |
The effect of low-dose and high-dose low-molecular-weight-heparin and aspirin thromboprophylaxis on clinical outcome and mortality in critical ill patients with COVID-19: A retrospective cohort study.
Topics: Anticoagulants; Aspirin; COVID-19; Critical Illness; Hemorrhage; Heparin, Low-Molecular-Weight; Huma | 2022 |
Low-Dose Aspirin for Venous Thromboembolism Prophylaxis is Associated With Lower Rates of Periprosthetic Joint Infection After Total Joint Arthroplasty.
Topics: Anticoagulants; Arthritis, Infectious; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kn | 2022 |
A retrospective study on IVF/ICSI outcomes in patients with persisted positive of anticardiolipin antibody: Effects of low-dose aspirin plus low molecular weight heparin adjuvant treatment.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2022 |
Cost-Effective Modeling of Thromboembolic Chemoprophylaxis for Total Ankle Arthroplasty.
Topics: Ankle; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Che | 2022 |
Some Points for the KDIGO 2021 Guideline for Prophylactic Anticoagulation in Membranous Nephropathy: Is It Clear Enough for Us to Follow?
Topics: Anticoagulants; Aspirin; Glomerulonephritis, Membranous; Hemorrhage; Heparin, Low-Molecular-Weight; | 2023 |
Aspirin and the Hip: Back to the Future? A 70-Year History: Commentary on an article by Leanne Ludwick, BS, et al.: "Aspirin May Be a Suitable Prophylaxis for Patients with a History of Venous Thromboembolism Undergoing Total Joint Arthroplasty".
Topics: Anticoagulants; Arthroplasty; Arthroplasty, Replacement, Hip; Aspirin; Heparin, Low-Molecular-Weight | 2022 |
Assessment of an Intervention to Reduce Aspirin Prescribing for Patients Receiving Warfarin for Anticoagulation.
Topics: Adult; Anticoagulants; Aspirin; Atrial Fibrillation; Hemorrhage; Humans; Male; Middle Aged; Venous T | 2022 |
Combined oral contraceptive-associated venous thromboembolism revealing an antiphospholipid syndrome: International retrospective study of outcomes.
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Contraceptives, Or | 2022 |
Incidence of venous thromboembolism in patients with peripheral arterial disease after endovascular intervention.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Female; Humans; Incidence; Male; Medicare; | 2023 |
Venous Thromboembolism Chemoprophylaxis in Knee Arthroscopy: A Break-Even Analysis of Cost.
Topics: Aspirin; Humans; Venous Thromboembolism | 2022 |
Editorial Commentary: Prophylaxis Against Deep Venous Thrombosis Should Be the Norm After Knee Arthroscopy.
Topics: Anticoagulants; Arthroscopy; Aspirin; Humans; Pulmonary Embolism; Venous Thromboembolism; Venous Thr | 2022 |
Editorial Commentary: Prophylaxis Against Deep Venous Thrombosis Should Be the Norm After Knee Arthroscopy.
Topics: Anticoagulants; Arthroscopy; Aspirin; Humans; Pulmonary Embolism; Venous Thromboembolism; Venous Thr | 2022 |
Editorial Commentary: Prophylaxis Against Deep Venous Thrombosis Should Be the Norm After Knee Arthroscopy.
Topics: Anticoagulants; Arthroscopy; Aspirin; Humans; Pulmonary Embolism; Venous Thromboembolism; Venous Thr | 2022 |
Editorial Commentary: Prophylaxis Against Deep Venous Thrombosis Should Be the Norm After Knee Arthroscopy.
Topics: Anticoagulants; Arthroscopy; Aspirin; Humans; Pulmonary Embolism; Venous Thromboembolism; Venous Thr | 2022 |
In THA or TKA, risk for symptomatic VTE was higher with aspirin vs. enoxaparin at 90 d.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin | 2022 |
In THA or TKA, risk for symptomatic VTE was higher with aspirin vs. enoxaparin at 90 d.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin | 2022 |
In THA or TKA, risk for symptomatic VTE was higher with aspirin vs. enoxaparin at 90 d.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin | 2022 |
In THA or TKA, risk for symptomatic VTE was higher with aspirin vs. enoxaparin at 90 d.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin | 2022 |
Utility of the Total Thrombus-Formation Analysis System as a Tool for Evaluating Thrombogenicity and Monitoring Antithrombotic Therapy in Pediatric Fontan Patients.
Topics: Anticoagulants; Aspirin; Child; Fibrinolytic Agents; Fontan Procedure; Humans; Prospective Studies; | 2023 |
Aspirin vs Enoxaparin and Symptomatic Venous Thromboembolism in Hip or Knee Arthroplasty-Reply.
Topics: Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement | 2023 |
Aspirin vs Enoxaparin and Symptomatic Venous Thromboembolism in Hip or Knee Arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement | 2023 |
Aspirin vs Enoxaparin and Symptomatic Venous Thromboembolism in Hip or Knee Arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement | 2023 |
Aspirin vs Enoxaparin and Symptomatic Venous Thromboembolism in Hip or Knee Arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement | 2023 |
Thromboprophylaxis after Extremity Fracture - Time for Aspirin?
Topics: Anticoagulants; Aspirin; Chemoprevention; Extremities; Fractures, Bone; Humans; Pulmonary Embolism; | 2023 |
Post-discharge patient-reported non-adherence to aspirin compared to enoxaparin for venous thromboembolism prophylaxis after hip or knee arthroplasty.
Topics: Aftercare; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; | 2023 |
Thromboprophylaxis in the Fontan Circulation: Long-Awaited Validation.
Topics: Anticoagulants; Aspirin; Fontan Procedure; Humans; Venous Thromboembolism; Warfarin | 2023 |
Trends of Venous Thromboembolism After Total Hip Arthroplasty in the United States: Analysis From 2011 to 2019.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Fibrinolytic Agents; Humans; Postoperative | 2023 |
Enoxaparin Is Better Than Aspirin for the Prevention of Venous Thromboembolism After Total Hip or Knee Arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Humans; Postoperative Complica | 2023 |
Comparison of 90-Day Adverse Events Associated With Aspirin and Potent Anticoagulation Use for Venous Thromboembolism Prophylaxis: A Cohort Study of 72,288 Total Knee and 35,142 Total Hip Arthroplasty Patients.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Cohort Studies; Factor Xa Inhibitors; Hepar | 2023 |
Safety and Efficacy of Rivaroxaban in Primary Total Hip and Knee Arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin | 2023 |
[Low-dose aspirin vs. low molecular weight heparin for thromboprophylaxis after fractures : Critical appraisal of the multicenter PREVENT CLOT trial conducted by the Major Extremity Trauma Research Consortium (METRC)].
Topics: Anticoagulants; Aspirin; Extremities; Fractures, Bone; Heparin, Low-Molecular-Weight; Humans; Treatm | 2023 |
Aspirin for venous thromboprophylaxis after fracture: ready for prime time?
Topics: Anticoagulants; Aspirin; Humans; Venous Thromboembolism | 2023 |
Aspirin for Venous Thromboembolic Prophylaxis Following Total Hip and Total Knee Arthroplasty: An Analysis of Safety and Efficacy Accounting for Surgeon Selection Bias.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Humans; Pu | 2023 |
Aspirin for Thromboprophylaxis after a Fracture.
Topics: Anticoagulants; Aspirin; Fractures, Bone; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; | 2023 |
Aspirin for Thromboprophylaxis after a Fracture.
Topics: Anticoagulants; Aspirin; Fractures, Bone; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; | 2023 |
Aspirin for Thromboprophylaxis after a Fracture.
Topics: Anticoagulants; Aspirin; Fractures, Bone; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; | 2023 |
Aspirin for Thromboprophylaxis after a Fracture.
Topics: Anticoagulants; Aspirin; Fractures, Bone; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; | 2023 |
Aspirin for Thromboprophylaxis after a Fracture.
Topics: Anticoagulants; Aspirin; Fractures, Bone; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; | 2023 |
Aspirin for Thromboprophylaxis after a Fracture. Reply.
Topics: Anticoagulants; Aspirin; Fractures, Bone; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; | 2023 |
In limb or pelvic fracture, aspirin was noninferior to enoxaparin for reducing all-cause death.
Topics: Anticoagulants; Aspirin; Enoxaparin; Extremities; Fractures, Bone; Humans; Venous Thromboembolism | 2023 |
Aspirin Noninferior to Low-Molecular-Weight Heparin for Thromboprophylaxis After Fracture.
Topics: Anticoagulants; Aspirin; Heparin, Low-Molecular-Weight; Humans; Venous Thromboembolism; Venous Throm | 2023 |
Atorvastatin Effect on Clopidogrel Efficacy in Patients with Peripheral Artery Disease.
Topics: Anticoagulants; Aspirin; Atorvastatin; Clopidogrel; Humans; Hydroxymethylglutaryl-CoA Reductase Inhi | 2023 |
Incidence of Thromboembolic Complications Following Kidney Transplantation with Short and Extended Aspirin Prophylaxis: A Retrospective Single-Center Study.
Topics: Adult; Aspirin; Humans; Incidence; Kidney Transplantation; Retrospective Studies; Venous Thromboembo | 2023 |
The impact of adopting low-molecular-weight heparin in place of aspirin as routine thromboprophylaxis for patients with hip fracture.
Topics: Anticoagulants; Aspirin; Heparin, Low-Molecular-Weight; Hip Fractures; Humans; Postoperative Complic | 2023 |
Twice-Daily Low-Dose Aspirin Is Similar to Enoxaparin for Thromboprophylaxis After Inpatient Treatment for Fracture.
Topics: Anticoagulants; Aspirin; Enoxaparin; Fractures, Bone; Humans; Inpatients; Venous Thromboembolism | 2023 |
Controversies in the Management of Antiphospholipid Syndrome.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Humans; Thrombosis; Venous Thromboembolism | 2023 |
Combination of enoxaparin and low-dose aspirin for thromboprophylaxis in selective patients after primary total joint arthroplasty in a Taiwanese population.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Enoxaparin; Humans; Postoperative Complicat | 2023 |
Risk Factors for Thromboembolic and Bleeding Events in Patients After the Fontan Operation (Insights from the National Database of Health Insurance Claims of Japan).
Topics: Anticoagulants; Aspirin; Female; Fontan Procedure; Humans; Insurance, Health; Japan; Male; Postopera | 2023 |
Is low-molecular-weight heparin superior to aspirin for VTE prophylaxis?
Topics: Anticoagulants; Aspirin; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Humans; Venous Thromboe | 2023 |
Venous Thromboembolism in Total Hip and Total Knee Arthroplasty.
Topics: Aftercare; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Cohort Studies; Female; Humans; | 2023 |
Capsule Commentary on Baumgartner et al., Aspirin Compared with Anticoagulation to Prevent Venous Thromboembolism after Knee or Hip Arthroplasty: a Large Retrospective Cohort Study.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Humans; Re | 2019 |
Anticoagulation in Revision Total Joint Arthroplasty: A Retrospective Review of 1917 Cases.
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspiri | 2019 |
Predicting the risk of venous thromboembolism in newly diagnosed myeloma with immunomodulatory drugs: External validation of the IMPEDE VTE score.
Topics: Aged; Aged, 80 and over; Aspirin; Female; Heparin; Humans; Immunomodulation; Male; Middle Aged; Mult | 2020 |
Aspirin as venous thromboembolic event prophylaxis post total hip and knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin | 2019 |
Comparison of the Efficacy and Safety of Aspirin and Rivaroxaban Following Enoxaparin Treatment for Prevention of Venous Thromboembolism after Hip Fracture Surgery.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Drug Ther | 2019 |
Selection Bias, Orthopaedic Style: Knowing What We Don't Know About Aspirin.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Humans; Po | 2020 |
Prophylaxis for Pediatric Venous Thromboembolism: Current Status and Changes Across Pediatric Orthopaedic Society of North America From 2011.
Topics: Aspirin; Enoxaparin; Guideline Adherence; Humans; North America; Orthopedic Procedures; Pediatrics; | 2020 |
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P | 2020 |
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P | 2020 |
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P | 2020 |
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P | 2020 |
Incidence of venous thromboembolism after total hip, total knee and hip fracture surgery at Waitemata District Health Board following a peer-reviewed audit.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2020 |
Primary prophylaxis of venous thromboembolism in extragonadal germ-cell tumour.
Topics: Anticoagulants; Antineoplastic Agents; Aspirin; Cisplatin; Enoxaparin; Hemorrhage; Humans; Male; Med | 2020 |
Aspirin for Postoperative Venous Thromboembolism Prophylaxis.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Humans; Re | 2020 |
Aspirin compared to enoxaparin or rivaroxaban for thromboprophylaxis following hip and knee replacement.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthropl | 2020 |
Low-Dose Aspirin Is Safe and Effective for Venous Thromboembolism Prevention in Patients Undergoing Revision Total Hip Arthroplasty: A Retrospective Cohort Study.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Humans; Incidence; Retrospective Studies; V | 2020 |
Reply to Letter to Editor: Low-Dose Aspirin is Adequate for Venous Thromboembolism Prevention Following Total Joint Arthroplasty: A Systematic Review.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Humans; Venous Thromboembolism | 2020 |
Letter to the Editor on "Low-Dose Aspirin is Adequate for Venous Thromboembolism Prevention Following Total Joint Arthroplasty: A Systemic Review".
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Humans; Systematic Reviews as Topic; Venou | 2020 |
Aspirin Is Associated With Reduced Rates of Venous Thromboembolism in Older Patients With Cancer.
Topics: Aged; Aged, 80 and over; Aspirin; Databases, Factual; Female; Fibrinolytic Agents; Hemorrhage; Hospi | 2020 |
Is Aspirin as Effective as the Newer Direct Oral Anticoagulants for Venous Thromboembolism Prophylaxis After Total Hip and Knee Arthroplasty? An Analysis From the National Joint Registry for England, Wales, Northern Ireland, and the Isle of Man.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; England; H | 2020 |
Multimodal prophylaxis in patients with a history of venous thromboembolism undergoing primary elective hip arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anesthesia, Conduction; Anticoagulants; Arthroplasty, Replacement, H | 2020 |
Persistent Wound Drainage among Total Joint Arthroplasty Patients Receiving Aspirin vs Coumadin.
Topics: Arthroplasty, Replacement, Hip; Aspirin; Drainage; Humans; Postoperative Complications; Retrospectiv | 2020 |
Low-Dose Aspirin is Safe and Effective for Venous Thromboembolism Prevention in Patients Undergoing Revision Total Knee Arthroplasty: A Retrospective Cohort Study.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Humans; Po | 2022 |
Pharmacologic Thromboprophylaxis Other Than Aspirin Is Associated With Increased Risk for Procedural Intervention for Arthrofibrosis After Anterior Cruciate Ligament Reconstruction.
Topics: Adolescent; Adult; Anesthesia; Anterior Cruciate Ligament Injuries; Anterior Cruciate Ligament Recon | 2021 |
Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action.
Topics: Adult; Aged; Anticoagulants; Aspirin; COVID-19; Critical Illness; Female; Hemorrhage; Heparin, Low-M | 2020 |
Venous thromboembolism prophylaxis in patients undergoing knee replacements: comparison of real-world outcomes.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Hum | 2021 |
No difference in patient compliance between full-strength versus low-dose aspirin for VTE prophylaxis following total hip and total knee replacement.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Humans; Pa | 2021 |
Discontinued Use of Outpatient Portable Intermittent Pneumatic Compression Devices May Be Safe for Venous Thromboembolism Prophylaxis in Primary Total Knee Arthroplasty Using Low-Dose Aspirin.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Humans; In | 2022 |
Efficacy and safety of aspirin and rivaroxaban for venous thromboembolism prophylaxis after total hip or knee arthroplasty: A protocol for meta-analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Blood Transfusion; Hemorrhage; Humans; Met | 2020 |
Comparison Between Currently Recommended Long-Term Medical Management of Coronary Artery Aneurysms After Kawasaki Disease and Actual Reported Management in the Last Two Decades.
Topics: Adolescent; Anticoagulants; Aspirin; Child; Coronary Aneurysm; Female; Guideline Adherence; Humans; | 2021 |
Risk-Stratified Venous Thromboembolism Prophylaxis after Total Joint Arthroplasty: Low Molecular Weight Heparins and Sequential Aspirin vs Aggressive Chemoprophylaxis.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement; Aspirin; Chemoprevention; Female; Heparin, Low-Mole | 2021 |
Low-Dose Aspirin Administered for Venous Thromboembolism Prophylaxis Reduces the Incidence of Heterotopic Ossification in Total Joint Arthroplasty.
Topics: Arthroplasty, Replacement, Hip; Aspirin; Humans; Incidence; Ossification, Heterotopic; Risk Factors; | 2021 |
Low-dose aspirin and the rate of symptomatic venous thromboembolic complications following primary shoulder arthroplasty.
Topics: Arthroplasty, Replacement, Shoulder; Aspirin; Humans; Incidence; Postoperative Complications; Pulmon | 2021 |
Non-Inferiority of Aspirin for Venous Thromboembolism Prophylaxis After Hip Arthroplasty in a Statewide Registry.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Female; Hu | 2021 |
Incidence and risk factors associated with venous thromboembolism following primary total hip arthroplasty in low-risk patients when using aspirin for prophylaxis.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Fema | 2022 |
Aspirin Is Safe for Venous Thromboembolism Prophylaxis for Patients With a History of Gastrointestinal Issues.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Humans; Postoperative Complications; Retros | 2021 |
Low-Dose vs Regular-Dose Aspirin for Venous Thromboembolism Prophylaxis in Primary Total Joint Arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Female; Humans; Retrospective Studies; Veno | 2021 |
Heparin versus aspirin thromboprophylaxis adds independent value to IMPEDE-VTE score for venous thrombosis prediction in multiple myeloma.
Topics: Anticoagulants; Aspirin; Heparin; Humans; Multiple Myeloma; Retrospective Studies; Risk Factors; Ven | 2021 |
Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Without a Clear Indication.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Female; Hemorrh | 2021 |
A retrospective analysis of bleeding risk with rivaroxaban, enoxaparin, and aspirin following total joint arthroplasty or revision.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin | 2021 |
A Retrospective Analysis Comparing Post-Operative Bleeding with Various Doses of Aspirin after Lower Extremity Joint Arthroplasty or Revision.
Topics: Anticoagulants; Arthroplasty; Aspirin; Dose-Response Relationship, Drug; Humans; Lower Extremity; Po | 2021 |
Thirty Days of Aspirin for Venous Thromboembolism Prophylaxis Is Adequate Following Total Knee Arthroplasty, Regardless of the Dose Used.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Humans; Re | 2021 |
2021 John N. Insall Award: Aspirin is effective in preventing propagation of infrapopliteal deep venous thrombosis following total knee arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Awards and Prizes; Female; Humans; M | 2021 |
A retrospective study of antithrombotic therapy use in an outpatient haemodialysis unit.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Drug Utilization; Du | 2021 |
Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study.
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Polycythemia Vera; Pro | 2022 |
No Increased Risk of Venous Thromboembolism in High-Risk Patients Continuing Their Dose of 75 mg Aspirin Compared to Healthier Patients Given Low-Molecular-Weight Heparin.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Heparin, L | 2021 |
Weight-Based Aspirin Dosing May Further Reduce the Incidence of Venous Thromboembolism Following Primary Total Joint Arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Humans; In | 2021 |
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bortezomib; Dexame | 2022 |
Effects of aspirin and statin use on venous thromboembolism prophylaxis and survival in patients with endometrial cancer.
Topics: Anticoagulants; Aspirin; Endometrial Neoplasms; Female; Humans; Hydroxymethylglutaryl-CoA Reductase | 2022 |
A risk-stratified approach to venous thromboembolism prophylaxis with aspirin or warfarin following total hip and knee arthroplasty: A cohort study.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Cohort Stu | 2021 |
Venous thromboembolism: Risk of recurrence lower with rivaroxaban than aspirin.
Topics: Anticoagulants; Aspirin; Humans; Recurrence; Rivaroxaban; Venous Thromboembolism | 2017 |
Trends of thromboprophylaxis and complications after major lower limb orthopaedic surgeries in Korea: National Health Insurance Claim Data.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2017 |
The risk of venous thromboembolism with aspirin compared to anticoagulants after hip and knee arthroplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthropl | 2017 |
Pharmacological thromboprophylaxis and its impact on venous thromboembolism following total knee and hip arthroplasty in Korea: A nationwide population-based study.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Eryt | 2017 |
Venous Thromboembolism Prophylaxis After TKA: Aspirin, Warfarin, Enoxaparin, or Factor Xa Inhibitors?
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Cohort Studies; D | 2017 |
In VTE, extending anticoagulation with rivaroxaban vs aspirin reduced recurrence without increasing bleeding.
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Recurrence; Rivaroxaban; Venous Thromboembolism | 2017 |
Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Cohort Studies; Enoxaparin; Factor X | 2017 |
CORR Insights
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Factor Xa Inhibitors; Humans; | 2017 |
Venous Thromboembolism Prevention: The Evidence for Aspirin?
Topics: Anticoagulants; Aspirin; Humans; Platelet Aggregation Inhibitors; Thromboembolism; Venous Thromboemb | 2017 |
Quality measures in high-risk pregnancies: Executive Summary of a Cooperative Workshop of the Society for Maternal-Fetal Medicine, National Institute of Child Health and Human Development, and the American College of Obstetricians and Gynecologists.
Topics: Antibiotic Prophylaxis; Aspirin; Cesarean Section; Congresses as Topic; Female; Fetal Growth Retarda | 2017 |
[Continued anticoagulation for unprovoked venous thromboembolism: guidance through the maze of recent studies].
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Rivaroxaban; Venous Thromboembolism | 2017 |
Early chemoprophylaxis is associated with decreased venous thromboembolism risk without concomitant increase in intraspinal hematoma expansion after traumatic spinal cord injury.
Topics: Adult; Anticoagulants; Aspirin; Chemoprevention; Female; Follow-Up Studies; Hematoma, Epidural, Spin | 2017 |
An umbrella arrives toward the end of the storm: Patient-tailored aspirin dosing improves late perioperative thromboprophylaxis.
Topics: Anticoagulants; Aspirin; Cardiac Surgical Procedures; Child; Fibrinolytic Agents; Humans; Venous Thr | 2017 |
Increased Incidence of Bleeding and Wound Complications With Factor-Xa Inhibitors After Total Joint Arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement; Aspirin; Chemoprevention; | 2018 |
European guidelines on perioperative venous thromboembolism prophylaxis: Chronic treatments with antiplatelet agents.
Topics: Anesthesiology; Anticoagulants; Aspirin; Blood Coagulation; Clopidogrel; European Union; Hemorrhage; | 2018 |
European guidelines on perioperative venous thromboembolism prophylaxis: Aspirin.
Topics: Anesthesiology; Aspirin; Critical Care; Dose-Response Relationship, Drug; Drug Administration Schedu | 2018 |
European Guidelines on perioperative venous thromboembolism prophylaxis: Executive summary.
Topics: Aged; Anesthesiology; Aspirin; Critical Care; Europe; Female; Humans; Intermittent Pneumatic Compres | 2018 |
Aspirin for Prophylaxis Against Venous Thromboembolism After Orthopaedic Oncologic Surgery.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Bone Neoplasms; Female; Humans; | 2017 |
Wishing It True Doesn't Make It So: Commentary on an article by Gregory M. Mendez, MD, et al.: "Aspirin for Prophylaxis Against Venous Thromboembolism After Orthopaedic Oncologic Surgery".
Topics: Anticoagulants; Aspirin; Humans; Orthopedic Procedures; Orthopedics; Venous Thromboembolism | 2017 |
Risk Factors for Postoperative Venous Thromboembolic Complications after Microsurgical Breast Reconstruction.
Topics: Adult; Aged; Aspirin; Body Mass Index; Comorbidity; Female; Humans; Mammaplasty; Microsurgery; Middl | 2018 |
Venous thromboembolic prophylaxis after simultaneous bilateral total knee arthroplasty: aspirin
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Dose-Respo | 2018 |
[Prolonged Secondary Prevention After Venous Thromboembolism].
Topics: Administration, Oral; Anticoagulants; Aspirin; Humans; Recurrence; Risk Factors; Secondary Preventio | 2018 |
Mobile Compression Reduces Bleeding-related Readmissions and Wound Complications After THA and TKA.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Asp | 2018 |
The Role of Aspirin and Unfractionated Heparin Combination Therapy Immediately After Total Hip and Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Bloo | 2018 |
Aspirin for thromboprophylaxis in major orthopedic surgery: old drug, new tricks?
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Contraindications, Drug; Drug Evaluation; | 2018 |
Low-Dose Aspirin Is Safe and Effective for Venous Thromboembolism Prophylaxis Following Total Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Electronic Health Records; Female; H | 2018 |
Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin; Humans; Myeloproliferative Disorders; Recurre | 2018 |
Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Conf | 2018 |
Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin.
Topics: Aspirin; Factor Xa Inhibitors; Female; Humans; Male; Platelet Aggregation Inhibitors; Risk Factors; | 2018 |
Type of Anticoagulant Used After Total Knee Arthroplasty Affects the Rate of Knee Manipulation for Postoperative Stiffness.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Female; Heparin, Low-Molecular-Weigh | 2018 |
Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population.
Topics: Anticoagulants; Aspirin; Cost Savings; Dose-Response Relationship, Drug; Drug Monitoring; Female; He | 2018 |
Using long term mortality to determine which perioperative risk factors of mortality following hip and knee replacement may be causal.
Topics: Aged; Anesthesia, Spinal; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2018 |
Should Aspirin Be Routinely Used for Venous Thromboembolism Prophylaxis After Total Knee Arthroplasty?: Even the Authors of This Commentary Cannot Agree.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Humans; Ve | 2019 |
Evaluation of a Simplified Risk Stratification Twice-Daily Aspirin Protocol for Venous Thromboembolism Prophylaxis After Total Joint Replacement.
Topics: Anticoagulants; Arthroplasty, Replacement; Aspirin; Humans; Postoperative Complications; Retrospecti | 2020 |
The Effectiveness of Aspirin for Venous Thromboembolism Prophylaxis for Patients Undergoing Arthroscopic Rotator Cuff Repair.
Topics: Adult; Aged; Aged, 80 and over; Arthroscopy; Aspirin; Case-Control Studies; Female; Humans; Male; Mi | 2019 |
Association of statins, aspirin, and venous thromboembolism in women with endometrial cancer.
Topics: Aspirin; Endometrial Neoplasms; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inci | 2019 |
No Difference Between Low- and Regular-dose Aspirin for Venous Thromboembolism Prophylaxis After THA.
Topics: Aged; Arthroplasty, Replacement, Hip; Aspirin; Female; Fibrinolytic Agents; Hemorrhage; Humans; Inci | 2019 |
Aspirin versus rivaroxaban in postoperative bleeding after total knee arthroplasty: a retrospective case-matched study.
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Blood Transfusion; Chemoprevention; Drainage; Factor | 2019 |
Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Data | 2019 |
Comparison of pharmacologic prophylaxis in prevention of venous thromboembolism following total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Chemoprevention; | 2019 |
Comparing Australian orthopaedic surgeons' reported use of thromboprophylaxis following arthroplasty in 2012 and 2017.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Australia; | 2019 |
Which Aspirin to Choose?
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Fibrinolytic Agents; Humans; Venous Thromb | 2019 |
Which Aspirin to Choose?-Reply.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Humans; Venous Thromboembolism | 2019 |
Clinical outcomes and risk factors of thromboprophylaxis with rivaroxaban versus aspirin in patients undergoing hip arthroplasty in low-incidence population: A nationwide study in Korea.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Femal | 2019 |
The Use of Aspirin for Prophylaxis Against Venous Thromboembolism Decreases Mortality Following Primary Total Joint Arthroplasty.
Topics: Aged; Arthroplasty, Replacement; Aspirin; Body Mass Index; Female; Fibrinolytic Agents; Humans; Male | 2019 |
As Good as Current Evidence Can Get: Commentary on an article by Alexander J. Rondon, MD, MBA, et al.: "The Use of Aspirin for Prophylaxis Against Venous Thromboembolism Decreases Mortality Following Primary Total Joint Arthroplasty".
Topics: Anticoagulants; Arthroplasty; Aspirin; Humans; Venous Thromboembolism | 2019 |
Clinical efficacy of risk-stratified prophylaxis with low-dose aspirin for the management of symptomatic venous thromboembolism after total hip arthroplasty.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement, Hip; Aspirin; Female; Huma | 2020 |
Potent Anticoagulation Does Not Reduce Venous Thromboembolism in High-Risk Patients.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement; Aspirin; Female; Heparin, Low-Molecular-Weight; Hum | 2019 |
Clinical Effectiveness of Aspirin as Multimodal Thromboprophylaxis in Primary Total Hip and Knee Arthroplasty: A Review of 6078 Cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthropl | 2019 |
Venous thromboprophylaxis after total hip arthroplasty: aspirin, warfarin, enoxaparin, or factor Xa inhibitors?
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Enoxaparin; | 2020 |
Direct oral anticoagulants versus aspirin for venous thromboembolism prophylaxis after orthopedic surgery.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Blood Transfusion; Female; Hemorrhage; Humans; | 2019 |
Second-Order Peer Reviews of Clinically Relevant Articles for the Physiatrist: Aspirin or Rivaroxaban for Venous Thromboembolism Prophylaxis After Hip or Knee Arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Humans; Pe | 2019 |
Thromboprophylaxis by rivaroxaban, aspirin, both, or placebo after hospitalization for medical illness.
Topics: Aspirin; Factor Xa Inhibitors; Hospitalization; Humans; Placebo Effect; Platelet Aggregation Inhibit | 2019 |
Aspirin Compared with Anticoagulation to Prevent Venous Thromboembolism After Knee or Hip Arthroplasty: a Large Retrospective Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2019 |
The role of prophylactic use of low molecular weight heparin or aspirin in thromboembolic events in primary membranous nephropathy.
Topics: Adult; Aged; Aspirin; Beijing; Female; Glomerulonephritis, Membranous; Heparin, Low-Molecular-Weight | 2019 |
The Role of Chemoprophylactic Agents in Modulating Platelet Aggregability After Traumatic Brain Injury.
Topics: Amitriptyline; Animals; Aspirin; Blood Coagulation; Brain Injuries, Traumatic; Disease Models, Anima | 2019 |
Aspirin Thromboprophylaxis Confers No Increased Risk for Aseptic Loosening Following Cementless Primary Hip Arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Hip Prosthesis; Humans; Prosthesis Design; | 2019 |
Aspirin for preventing venous thromboembolism.
Topics: Aspirin; Female; Humans; Male; Platelet Aggregation Inhibitors; Venous Thromboembolism | 2013 |
Aspirin for preventing venous thromboembolism.
Topics: Aspirin; Female; Humans; Male; Platelet Aggregation Inhibitors; Venous Thromboembolism | 2013 |
Aspirin for preventing venous thromboembolism.
Topics: Aspirin; Female; Humans; Male; Platelet Aggregation Inhibitors; Venous Thromboembolism | 2013 |
Aspirin for long term maintenance therapy of venous thromboembolism.
Topics: Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Factors; Sec | 2013 |
Cost-effectiveness of low-molecular-weight heparin compared with aspirin for prophylaxis against venous thromboembolism after total joint arthroplasty.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement; Aspirin; Cost-Benef | 2013 |
Prophylaxis against venous thromboembolism after arthroplasty: establishing value requires more than one perspective. Commentary on an article by John T. Schousboe, MD, PhD, and Gregory A. Brown, MD, PhD: "Cost-effectiveness of low-molecular-weight hepari
Topics: Arthroplasty, Replacement; Aspirin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Huma | 2013 |
Aspirin after dalteparin was noninferior to continued dalteparin for preventing VTE after total hip arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Dalteparin; Female; Humans; Male; Platelet | 2013 |
[Prevention of recurrent thromboembolisms: WARFASA (aspirin for the prevention of recurrent venous thromboembolism - the Warfarin and Aspirin Study)].
Topics: Aspirin; Female; Humans; Male; Platelet Aggregation Inhibitors; Venous Thromboembolism | 2013 |
Aspirin versus low-molecular-weight heparin after total hip arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Dalteparin; Female; Humans; Male; Platelet | 2013 |
Aspirin versus low-molecular-weight heparin after total hip arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Dalteparin; Female; Humans; Male; Platelet | 2013 |
[Thrombosis prophylaxis after hip surgery- aspirin is not inferior to heparin].
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Dalteparin; Female; Humans; Male; Platelet | 2013 |
Use of ASA after warfarin for unprovoked VTE.
Topics: Anticoagulants; Aspirin; Drug Administration Schedule; Fibrinolytic Agents; Humans; Venous Thromboem | 2013 |
Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Biomarkers; Female; Fibrinolytic Agents; Gl | 2014 |
Thromboprophylaxis with dabigatran leads to an increased incidence of wound leakage and an increased length of stay after total joint replacement.
Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replace | 2014 |
Statins, aspirin and risk of thromboembolic events in ovarian cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Carcinoma, Ovarian Epithelial; | 2014 |
Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Drug Therapy, Combina | 2014 |
Prevalence of deep vein thrombosis in acutely admitted ambulatory non-surgical intensive care unit patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; APACHE; Aspirin; Clopidogrel; Female; Fibrin Fibrinogen Deg | 2014 |
An aspirin a day to keep the clots away: can aspirin prevent recurrent thrombosis in extended treatment for venous thromboembolism?
Topics: Anticoagulants; Aspirin; Female; Humans; Male; Platelet Aggregation Inhibitors; Venous Thromboemboli | 2014 |
Aspirin can continue to reduce blood clot risk after anticoagulants for venous thromboembolism, study finds.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Seconda | 2014 |
[Aspirin or non-steroidal analgesics increase risk of bleeding in anticoagulated patients].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Female; Hemorrhage; Humans; Male; | 2014 |
Aspirin increases the risk of venous thromboembolism in surgical patients.
Topics: Adult; Aged; Aspirin; Female; Humans; Intensive Care Units; Logistic Models; Male; Middle Aged; Plat | 2014 |
[What kind of thrombosis prevention for travel?].
Topics: Air Travel; Anticoagulants; Aspirin; Combined Modality Therapy; Exercise; Heparin, Low-Molecular-Wei | 2014 |
5000 years old and still going strong.
Topics: Animals; Aspirin; Blood Coagulation; Blood Platelets; Fibrinolytic Agents; Humans; Platelet Aggregat | 2014 |
Mobile compression devices and aspirin for VTE prophylaxis following simultaneous bilateral total knee arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Chemoprevention; Female; Humans; Int | 2015 |
Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
Topics: Administration, Oral; Anticoagulants; Aspirin; Female; Hemorrhage; Humans; Male; Middle Aged; Mortal | 2015 |
Cost-effective prophylaxis against venous thromboembolism after total joint arthroplasty: warfarin versus aspirin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2015 |
Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Veno | 2015 |
Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Veno | 2015 |
Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Veno | 2015 |
Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Veno | 2015 |
Prevention of venous thromboembolism after total joint arthroplasty: aspirin is enough for most patients.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Humans; Ve | 2015 |
ACP Journal Club: after initial anticoagulation for a first unprovoked venous thromboembolism, aspirin reduced recurrence.
Topics: Anticoagulants; Aspirin; Female; Humans; Male; Platelet Aggregation Inhibitors; Venous Thromboemboli | 2015 |
Staged venous thromboemolic events prophylaxis with low-molecular-weight heparin followed by aspirin is safe and effective after arthroplasty.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip | 2015 |
Direct Costs of Aspirin versus Warfarin for Venous Thromboembolism Prophylaxis after Total Knee or Hip Arthroplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthropl | 2015 |
Administration of Aspirin as a Prophylaxis Agent Against Venous Thromboembolism Results in Lower Incidence of Periprosthetic Joint Infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; | 2015 |
Duration of anticoagulation: the decision-making process.
Topics: Anticoagulants; Aspirin; Decision Making; Humans; Platelet Aggregation Inhibitors; Practice Guidelin | 2015 |
Venous thromboembolism rates in patients with lower limb immobilization after Achilles tendon injury are unchanged after the introduction of prophylactic aspirin: audit.
Topics: Achilles Tendon; Adolescent; Adult; Aged; Anticoagulants; Aspirin; Drug Administration Schedule; Fem | 2016 |
[Case-control study on three antithrombotic agents for the prevention of venous thromboembolism after unilateral total knee arthroplasty].
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Case-Control Studies; Female; Fibrinolytic Agents; H | 2015 |
The Effectiveness of a Risk Stratification Protocol for Thromboembolism Prophylaxis After Hip and Knee Arthroplasty.
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspiri | 2016 |
Arguments favoring low versus high dose aspirin in the prophylaxis of venous thromboembolism.
Topics: Anticoagulants; Aspirin; Blood Platelets; Dose-Response Relationship, Drug; Humans; Orthopedic Proce | 2016 |
Aspirin for thromboprophylaxis after primary lower limb arthroplasty: early thromboembolic events and 90 day mortality in 11,459 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacemen | 2016 |
Tranexamic Acid Can Be Administered to Arthroplasty Patients Who Receive Aspirin for Venous Thromboembolic Prophylaxis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty; Aspirin; Blood Loss, Surgical; Cohort Studies; Female; | 2016 |
Letter to the Editor on "Rate of Transfusions Following Total Knee Arthroplasty in Patients Receiving Lovenox or High Dose Aspirin".
Topics: Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Venous | 2016 |
Risk-Stratified Venous Thromboembolism Prophylaxis After Total Joint Arthroplasty: Aspirin and Sequential Pneumatic Compression Devices vs Aggressive Chemoprophylaxis.
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspiri | 2016 |
Aspirin Is as Effective as and Safer Than Warfarin for Patients at Higher Risk of Venous Thromboembolism Undergoing Total Joint Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Fema | 2016 |
Aspirin Can Be Used as Prophylaxis for Prevention of Venous Thromboembolism After Revision Hip and Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Fema | 2016 |
Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.
Topics: Aged; Aged, 80 and over; Antithrombins; Aspirin; Atrial Fibrillation; Comorbidity; Creatinine; Dabig | 2016 |
Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Aspirin; Dabigatran; Humans; Italy; Pyrazoles; Pyridones; Riva | 2016 |
Rate of Transfusions After Total Knee Arthroplasty in Patients Receiving Lovenox or High-Dose Aspirin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Blood Transfusion | 2016 |
Safety and efficacy of new oral anticoagulants and low-molecular-weight heparins compared with aspirin in patients undergoing total knee and hip replacements.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthr | 2016 |
Impact of recent guideline changes on aspirin prescribing after knee arthroplasty.
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Humans; Male; Orthopedic Surgeons; Platelet | 2016 |
Aspirin, the Unsung Champion of Deep Venous Thrombosis Chemoprophylaxis: A Historical Perspective: Commentary on an article by Javad Parvizi, MD, FRCS, et al.: "Low-Dose Aspirin Is Effective Chemoprophylaxis Against Clinically Important Venous Thromboembo
Topics: Anticoagulants; Arthroplasty; Aspirin; Chemoprevention; Humans; Pulmonary Embolism; Thromboembolism; | 2017 |
Low-Dose Aspirin Is Effective Chemoprophylaxis Against Clinically Important Venous Thromboembolism Following Total Joint Arthroplasty: A Preliminary Analysis.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Chemoprevention; Cross-Ove | 2017 |
Intermittent Pneumatic Compression for the Prevention of Venous Thromboembolism after Total Hip Arthroplasty.
Topics: Adult; Age Factors; Aged; Arthroplasty, Replacement, Hip; Asian People; Aspirin; Computed Tomography | 2017 |
Thromboprophylaxis for patients at high risk of VTE.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Heparin; Humans; Postoperative Com | 2008 |
Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Topics: Antibodies, Antiphospholipid; Antithrombin III Deficiency; Aspirin; Evidence-Based Medicine; Female; | 2008 |
Antiplatelet drugs and risk of venous thromboembolism: results from the EDITH case-control study.
Topics: Adult; Aged; Aspirin; Case-Control Studies; Female; Humans; Male; Middle Aged; Odds Ratio; Platelet | 2008 |
VTE prevention in major orthopedic surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Enoxaparin; Fondaparinux; Humans; Orthopedi | 2008 |
VTE prevention in major orthopedic surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Fondaparinux; Heparin, Low-Molecular-Weight | 2008 |
Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study.
Topics: Aged; Aged, 80 and over; Arterial Occlusive Diseases; Aspirin; Case-Control Studies; Female; Humans; | 2009 |
Venous thromboembolism debate in joint arthroplasty.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Re | 2009 |
Perioperative anticoagulant management.
Topics: Adult; Aged; Anticoagulants; Aspirin; Drug Administration Schedule; Drug Synergism; Female; Fondapar | 2009 |
Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients?
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Cohort Studies; Female; Fondaparinux | 2010 |
Cost-effectiveness of prolonged thromboprophylaxis after cancer surgery.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Cost-Benefit Analysis; Heparin, Lo | 2010 |
SCIP: VTE prevention controversy.
Topics: Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Postoperative Complications; Quality A | 2009 |
How can we reduce disagreement among guidelines for venous thromboembolism prevention?
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Blood Loss, Surgical; Cast | 2010 |
Re: Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients?
Topics: Acute Disease; Arthroplasty, Replacement, Knee; Aspirin; Humans; Platelet Aggregation Inhibitors; Ve | 2010 |
Use of the Delphi method to facilitate antithrombotics prescription during pregnancy.
Topics: Anticoagulants; Aspirin; Delphi Technique; Female; Heparin, Low-Molecular-Weight; Humans; Pregnancy; | 2010 |
Prevention and treatment of cardioembolic stroke: a case study.
Topics: Aged; Aspirin; Atrial Fibrillation; Embolism; Female; Fibrinolytic Agents; Humans; Risk Factors; Str | 2009 |
Aspirin and compression devices versus low-molecular-weight heparin and PCD for VTE prophylaxis in orthopedic oncology patients.
Topics: Adult; Aged; Aspirin; Bone Neoplasms; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Interm | 2010 |
Effect of anticoagulation on endothermal ablation of the great saphenous vein.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Catheter Ablation; Drug Thera | 2011 |
Improving Practices in US Hospitals to Prevent Venous Thromboembolism: lessons from ENDORSE.
Topics: Adult; Aged; Anticoagulants; Aspirin; Female; Hospitals; Humans; Intermittent Pneumatic Compression | 2010 |
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
Topics: Activated Protein C Resistance; Aged; Anticoagulants; Aspirin; Boronic Acids; Bortezomib; Dexamethas | 2011 |
The Australian arthroplasty thromboprophylaxis survey.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Attitude o | 2012 |
Dose-related effect of statins in venous thrombosis risk reduction.
Topics: Aged; Aspirin; Atherosclerosis; Cerebral Infarction; Clopidogrel; Cohort Studies; Cross-Sectional St | 2011 |
Prevention of venous thromboembolism after hip or knee arthroplasty: findings from a 2008 survey of US orthopedic surgeons.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Drug Monit | 2012 |
The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after hip replacement: a non-randomised comparison from information in the National Joint Registry.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Drug Evaluation; England; Female; Hep | 2011 |
Little impact of antiplatelet agents on venous thromboembolism after hip fracture surgery.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Female; Hip Fractures; Humans; | 2011 |
Obstetric complications and pregnancy-related venous thromboembolism: the effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation.
Topics: Abortion, Spontaneous; Adult; Aspirin; Case-Control Studies; Drug Therapy, Combination; Factor V; Fe | 2012 |
Incidence of venous thromboembolism in elective foot and ankle surgery with and without aspirin prophylaxis.
Topics: Ankle; Aspirin; Female; Foot; Humans; Male; Platelet Aggregation Inhibitors; Postoperative Care; Pos | 2012 |
Thromboprophylaxis in multiple myeloma: is the evidence there?
Topics: Antineoplastic Agents; Aspirin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Immunomo | 2012 |
The reemergence of aspirin for the prevention of venous thromboembolism.
Topics: Anticoagulants; Aspirin; Humans; Platelet Aggregation Inhibitors; Thromboembolism; Venous Thromboemb | 2012 |
DVT prophylaxis with aspirin in orthopedic surgery patients.
Topics: Aspirin; Humans; Orthopedic Procedures; Platelet Aggregation Inhibitors; Practice Guidelines as Topi | 2012 |
Aspirin and the prevention of venous thromboembolism.
Topics: Aspirin; Female; Humans; Male; Platelet Aggregation Inhibitors; Venous Thromboembolism | 2012 |
Assessment of venous thromboembolism risk and adequacy of prophylaxis in selected acute care medical centres in Arabian Gulf States: results from the ENDORSE study.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arabs; Aspirin; Critical Car | 2012 |
The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after knee replacement: a non-randomised comparison using National Joint Registry Data.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Drug Evaluation; Drug Utilization; E | 2012 |
Aspirin and recurrent venous thromboembolism in patients with symptomatic atherosclerosis: retrospective cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atherosclerosis; Female; Fibrinolytic Agents; Huma | 2012 |
Aspirin for prevention of thromboembolism recurrence.
Topics: Aspirin; Female; Humans; Male; Platelet Aggregation Inhibitors; Venous Thromboembolism | 2012 |
Aspirin for prevention of thromboembolism recurrence.
Topics: Aspirin; Female; Humans; Male; Platelet Aggregation Inhibitors; Venous Thromboembolism | 2012 |
Aspirin for prevention of thromboembolism recurrence.
Topics: Aspirin; Female; Humans; Male; Platelet Aggregation Inhibitors; Venous Thromboembolism | 2012 |
Aspirin for dual prevention of venous and arterial thrombosis.
Topics: Aspirin; Female; Humans; Male; Platelet Aggregation Inhibitors; Venous Thromboembolism | 2012 |
Aspirin for venous thromboembolism prevention and treatment: a renewal?
Topics: Aspirin; Humans; Venous Thromboembolism | 2012 |
Aspirin prevents recurrent venous thromboembolism.
Topics: Aspirin; Clinical Trials as Topic; Fibrinolytic Agents; Humans; Secondary Prevention; Venous Thrombo | 2012 |
Aspirin given for up to 2 years after initial anticoagulant treatment reduces the risk of venous thromboembolism recurrence without increasing risk of major bleeding.
Topics: Aspirin; Female; Humans; Male; Platelet Aggregation Inhibitors; Venous Thromboembolism | 2013 |
A retrospective cohort study of venous thromboembolism(VTE) in 1035 Japanese myeloma patients treated with thalidomide; lower incidence without statistically significant association between specific risk factors and development of VTE and effects of throm
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cohort Studies; Female; Humans; Incidence; Japan; Male; Mid | 2013 |
PURLs: a safer way to prevent VTE recurrence.
Topics: Aspirin; Female; Humans; Male; Platelet Aggregation Inhibitors; Venous Thromboembolism | 2012 |
[Aspirin and prevention of thromboembolism: the next chapter of a long story].
Topics: Aspirin; Female; Humans; Male; Platelet Aggregation Inhibitors; Venous Thromboembolism | 2013 |
[Does aspirin still play a role in secondary prevention of venous thromboembolism?].
Topics: Aspirin; Female; Humans; Male; Platelet Aggregation Inhibitors; Venous Thromboembolism | 2013 |
[Aspirin for preventing the recurrence of venous thromboembolism].
Topics: Aspirin; Female; Humans; Male; Platelet Aggregation Inhibitors; Venous Thromboembolism | 2013 |
Incidence of symptomatic thromboembolic disease after patellofemoral arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Female; Hu | 2012 |
Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; | 2007 |
Central venous catheter-related thrombosis in cancer patients: what we know and what we need to know.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; | 2008 |
Feasibility of an easy-to-use risk score in the prevention of venous thromboembolism and placental vascular complications in pregnant women: a prospective cohort of 2736 women.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Cohort Studies; Enoxaparin; Female | 2008 |
Multimodal thromboprophylaxis following primary hip arthroplasty: the role of adjuvant intermittent pneumatic calf compression.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Aspirin; Early Ambulation; Epidemiol | 2008 |